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Abstract
Galanin and neuropeptide Y (NPY) are not normally produced to any significant
extent by primary afferent neurones. After peripheral nerve injury however, there is a
marked increase in their synthesis - galanin mainly in small to medium sized
neurones, and NPY mainly in large neurones. There is evidence of transport of these
newly produced peptides to the dorsal horn, but it is not known what stimuli result in
their release in the spinal cord. The antibody microprobe technique was therefore
used to study the factors that might result in release of these peptides. The model
that has been studied involved placement of four loose ligatures around one sciatic
nerve in the rat, reliably resulting in the development of behavioural evidence of
neuropathic pain.
In addition to observing for the characteristic signs associated with this model, the
development of neuropathic pain was assessed quantitatively by the paw withdrawal
response to von Frey hairs and pin prick. Thus, all the animals used in the study of
peptide release or functional changes in the spinal cord, 10 to 14 days later, did
indeed have evidence of neuropathic pain.
A general assessment of altered spinal cord responses, found significant changes in
the neuropathic rats. There was found to be a bilateral increase in the cord dorsum
potentials evoked by A fibre stimulation of the injured nerve, as compared tot he
normal nerve, despite a decrease in the afferent volley from the injured nerve. As the
synthesis of both galanin and NPY is stimulated by peripheral nerve injury,
alterations in their spinal release was studied, including the effects of A fibre
stimulation on this central release.
Microprobes bearing immobilised antibodies to galanin were inserted into the spinal
cord of neuropathic rats. An increased area of immunoreactive (ir)-galanin release
was detected in the superficial dorsal horn ipsilateral to nerve injury, as compared to
that normally found. This occurred in the absence of any active peripheral
stimulation, in an area of the dorsal horn where the small primary afferent fibres that
have started to synthesise galanin terminate. Ir-galanin release was not increased by
electrical stimulation of the injured nerve at a strength sufficient to activate A fibres,
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but there was an increase in release as C fibres were stimulated. Conduction block
proximal to the dorsal root ganglia did not reduce the increased basal ir-galanin
release found ipsilateral to the nerve injury. An increase in ir-galanin release was
seen, however, on the contralateral side of the cord, after all neuronal input had been
blocked from the injured nerve.
Previous studies in this laboratory have found that, on the side ipsilateral to nerve
injury, ir-NPY was released spontaneously in the dorsal horn and this release was
increased by electrical stimulation of the injured nerve sufficient to activate only A
fibres. The large diameter primary afferent neurones that synthesise NPY after nerve
injury terminate in the deep dorsal horn, where ir-NPY was released, making it
probable that these fibres are the source of this ir-NPY. Using antibody coated
microprobes, the present studies found that the spontaneous release of ir-NPY was
not altered by conduction block of the injured nerve proximal to the dorsal root
ganglia. It appears therefore, that release ofNPY in the spinal cord from large
diameter primary afferent neurones does not require any peripheral neuronal
impulses.
The large diameter neurones that start to produce NPY express the neurotrophin-3
(NT-3) receptor, trkC. It has also been shown that exogenous NT-3 can attenuate
some of the increases in spinal levels of NPY, after bilateral axotomy. The effect of
exogenous NT-3 on NPY release was therefore studied using a chronic infusion of
NT-3 delivered to the nerve injury site and antibody microprobes to measure
spontaneous NPY release. It was found that NT-3 infusion had no effect on
spontaneous NPY release, but a minor alleviation of mechanical hypersensitivity was
noted 10 to 14 days after nerve injury, in those rats receiving exogenous NT-3.
These studies have determined some of the stimuli responsible for spinal release of
galanin and NPY after peripheral nerve injury, and excluded others. Further work is
required to correlate these results with functional effects and possible role in the
modulation of nociceptive transmission.
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Chapter 1. General introduction
1.1 Clinical Aspects of Neuropathic Pain
There is a significant difference between the normal 'physiological' pain that occurs as
a response to acute tissue injury, which serves a protective function, and the
pathological process that results in chronic pain problems, which apparently serve no
useful function 466. This type of pain is destructive in that many of the patients will
have suffered for some considerable time, with major implications for themselves,
their family and eventually for society. The exact incidence of neuropathic pain is
difficult to determine, but some 40% of patients referred to pain clinics will have at
least a component of their pain related to neural factors.
The definition of neuropathic pain has been varied, but relates to a group of chronic
pain syndromes in which there is a neural component to the pain experienced. This is
a heterogeneous group, making it difficult to study clinically. An attempt has been
made recently, by the International Association for the Study of Pain, to try and
classify these syndromes into two groups: Complex Region Pain Syndrome types I
and II 390, to try to improve diagnosis of the syndromes, and evaluation of new
treatments. This classification is based on signs and symptoms, as it is not yet possible
to accurately diagnose these pain syndromes on the basis of pathological changes. The
features of the classification are outlined in Table 1.
Empirical findings have implicated the sympathetic nervous system in the development
of some forms of neuropathic pain. This has been reviewed succinctly by Bennett,
1991 30. There are often signs of abnormal sympathetic activity, such as abnormal skin
temperature and trophic skin changes and sympathectomy often relieves the painful
syndrome. Indeed, the term Reflex Sympathetic Dystrophy was commonly used as a
diagnostic label, until it was replaced by Complex Regional Pain Syndrome Type 139°.
Evidence for changes in the sympathetic nervous system after peripheral nerve injury
OQ 1 Q 1 C
are increasing. There are several reviews ' ' on the interactions of the
sympathetic and sensory nervous system that might produce chronic pain. Possible
explanations for the exacerbation of pain by the sympathetic nervous system include:
ephaptic transmission, the influence of adrenergic receptors on sensory neurones
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associated with increased ectopic discharges, indirect coupling of sympathetic and
sensory neurones, sensitisation of nociceptive afferents and sensitisation of dorsal
horn neurones.
Complex Regional Pain Syndrome Type II was previously known as causalgia, and
was first documented after the American civil war 285. It is a chronic pain syndrome
that may develop soon after trauma to a peripheral nerve. There is variable
involvement of the sympathetic nervous system, secondary hyperalgesia and mirror
image pain43'274. The exact definition has been debated, probably reflecting the
heterogeneous nature of the response to peripheral nerve injury 364
The term neuropathic pain is a more general term, which includes causalgia, but also
refers to a much wider variety of mono- and poly-neuropathies. Neuropathic pain may
be due to many factors, and often the aetiology is not known. Possible causes include
nerve injury due to trauma, whether accidental or secondary to surgery, ischaemia,
infection, inflammation or compression (e.g. haematoma, malignancy), and secondary
to specific disease processes or systemic disorders, such as diabetes, rheumatoid
arthritis, myeloma or alcohol abuse 361. The natural history of the condition is affected
by the underlying aetiology, but the duration of the condition can range from months
to years or even decades, and is often refractory to all currently available forms of
therapy. Often patients have been treated by a number of specialists, without a
coherent overview of treatment aims. Prior to referral to a pain clinic, they have
usually already been subjected to a number of treatments, both medical, surgical and
psychiatric, with varying degrees of success. The treatments themselves may
exacerbate or at least complicate the original problem 127.
Perhaps one of the main reasons that there are so many treatments, that are often
ineffective in the long-term, is that the underlying pathophysiology of the central
response to peripheral nerve injury is still not well understood. This makes it almost
impossible to formulate specifically designed treatment to alter or prevent the
underlying neural changes that result in neuropathic pain.. The advent of animal
models is greatly improving the understanding of the neural mechanisms underlying
the neuropathic pain states 31. As understanding of the mechanisms of neuropathic
pain increase, a more logical approach can be used to developing rational treatment
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strategies. Additionally, it may be possible to target pain management in the peri¬
operative period in order to prevent or minimise the incidence of chronic pain
problems developing after surgery 133.
In this thesis the term " neuropathic pain" will be used to describe a peripheral
mononeuropathy resulting in pain-related behaviour, as this is the loose definition
used to describe the animal models.
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Table 1. Classification of chronic pain syndromes
This shows the reclassification of reflex sympathetic dystrophy and causalgia into
more strict categories. This was the result of a consensus conference of the IASP, as
described by Stanton-Hicks et al, 1995 390.
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Classification of Chronic Pain Syndromes
Complex Regional Pain Syndrome (CRJPS)
The diagnosis is excluded by the existence of conditions that would otherwise account
for the degree of pain and dysfunction.
There is variable involvement of the autonomic nervous system
Spontaneous pain or allodynia/ hyperalgesia not limited to territory of single nerve,
with pain disproportionate to the inciting event. Evidence (or previous evidence) of
oedema, skin blood flow, or abnormal sudomotor activity in the region of the pain
since the event
Type I (Reflex Sympathetic
Dystrophy)
Type II (Causalgia)
Develops after initiating noxious
event, without definable nerve lesion
Develops after a nerve injury
Spontaneous pain or allodynia/
hyperalgesia not limited to territory of
single nerve, with pain
disproportionate to the inciting event
Spontaneous pain or aliodynia/ hyperalgesia,




One of the original animal models of peripheral nerve injury is that of complete nerve
transection, or axotomy, with or without associated neuroma formation at the site of
transection. This has provided much useful information about the central response to
peripheral nerve injury. It is now likely that previously held ideas of a hard-wired
central nervous system 309, responding to varying peripheral inputs are no longer
tenable 465. There is an accumulating body of evidence for significant plasticity in the
central nervous system with biochemical, structural and functional changes occurring
in response to events in the periphery 87. However, a major disadvantage of the
axotomy model is that it is difficult to correlate the changes found with the occurrence
of pain. The degree of autotomy, where the animals gnaw at the denervated limb, has
been used as an indicator of pain, with a scoring system for this to grade severity.
There is debate as to whether or not this actually reflects painful sensation, or is due
to the complete denervation of the limb and the animal ceasing to recognise it as its
own 67-354. As a result of this problem several animal models using a partial nerve
injury have been developed. These models display altered behaviour and there are a
variety of tests that have been used to test for the presence of mechanical, thermal or
chemical allodynia and hyperalgesia. This allows some degree of correlation of central
changes after nerve injury with the severity of pain-related behaviour and also the
testing of interventions on the development of neuropathic pain syndromes. The three
models that have been studied most extensively, mainly in the rat, are:
1. A chronic constriction injury of the sciatic nerve ( Bennett and Xie, 1988 33).
2. Partial ligation of the sciatic nerve (Seltzer and Shir, 1990 366).
3. Spinal nerve ligation ofL5 +/- L6 (Kim and Chung, 1992 201).
The general characteristics of these models and the changes associated with them are
as follows:
1.2.1. Chronic Constriction Injury (CCI)33
This is the model that has been used for the studies outlined in chapters 3-5. A more
detailed description of the production of the nerve injury is given in section 2.2.1.
Briefly, four loose ligatures of 4/0 chromic gut were placed around the sciatic nerve at
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mid-thigh level, under sodium pentobarbitone anaesthesia, resulting in the
development of behavioural evidence of neuropathic pain.
General changes associated with the model33:
Characteristic changes in gait were seen, with motor behaviour consistent with pain.
Pain-related behaviours reached a maximum at two weeks after surgery, and had
effectively resolved at two to four months. Trophic changes of the skin and nails were
also found, with some oedema of the affected paw. Skin temperature changes were
initially very variable 32, with the injured hindpaw becoming more consistently colder
as the injury developed. Neither autotomy nor mirror image pain were major features
of the CCI model, nor was there any difference in behavioural signs seen between
male and female rats. Variable effects of sympathectomy were seen on development
or alleviation of the pain syndrome 31U36.
Evidence for evoked pain
1. Response to mechanical stimuli 12: Using Randall and Selitto's method j45 of paw
withdrawal to a graded mechanical pressure, Bennett's group did not find evidence
of mechanical hypersensitivity 33. Using a modification of this method , by
measuring the vocalisation threshold to increasing pressure on the hindpaw, a
decrease in threshold on the side of nerve injury was found from day 5, reaching a
minimum at 2 weeks and resolving by 8 weeks 12. A decrease in threshold was
taken to indicate the presence of mechanical allodynia, as vocalisation was elicited
at pressures that had not previously given a response. The disparate results
obtained may reflect the effect of muscle weakness in the injured leg, and it was
indeed noted by Bennett that there were several cases in which the hindpaw was
not withdrawn, possibly reflecting an inability to move the leg. The presence of
mechanical hyperalgesia was determined by an increased response to noxious paw
pinch 12.
2. Response to thermal stimuli: The hindpaw on the side of nerve injury showed a
decreased paw withdrawal latency and increased paw withdrawal duration, to
radiant heat. Placement on a cold surface showed an increase in both paw
withdrawal duration and frequency on the side of nerve injury. A role of the
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saphenous nerve in these behavioural responses was excluded as complete
transection of the saphenous nerve did not alter the hyperalgesic response 33. Both
hot and cold thermal hypersensitivity were found as measured by immersion in
water at varying temperatures 12.
3. Response to chemical stimuli: Mustard oil applied to the skin evoked a much
greater response after nerve injury, with a significantly prolonged increase in paw
withdrawal duration 33.
1.2.2. Partial ligation of the sciatic nerve (PNL) 366.
This model was described by Seltzer and Shir in 1990 and involved tight ligation of
one half to one third of the dorsal part of the sciatic nerve, just distal to the branching
off of the nerve to biceps semitendinosis, near the greater trochanter.
General changes associated with the model:
Abnormal hind limb posture and grooming behaviour were noted, although no
autotomy was seen. A marked feature was the bilateral effect on pain-related
behaviour, possibly correlating with the clinically seen mirror image pain. Another
feature is the role of the sympathetic nervous system, with sympathectomy alleviating
or preventing the development of the syndrome j75.
Evidence for evoked pain 366
1. 1. Response to mechanical stimuli: Bilateral mechanical allodynia was
demonstrated using von Frey hairs, and mechanical hyperalgesia was demonstrated
by a bilaterally exaggerated response to pin prick, especially on the side of nerve
injury.
2. Response to thermal stimuli: Bilateral increases in response to noxious heat
stimulation were reported, becoming ipsilateral to the injury as the stimulus
strength increased. Cold stimulation elicited a lesser response bilaterally in the
nerve injured animals compared to controls. There was no evidence therefore for
cold allodynia in this model - in fact, the reverse seems to be true, with cold
decreasing sensitivity 366.
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1.2.3. Spinal nerve ligation (SNL)201
This model was first described by Kim and Chung in 1992 and involves tight ligation
of L5 and L6 spinal nerves, or L5 spinal nerve alone.
General changes associated with the model
After nerve injury, there was abnormal gait, posture and grooming, with licking and
biting of the paw. Although it has been shown that at least part of these abnormal
behaviours are related to motor damage, a component is due to sensory abnormalities
and may indicate spontaneous pain 305. No evidence of autotomy was seen.
A role of the sympathetic nervous system in the prominent mechanical allodynia seen
was suggested by the alleviation of allodynia by sympathectomy 203, or alpha-2
agonists such as clonidine 482
Evidence for evoked pain 201
1. 1. Response to mechanical stimuli: There was a marked increase in response to
both low and high threshold stimulation with von Frey hairs on the side ipsilateral
to nerve injury.
2. Response to thermal stimuli: Noxious radiant heat stimulation showed a marked
decrease in latency on the side ipsilateral to nerve injury.
1.2.4 Overview of animal models
The main features of the models described are summarised in Table 2. Other models
of partial nerve injury have been developed, such as sciatic cryoneurolysis 84, diabetes-
induced neuropathy 353, or secondary to toxic levels of pyridoxine 158. None of these
other models have been as extensively investigated as those described here, and in
some cases produce additional systemic problems, such as those associated with
diabetes mellitus, as well as the neuropathy, making interpretation of findings more
complex.
The Bennett and Xie model33 has been used in the present studies because it has been
so extensively studied, and thus allows integration of these results with those from
other investigators to help improve understanding of the mechanisms of neuropathic
pain. It is safe and simple to set up, and reliably results in the development of
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behavioural signs of neuropathic pain. There is a low incidence of autotomy, wound
infection and other morbidity. This allows study of a chronic pain syndrome using
minimum number of rats, with minimum suffering (both severity and duration), thus
following Home Office guidelines to try and reduce animal usage. Although much
work can be done in vitro, in vivo studies are still necessary to understand the
dynamics of neuropathic pain syndromes.
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Table 2. Comparison of animal models of neuropathic pain
The main features of each model, and the advantages and disadvantages of each are
summarised. This has been reviewed by Bennett31, and more recently by Kim et al 200.
CCI= Chronic constriction injury; PNL= Partial nerve ligation; SNL= Spinal nerve
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1.2.5 Aetiology of neuropathic pain in the CCI model
The chronic constriction injury model of Bennett and Xie results in development of
pain behaviours that have much in common with the neuropathic pain syndromes that
are seen clinically. It is unclear however, what specific aspects of the nerve injury
underlie the development of the pain syndrome seen in the rat. Several causes have
been postulated:
Physical causes
At least part of the underlying mechanism is due to physical constriction of the nerve,
as use of variable diameter polyethylene cuffs instead of sutures to produce the injury
resulted in neuropathic behaviour only with small diameter cuffs 295. Physical
compression of the nerve, may result in the extensive endoneurial oedema that is
found, leading subsequent fibre damage with degeneration and pain-related
behaviours 23'297. Although at the time of ligature placement, the endoneurial blood
flow does not appear to be disrupted 33, there is evidence of decreases in local blood
flow at the nerve injury site at a time when thermal hyperalgesia is apparent 304. Thus
disturbances in the microvasculature around the nerve may also play a role in the
changes that occur.
Chemical causes
The type of suture material itself, rather than the physical constriction of the nerve
might be important. It has been proposed that a chemical constituent of the chromic
gut is important, as a variety of suture materials laid alongside the nerve had different
effects on behaviour. Thus, chromic gut, but not other materials, either loosely around
the nerve, or laid alongside resulted in the development of guarding behaviour and
188 9/C1 , ATX
thermal hyperalgesia ' , and changes in neuropeptide levels in the dorsal horn
A constituent in chromic gut may alter the chemical milieu of the nerve in such a way
as to result in the development of pain. Either chromic salts or pyrogallol in the
sutures 66'261 may have effects on neuronal function or a toxic action. Chromic gut
initiates an inflammatory response, that could be important in the development of pain
behaviour. The presence of a pro-inflammatory material may initiate an inflammatory
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response with release of cytokines and activation of primary afferent neurones 385,43°.
Increasing the inflammatory response by addition ofFrcund's complete adjuvant next
to the suture material resulted in increased pain-related behaviour , providing further
evidence for a role for peri-axonal inflammation in the development of neuropathic
pain66. An additional factor might be the generation of an acidic pH, possibly
secondary to induced inflammation, in the area immediately around the ligatures.
Capsaicin-sensitive fibres can be activated by reductions in pH 136-137> ancj these fibres
may be involved in the development of pain-related behaviour 271.
Finally, after nerve injury, the normal metabolic processes of the neurone are altered.
In particular, there is a decrease in retrograde transport of substances such as nerve
growth factor, and other neurotrophins. The alteration of the supply of neurotrophins
to the primary afferent cell bodies in the dorsal root ganglia may well have major
consequences for neuronal phenotype and function 93'176.
It seems likely that the development of neuropathic pain secondary to the placement
of loose ligatures around the sciatic nerve is a combination of physical and chemical
factors.
1.2.6 Morphological changes associated with the CCI model
There are marked morphological changes in fibre composition of the sciatic nerve
after a chronic constriction injury, that develop with time after ligature placement. In
the original description of the modelj3, marked constrictions were found beneath each
of the four ligatures. The epineurial vasculature was obstructed and swelling was
evident around the lesion, particularly on the proximal side. From 3 days after the
initial injury, a dense mass of connective tissue surrounded the nerve and the ligatures,
anchoring it to the surrounding muscle. After two to four months, the connective
tissue had been resorbed, although the ligated region was still thinner than the rest of
the nerve.
At 10 to 14 days myelinated fibres had degenerated extensively, with almost no large
myelinated fibres being found distal to the lesion, although smaller myelinated and
unmyelinated fibres could still be seen. The large myelinated fibre loss appeared to be
more uniform than that seen with the smaller myelinated fibres, which were variably
affected according to which fascicle was studied. At ultrastructural level, the few
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large fibres which remained were in an advanced state of degeneration. The effect on
unmyelinated fibres was varied, with evidence of significant reductions in total number
distal to injury, when compared to proximal. 1cm proximal to the ligatures, the
morphology appeared to be normal, with no sign of degenerating fibres, thus
indicating that most of the damaged axons had survived centrally, with a partial and
differentiating deafferentation caused by the constriction injury. There was significant
variability in amount of degeneration seen between nerves from different animals,
indicating the variable nature of the lesion. These changes occurred at a time when the
behavioural evidence of neuropathic pain was at a maximum 23,297.
Other studies have confirmed damage to all fibre classes distal to the injury site, with a
particularly marked reduction in large myelinated fibres. Massive Wallerian
degeneration was seen distally, especially in the outer portion of the transverse
sections. Proliferating Schwann cells surrounded small myelinated and unmyelinated
fibres. Neuroma formation was also seen, with disruption of the perineurium, at the
site of nerve injury 53'317.
1.2.7 Correlation of behavioural responses with morphology
It has been suggested that the major changes in composition of the sciatic nerve after
loose ligature placement may be related to the development of behavioural evidence
of neuropathic pain. Alterations in all fibre types are found, mainly distal to the injury
site, and the time course of these changes has been studied in parallel with behavioural
changes. There is some discrepancy between the behavioural results obtained by the
various groups, although the morphological changes seem less variable.
Thus, Guilbaud's group 134>154 found both hot and cold allodynia/ hyperalgesia and
mechanical allodynia were maximal at week 2, as was evidence of degeneration of the
injured nerve, with massive Wallerian degeneration of large myelinated fibres,
Between weeks 10-12 behavioural signs of neuropathic pain had disappeared, but
less than half the fibres had returned to normal. Other groups 53'69 have found a similar
correlation between the onset of heat hyperalgesia and fibre loss. The subsequent
progression of fibre loss and behavioural changes did not seem to be related, with the
behavioural signs resolving at 28-35 days after surgery, at a time when there were still
major fibre abnormalities. Using acetyl cholinesterase transport as a monitor of axonal
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regeneration, no correlation was found between transport rate and neuropathic pain
behaviour 128.
Although there does not seem to be a strong correlation with the time course of
morphological changes in the injured nerve and the neuropathic pain syndrome, it is
likely that there is a link. It is, of course, difficult to assess the relative numbers of
myelinated and unmyelinated fibres in a nerve where both degeneration and
regeneration are occurring simultaneously. Fibres classified as unmyelinated fibres
may in fact be regenerating, but demyelinated A fibres. Furthermore, there are few
studies of electrophysiological properties of these injured fibres which might help to
establish their origin, and help to relate function to anatomy.
1.2.8 Neuropeptide changes
Primary afferent neurones respond to peripheral nerve injury by major alterations in
neuropeptide production (reviewed by Hokfelt,1994 164). There are corresponding
changes in peripheral and central transport of these substances, and subsequent
changes in the spinal cord. There were striking alterations in neuropeptide synthesis in
the cell bodies of the dorsal root ganglia and in neuropeptide levels in the dorsal horn
of the spinal cord, both after complete nerve transection 425>492 and after partial
chronic constriction injury of the nerve 30S.
The synthesis of several peptides, normally produced by primary afferent neurones,
was markedly decreased. Thus, substance P (SP), somatostatin and calcitonin gene-
related peptide (CGRP) all decreased. In contrast, galanin, neuropeptide Y (NPY),
vasoactive intestinal peptide (VIP), cholecystokinin (CCK), dynorphin and pituitary
adenylate cyclase activating polypeptide (PACAP) increased. The effects of nerve
injury on galanin and neuropeptide Y are discussed in some detail in chapters 4 and 5,
but the changes in other peptides are discussed briefly as follows.
Substance P (SP)
SP was found in about 30% of cells in the rat dorsal root ganglia, mainly of small or
medium diameter. Transection of the sciatic nerve resulted in a decrease in SP mRNA
in the dorsal root ganglia, being most pronounced at 10 to 14 days after the injury,
and accompanied by a decrease in SP fibres in the spinal cord 183'316 SP levels
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decreased in the superficial dorsal horn of the spinal cord 20, and in some studies this
decrease occurred bilaterally, peaking at day 14, and accompanied by decreased
transport of SP from the dorsal root ganglia 425>426. A similar marked decrease in SP
production by primary afferent neurones was seen in the CCI model 308, with an
ipsilateral decrease in dorsal horn levels after 7-28 days \ becoming bilateral by 60
days 191'473. Functional studies of SP indicate a mainly excitatory role in both rats and
primates 98'474, with some evidence that it potentiated the effect of excitatory amino
acids 286'307,383. SP was released in the spinal cord in response to painful peripheral
stimuli, and it has been postulated to play a role on the transmission of nociceptive
information 108'112'456. The major decrease in SP levels after nerve injury may reflect
that it plays a lesser role in nociceptive processing in these states, although after
axotomy, tachykinin antagonists still had an inhibitory effect on the nociceptive flexor
reflex 250.
Somatostatin
Somatostatin was found in about 20% of rat dorsal root ganglia cells, of small to
medium size I96-425, but its production by primary afferent neurones in dorsal root
ganglia was markedly decreased after axotomy in the rat. A decrease from relatively
high levels in the monkey dorsal root ganglia was also seen after axotomy 370-495. The
functional effects of somatostatin were mixed, with evidence of excitation in some
circumstances 474 However, it may also have an inhibitory role 159-j46 in nociceptive
pathways, as a longer acting analogue has had some limited success in reducing
• • 288 335
morphine requirements in cancer patients ' .
Calcitonin gene-related peptide (CGRP)
In the normal animal, CGRP was one of the most abundant neuropeptides in cells of
the dorsal root ganglia, 18M25-426. It co-existed with SP, somatostatin and galanin. In
the dorsal horn it was found in large dense core vesicles (LDCVs) of primary afferent
terminals, in laminae I and II, decreasing after axotomy, when it became localised
mainly to small "dot-like" structures 493. There are variable reports of the effect of
nerve injury, with some evidence that axotomy had little or no effect on CGRP levels
in the dorsal root ganglia, and a minor decrease in CGRP containing fibres in the
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superficial dorsal horn 425. There was however a significant decrease in CGRP-
containing LDCVs in the dorsal root ganglia, as well as evidence for a marked
decrease in its production by dorsal root ganglia cells after axotomy in the monkey
49:3,495 Additionally, in the CCI model, the expression of CGRP mRNA in the dorsal
root ganglia fell to approximately half of its normally abundant levels 308. A more
recent study using spinal nerve ligation, found an overall decrease in CGRP mRNA
levels in the dorsal root ganglia, but a sub-population of medium to large sized
neurones showed an increase. In the dorsal horn, little change was found in the
superficial laminae, but an increase in CGRP-ir was found in deeper laminae 280.
There is considerable evidence that CGRP acts as an excitatory transmitter involved
with nociception both in normal animals 79'359 and in inflammatory states 312. In the
CCI model, although a CGRP antagonist still increased mechanical and thermal
thresholds, it was much less marked than that seen with uninjured rats 487.
Vasoactive intestinal peptide (VIP)
Very low levels of VIP were found in primary afferent neurones, with some VIP being
found in intrinsic neurones of the spinal cord 13°. An ipsilateral increase in VIP levels
in dorsal root ganglia was detectable after axotomy or partial nerve injury, mainly in
small to medium sized neurones, often co-localised with galanin 308,493. There was a
corresponding increase in VTP-containing fibres in the central area of the superficial
dorsal horn of, mainly in large dense core vesicles in laminae I and II 370,425,492 ypp
had a predominantly excitatory role, and its increased production by primary afferent
neurones after nerve injury has led to the suggestion that it may take over the role of
OT4 ,i . • , , 456,457SP in the nerve injury state
Cholecystokinin (CCK)
CCK has been found in a few dorsal root ganglia cells, of mainly small to medium
sized in uninjured rats 186,425. In the spinal cord, most of the CCK present was thought
to arise from local dorsal horn neurones, or descending tracts 497. Initial studies gave
very variable results of the effect of axotomy on CCK levels, often showing a
decrease. This was subsequently found to be due to technical problems with the
antibody used and better controlled studies have found an increase in CCK mRNA in
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primary afferent neurones after peripheral nerve injury 475. Functionally, CCK
inhibited the action of morphine, possibly explaining the reduced efficacy of opioids in
neuropathic pain states 13-314-475. CCK also facilitated the nociceptive flexor reflex,
whereas CCK-B antagonists inhibit this reflex 457.
Dynorphin
Dynorphin, a kappa opioid agonist, was found in the dorsal horn of the rat,
particularly in laminae I, II and V of normal rats 28T In the CCI model, there was an
ipsilateral increase in dynorphin, peaking at day 10. This increase was seen in laminae
I-II initially, then at later time periods an increase was seen predominantly in deeper
laminae VI-VII189. In another model of unilateral partial nerve injury, sciatic
cryoneurolysis, a bilateral increase in dynorphin levels was found in laminae II-III of
the dorsal horn, the magnitude of this increase correlating with the severity of
autotomy 429. The functional role of dynorphin after nerve injury is unclear 174, but it
may inhibit any analgesic actions of morphine 315, and this may be mediated via an
• • 428 •
interaction with a non-opioid receptor, rather than the kappa receptor . There is
also some evidence that dynorphin may have an inhibitory role, both in inflammation
393 and after nerve injury 422.
Pituitary adenylate cyclase activating polypeptide (PACAP)
PACAP, a peptide with a structure similar to VIP, has been found in abundance in
nerve fibres in the superficial dorsal horn of the rat, with some extension into deeper
layers. Further areas of PACAP were present in the lateral funiculus, and into the
interomediolateral cell column, but there was no PACAP-immunoreactivity in the
ventral horn. Many dorsal root ganglia neurones also contained PACAP, with the
densest staining being in small sized cells 113'296. After sciatic nerve transection, an
ipsilateral increase in PACAP mRNA levels were found in dorsal root ganglia, with an
increased population of neurones now expressing PACAP. However, PACAP-
containing fibres in the superficial dorsal horn may either increase 489 or decrease 499.
Increases in PACAP mRNA were found from as early as 15 hours after axotomy,
peaking at day 3 and declining after day 10. These changes occurred earlier than those
seen with other neuropeptides after nerve injury 489. PACAP may have an excitatory
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effect on transmission of primary afferent information, as it has been shown that
topical application of PACAP increased cell firing in the dorsal horn92.
1.2.9 Degenerative changes in the dorsal horn
Normally, the central terminals of primary afferent neurones distribute to distinct and
specific laminae in the spinal dorsal horn49'461. However, after peripheral nerve injury,
primary afferent fibres are damaged. There is evidence for effects on the central
organisation of primary afferent terminations 24°- Retrograde transport of the C fibre
specific lectin BSI-B4, from the injury site, was impaired, as from 4 days after sciatic
axotomy, it was only transported as far as the cell bodies in the dorsal root ganglia,
and not into the normal site of termination in lamina II 206.
There may also be transsynaptic damage to local and descending systems in the spinal
cord 306, with major changes in the dorsal horn somatotopic map 40°. The initial injury
barrage from the injured nerve may be excitotoxic, damaging cells in the spinal cord.
In the CCI model, there was an increased incidence of hyperchromatic and pyknotic
cells, likely to be degenerating neurones, found bilaterally from laminae I-IV,
especially in medial laminae I-II. Transsynaptic degeneration after chronic constriction
injury was increased in the superficial dorsal horn both by strychnine and bicuculline
(glycine and gamma amino butyric acid (GABA) receptor antagonists respectively)
398,399
appearance of these cells led to the suggestion that inhibitory cells were
preferentially damaged in the spinal cord. There may also be a link between the
damage caused by the initial injury discharge and the induction of neuropathic pain.,
as preventing the injury discharge decreased pain behaviour and augmenting it
increased neuropathic pain after partial nerve ligation 365 or in the CCI model 484 The
time course of behavioural changes in the CCI model also correlated with the time
course of reductions in GABA levels in the superficial dorsal horn 175.
Descending and ascending influences to and from the brainstem to the spinal cord
were also affected. There was an increase in serotonin and noradrenaline on both sides
of the dorsal horn 7 days after a unilateral chronic constriction injury, thought to
originate from descending control systems 360. The responses of neurones in the
spinothalamic tract to mechanical and thermal stimulation were altered in primates
with either a chronic constriction injury of one sciatic nerve 333, or tight spinal nerve
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ligation 332 There was much higher background activity, with increased after-
discharge in response to stimulation. Alterations in the number of inhibitory neurones,
the effects of descending and ascending systems and the pattern of neurotransmitter
co-existence may lead to impaired inhibitory function and central hyperexcitability
after peripheral nerve injury.
1.2.10 Regenerative changes in the dorsal horn
As well as degenerative changes occurring in the dorsal horn after nerve injury, there
are also regenerative changes occurring in parallel50. There is much new work on
central axonal regeneration, some of which has been reviewed by Brosamle 48.The
effects of these changes on nociceptive transmission and their role in the development
of neuropathic pain is not yet understood.
Coggeshall has reviewed the evidence for a central regenerative response to peripheral
nerve injury in 1994 68. The different types of sprouting that can occur are outlined:
1. Collateral sprouting is when central processes of undamaged or unconditioned
dorsal root cells sprout into a neighbouring denervated area of cord 96'376
2. Reactive collateral sprouting is when the central processes of conditioned dorsal
root ganglion cells sprout into a neighbouring denervated region 462.
3. Reactive sprouting is when central processes of conditioned dorsal root ganglion
cells sprout into different laminae in the cord. This type of sprouting is confined to
the somatotopic boundaries of the injured nerve j76.
It was noted by Woolf and co-workers that after axotomy, there was an increase in
production of a membrane phosphoprotein, Growth-Associated Protein GAP-43, by
primary afferent neurones in the dorsal root ganglia 467. GAP-43 is associated with
neuronal development and is presumed to influence synapse formation and neurite
elongation35'63. In transgenic mice overexpressing GAP-43 new synapses form
spontaneously and there is significantly increased sprouting after injury. GAP-43
seems to be important in transducing intra- and extra-cellular signals to regulate
organisation of the cytoskeleton (reviewed by Benowitz and Routtenberg, 1997 35).
GAP-43 appeared 3 days after axotomy in primary afferent cell bodies and 4 days
after axotomy in the spinal cord, reaching a maximum at 14-21 days, in the substantia
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gelatinosa ipsilateral to injury. The majority of labelled structures were unmyelinated
axons, although a few myelinated elements were found, and in most cases GAP-43
seemed to be associated with growth cone-like structures. No labelling was found if
the dorsal roots had been cut, indicating that the GAP-43 is likely to be of primary
afferent origin 71. Further work has confirmed the primary afferent origin of GAP-43
in the superficial dorsal horn, where it seems to be found mainly in unmyelinated
fibres, even those showing signs of degeneration. Virtually none is found in A fibres
sprouting into the superficial dorsal horn97.
Further work on regeneration the dorsal horn, found evidence of extension of the site
of termination of A-beta fibres into lamina II, an area where small fibres normally
terminate 468. Using Choleragenoid beta- horse radish peroxidase (CB-HRP) as a
marker for large myelinated fibres, injected at the nerve injury site, detectable levels
were found in lamina II by one week, reaching a maximum at 2 weeks after axotomy.
The labelling in the dorsal horn was restricted mainly to axons and terminals of
primary afferent fibres, with none in neuronal or glial cell bodies. The structure of the
labelled terminals was compatible with A fibres, and similar throughout laminae I-IV,
with a much higher proportion of undeveloped synapses labelled after nerve injury
than in naive rats. GAP-43 appeared in almost the same area of the dorsal horn as
CB-HRP after axotomy. This was seen after both nerve transection and nerve crush
469. Thus, in approximately the same area of the superficial dorsal horn, there were
increases in GAP-43 from unmyelinated fibres and new terminations from myelinated
fibres sprouting from the deep dorsal horn to this more superficial area. The
functional significance is not clear, but if these anatomical changes are relevant to the
neuropathic syndrome, then there should be some correlation between behavioural
changes and anatomical changes.
After a chronic constriction injury, when signs of thermal hyperalgesia were present,
there was a substantial increase in GAP-43, in ipsilateral laminae I and II of the dorsal
horn, similar to that seen after axotomy. Dorsal rhizotomy markedly reduced the
GAP-43 response seen, indicating that it was mainly of primary afferent origin. 50'51.
Evidence of A fibre sprouting was also found in rats subjected to tight ligation ofL5/6
spinal nerve roots, associated with a decrease in cell numbers in dorsal root ganglia
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• After sciatic nerve transection or crush, there was no apparent decrease in
Myelinated fibres in the dorsal roots, with these becoming the predominant type after
nerve injury as unmyelinated axons were decreased by about 50% 70.
1.2.11 Stimulus for central regeneration
The nature of the signals controlling neuronal regeneration and GAP-43 expression
are not clear. A role for a peripherally derived control factor seems likely as GAP-43
mRNA levels increased in the lumbar dorsal root ganglia after peripheral axotomy but
not central dorsal root section63. Injury-induced C fibre degeneration may stimulate A
fibre sprouting, as capsaicin treatment results in the same sprouting response into
lamina II, as that seen after axotomy 255. There are at least two possible signals
underlying regeneration:
1. A peripherally-derived signal produced after nerve injury that is transported
centrally after nerve injury may act as a stimulus to induce reorganisation in the
dorsal horn j44.
2. Peripheral nerve injury may decrease or stop central transport of a peripherally
derived growth factors necessary for maintaining normal neuronal phenotype of
primary afferents and/or dorsal horn neurones.
Transgenic mice, over-expressing NGF, were found to have several ectopic sites of
SP-ir and CGRP-ir in the white matter of the spinal cord, that were abolished by
capsaicin treatment of adult mice 253. Further evidence for a role ofNGF is provided
by a study delivering intrathecal neurotrophins to rats that had undergone sciatic
axotomy. In the control group, evidence of A fibre sprouting and decreased CGRP-ir
was found 2 weeks after axotomy. However, in those animals that had intrathecal
NGF infusions, these changes were virtually abolished. Neither BDNF nor NT-3 were
effective in preventing the changes29. NGF does not appear to be needed for the early
expression of GAP-43, which is likely to be under the control of some other
neurotrophin. In an in vitro culture model, using adult dorsal root ganglia cells, NGF
did not regulate the neurite outgrowth that was found, especially after axotomy U6>173.
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1.2.12 The sympathetic nervous system and behaviour
There is evidence for a link between the sympathetic nervous system and pain-related
behaviour after nerve injury. Interventions to diminish sympathetic input alleviate
some of the signs of neuropathic pain seen after a chronic constriction injury. Thus,
either a chemical sympathectomy, with guanethidine 3U'336, or a surgical
sympathectomy 8S, before or after the nerve injury, have been reported to reduce the
subsequent hypersensitivity to thermal stimuli with inconsistent effects on mechanical
hypersensitivity. Additionally, pre-treatment with an alpha-2 agonist, clonidine,
delayed the development of thermal hyperalgesia, although the severity eventually
reached was not altered 483.
Similar effects on behaviour were found in the partial nerve ligation model, after
guanethidine, as there was a delay in development of thermal hyperalgesia and no
effect on mechanical allodynia, although if given several months after the injury, both
mechanical and thermal signs were alleviated 375. In the spinal nerve ligation model,
there is evidence for a major involvement of the sympathetic nervous system 200, since
sympathectomy at the L5 level completely abolished the abnormal sensory signs, as
well as sympathetic sprouting seen after nerve injury (see section 1.2.13) 65'203
However, lesioning preganglionic fibres had no effect on the hypersensitivity seen,
indicating that the postganglionic fibre contribution is independent of sympathetic
outflow, and is likely to involve sensory-sympathetic interaction within the dorsal root
ganglia 205.
Of the animal models studied, that ofBennett and Xie probably demonstrates the least
sympathetic involvement 200. The reason for this difference is not understood, but the
distance of the nerve injury site from the dorsal root ganglia may be an important
factor in the degree of sympathetic sprouting occurring after nerve injury 202.
After a chronic constriction injury of the sciatic nerve there were alterations in
hindpaw temperature, with a significant difference in paw temperature appearing
between the injured and uninjured paw. The pattern of this change developed over
time, progressing from abnormally hot to abnormally cold over several weeks. There
was a high degree of variability in temperature changes within animals, with
significantly increased asymmetry and lability after nerve injury 220'436. Surgical
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sympathectomy significantly suppressed the temperature abnormalities seen in the first
week, but subsequently had no effect 437.
1.2.13 Interaction between sympathetic and sensory nervous systems
Anatomical changes
As well as behavioural evidence of a link between the sympathetic and sensory
systems, there is also anatomical evidence 65-264'343. McLachlan et al, 1993 264 found
that about two weeks after nerve transection, sympathetic efferents sprouted into
dorsal root ganglia. Normally noradrenergic axons form varicose plexuses around
blood vessels in the dorsal root ganglia, near the perimeter, but not penetrating into
the dorsal root ganglia. However, post-axotomy, noradrenergic fibres penetrated into
the dorsal root ganglia, forming basket-like structures around large diameter primary
afferent neurones. This sprouting occurred to a much lesser extent contralaterally.
The sprouting fibres appeared to be derived from the perivascular plexuses, as the
sympathetic fibres within the lesioned nerve itself degenerated after transection.
Repetitive stimulation of the sympathetic outflow resulted in firing of myelinated
primary afferent neurones, that was blocked by phentolamine, indicating the potential
for functional coupling of these noradrenergic neurones with primary afferent fibres in
the dorsal root ganglia.
Sprouting of sympathetic fibres after partial nerve injury occurred earlier than after
axotomy 64'6 '343, with sympathetic sprouting occurring at a time when neuropathic
pain behaviours were developing. A possible reason for the earlier sprouting after
partial, as opposed to complete, nerve injury is that the products of Wallerian
degeneration may contain a stimulus for sympathetic sprouting. In a strain of mice
with delayed Wallerian degeneration after nerve injury, both the behavioural signs of
neuropathic pain 303 and the degree of sympathetic sprouting were delayed compared
to normal mice 344.
Both NGF and LIF are produced after axotomy by non-neuronal cells4 , with
evidence for neuronal retrograde transport of these compounds 412,42°. They may be
involved in the induction of sympathetic sprouting after nerve injury, as transgenic
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mice overexpressing NGF in the skin, showed novel sympathetic sprouting in
trigeminal ganglia 80.
Functional changes
Electrophysiological studies have found evidence for changes in primary afferent cell
firing in response to adrenaline or noradrenaline depending on fibre type. There was a
marked increase in responsiveness of polymodal C fibres to sympathetic stimulation or
injection of noradrenaline, after partial nerve transection, although the A-delta fibres
did not show any change44'358. It is possible that the alterations in sympathetic
innervation in the dorsal root ganglia after nerve injury may result in the generation of
spontaneous activity in the injured nerve 230, occurring both at the nerve injury site 89
and the dorsal root ganglia90. In anaesthetised rats, after sciatic nerve transection,
primary afferent fibres displayed spontaneous firing 275'441, partly originating from the
dorsal root ganglia. Sympathetic stimulation altered the firing rate of the majority of
neurones 276. In the CCI model, topically applied noradrenaline increased the
spontaneous activity of most C fibres and A delta fibres, but had little effect on the
rate of discharge of A beta fibres 472
Dorsal root ganglia in culture, devoid of vascular supply and sympathetic innervation
still showed increased sensitivity to noradrenaline and evidence of spontaneous
activity if there had been a prior nerve injury (CCI), unlike the dorsal root ganglia
taken from preparations without a chronic nerve injury 488.
The changes seen after nerve injury may be partly due to receptor changes. In normal
rats, noradrenaline effects were mediated by beta-adrenoceptors in the dorsal root
ganglia, whereas axotomized rats showed an alpha-2 adrenoceptor mediated effect
After spinal nerve ligation, there were alterations in the sub-types of alpha-2
adrenoceptors from that normally found 144 in dorsal root ganglia cells, that might be
related to functional changes 62.
The involvement of the sympathetic nervous system in the development and
maintenance of neuropathic pain is variable, both in animal models and clinically 40'219,
which may explain the variable effects of sympathetic manipulations on the
development and treatment of neuropathic pain.
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1.3 Galanin
1.3.1 Synthesis and structure
Galanin is a C-terminally amidated 29 amino acid peptide first isolated in 1983 41°. It
was isolated from porcine intestine and has the following sequence: Gly-Trp-Thr-Leu-
Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-
Asp-Lys-Tyr-Gly-Leu-Ala-NH2. It was called galanin based on its N terminal and C
terminal amino acids (Glycine & Alanine). Although the C terminal tetrapeptide is
structurally similar to that of SP (Phe-Gly-Leu-Met) 41°, it is unlikely that there is any
overlap on receptor activation (see section 1.3.4). Galanin is found in a wide range of
species, with strict conservation of its primary sequence, especially the first 15
residues 198.
Galanin was found to exist in multiple conformational states, consistent with the
extended and folded backbone conformations of 2 alpha-helical regions separated by a
flexible hinge, at Pro 13 216.
It is produced from a 123 amino acid preprohormone, preprogalanin, that includes a
60 amino acid long flanking peptide called Galanin Messenger Associated Peptide
(GMAP), a signal peptide and galanin itself26'27. The importance of peripheral
neurotrophic factors in the regulation of neuronal galanin synthesis is unknown
although there is some evidence that the transport of substances from the periphery
may be important. Nerve growth factor may regulate some of the peptides, but many
of the neurones containing galanin do not have nerve growth factor receptors 196,426.
1.3.2 Metabolism
In vitro, galanin(l-29) has a half life of between 60 and 120 min, depending on the
tissue studied. Thus with a hippocampal membrane preparation, it had a tj/2 of 100
minutes 224, whereas with a spinal cord preparation, it had a tj/2 of 60 min 26. Galanin
appeared to be a relatively stable peptide that is predominantly degraded by
endopeptidases, that were partially inhibited by bacitracin 1%, and may include a
phosphoramidon-sensitive zinc metalloprotease 26'224. None of the galanin metabolites
27
appear to have any affinity at the galanin receptor. Although galanin binding sites do
seem to be concentrated in areas where galanin is distributed (see section 1.3.5), there
is a possibility of paracrine effects at areas distant from its site of release, because of
its relatively long half life. There have been several N terminally truncated forms of
the peptide, gal(7-29) and gal(9-29), isolated from the adrenal medulla that appear to
have low agonist activity at the spinal cord galanin receptors 28. They have a longer
11/2 than galanin itself, and the lower affinity at the receptor would be predicted from
the fact that the N terminus sequence of amino acids is the major determinant of
receptor-ligand interaction (see section 1.3.3).
1.3.3 Galanin receptors
Pharmacological studies of binding sites
Early pharmacological studies of galanin binding in the lumbar spinal cord found a
single population of high affinity binding sites. The N-terminal amino acids (1-15)
were very well conserved between species, and these peptides were sufficient and
necessary for receptor binding and agonist activity 22. Gal(l-12) is the shortest
fragment with agonist activity, and includes the four most important pharmacophores
- Glyl; Trp2; Asn5; Tyr9 needed for receptor interaction 21. Binding studies, using the
newer chimeric peptide antagonists, have found high and low affinity binding sites in
the cord - this heterogeneous binding may indicate the presence of more than one
galanin receptor site or it may reflect pharmacokinetic variables between the peptides
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In the adult rat spinal cord, galanin binding sites showed dense labelling in laminae I-
III, moderate labelling in laminae IV-V and around the central canal, with low to
moderate levels in the ventral horn and the white matter. The distribution of galanin
binding sites correlated well with the distribution of galanin-containing fibres in the
normal rat. Galanin binding sites were increased bilaterally by neonatal capsaicin
treatment and unilaterally by dorsal rhizotomy 192-193. These specific galanin binding
sites may be post-synaptic to primary afferents, although there is some evidence for
presynaptic binding sites, as galanin had a greater inhibitory action on the plasma
extravasation induced by C fibre stimulation than on the response to exogenously
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applied SP. This may be due to actions at a presynaptic site on the stimulated fibres,
or the greater effect on C fibre response may be due to the release of substances other
than SP 477.
Galanin binding sites changed during development. In early postnatal stages, there
was a high density of galanin binding in the superficial dorsal horn, with some
labelling in the deeper dorsal horn and very low levels around the central canal and the
ventral horn. Three to four weeks postnatally, there was a generalised decrease in
galanin binding throughout the cord. The regional alterations in galanin binding during
development may indicate a role for peptides in neuronal growth and organisation of
the spinal cord 193.
Molecular studies of galanin receptors
In 1995, the first galanin receptor, GalRl, was cloned, showing high sequence
similarity to somatostatin (-30%) and delta opioid receptors 3j4. It was subsequently
found to be widely distributed in the central nervous system, particularly in the
superficial dorsal horn 244. Using in situ hybridisation GalRl mRNA was found to be
present in 23% of lumbar dorsal root ganglia neurones, the majority of which also
expressed CGRP mRNA, and were of small to medium size. Although galanin
receptor mRNA was found in dorsal root ganglia cells, the actual expression of the
receptor protein may be much less, as radiolabelled galanin showed very low levels of
binding in the dorsal root ganglia 481.
The GalRl belongs to the G-protein coupled family, with seven transmembrane
domains and appears to inhibit forskolin-stimulated cAMP production 114.
The domains on the human GalRl, from a Bowes melanoma cell line, were studied to
determine the amino acids required for galanin binding and receptor activation. At
least three ligand-receptor interactions were needed - Trp2-His264, Tyr9-Phe282 and
N terminus of galanin bound to Glu271 for receptor activation I98.
Until recently, although pharmacological studies had indicated more than one galanin
receptor sub-type, only GalRl had been cloned. However, a second galanin receptor,
GalR2, was cloned from rat brain 125,443. It contained seven transmembrane domains,
sharing only 40% sequence similarity with GalRl, with the greatest difference being at
the amino and carboxyl termini. There was some conservation of G-protein coupled
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receptor features. The major pharmacological difference detected between GalRl and
GalR2 was that the galanin fragment Gal (2-29) had a much higher affinity for GalR2.
Activation of GalR2, like GalRl, led to inhibition of forskolin-stimulated cAMP
production. GalR2 had a much wider distribution outside the CNS than GalRl, with
strong signals being detected in the kidney, testis, skeletal muscle and liver. GalR2
was 26 amino acids longer than GalRl, at the amino terminus. It showed a 10 fold
lower affinity for human galanin, although the potency order for the chimeric peptides
was the same: M35>M40>C7 169. Both GalRl and GalR2 require the 2 amino
terminal residues for high affinity binding.
Further study of galanin receptor distribution found GalR2 mRNA in almost 25 % of
normal rat dorsal root ganglia cells, of mainly small size 372 GalR2 mRNA was often
co-localised with CGRP mRNA, and 20% of the GalR2-containing cells also
contained GalRl mRNA. Axotomy markedly decreased expression of GalR2 mRNA
in dorsal root ganglia cells 372.
A third galanin receptor, GalR3 has now been cloned 444. It showed approximately
50% sequence similarity with Gal R1 and 2, but differs from these two receptors in
that its distribution is more limited, with none being found in the brain.
All the galanin receptors cloned to date appear to belong to the G-protein superfamily
of receptors. A pertussis toxin-sensitive G protein coupled galanin receptor 83 reduces
intracellular calcium, either by inhibiting adenylate cyclase, opening K+ channels or
closing N type calcium channels. No effect of galanin was found on basal levels of
cAMP, cGMP or inositol monophosphate, but K+-stimulated cGMP production was
inhibited by galanin. This inhibition could either be a direct effect by inhibition of
guanylate cyclase, or could be mediated via closure of voltage sensitive calcium
channels 22.
1.3.4 Antagonists
There are some high affinity chimeric peptide antagonists for the spinal cord galanin
receptor, as reviewed by Bartfai, 1992 22 These recognise 2 receptors in which the
galanin receptor recognition site is in the N-terminal of galanin and the C-terminal
binds to other receptors, such as substance P. The conformation is stabilised by an a-
helical structure at the C-terminus. These antagonists include: galantide(M-15), which
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is gal(l-15) pro-SP(5-l 1) amide; the more potent spantide derivative (gal(l-15)pro-
spantide), and M-35 (gal(l-12) pro-bradykinin2-9 amide). There are several problems
with these peptide antagonists, in that they are not very stable, and that there is a
possibility of binding both to the galanin receptor and to the other peptide receptor
from which the chimera was produced. More recently high affinity chimeric peptide
antagonists have been developed that are oxidatively stable. There are several of these
available: C7, M32, M38 and M40. The last two have nonsense C-terminals, thus
avoiding problems with bi-receptor activation 479.
1.3.5 Distribution of galanin
Galanin is widely distributed in the central nervous system, and is found in both the
brain and spinal cord. There does appear to be some variation between species,
therefore care must be taken when making comparisons 56'115'214-357
Brain
In the rat, galanin has been found mainly in the posterior pituitary and hypothalamus,
with undetectable levels in the frontal, parietal and occipital cortices and the
cerebellum. The area with the highest levels of galanin in cell bodies was the
hypothalamus, with fibres spreading to the periventricular nucleus 56. A high
proportion of locus coeruleus neurones containing galanin (with many also containing
tyrosine hydroxylase) had fibres projecting to the hypothalamus, cortex and spinal
cord. In addition, some of these fibres contained NPY, again often co-localised with
tyrosine hydroxylase positive neurones in the locus coeruleus 166. In primate brain,
galanin was even more widespread. It was found in the hippocampus, cortex,
hypothalamus, thalamus, pituitary, in all the circumventricular organs, the
periaqueductal grey and the locus coeruleus. In humans, galanin was found in cell
bodies in the supraoptic nucleus and the locus coeruleus, whereas in monkeys, galanin
was found only in fibres in these areas 214.
Spinal cord and primary afferent neurones
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In the rat spinal cord, there was a rostrocaudal increase in galanin with the highest
levels being found in the lumbar and sacral spinal cord. Galanin was found both in cell
bodies and fibres, being most abundant in laminae I - II, X (around central canal),
Lissauer's tract and the dorsolateral funiculus 452-497. Galanin is found in intrinsic
neurones of the spinal cord, as well as in descending systems 269. Galanin was found in
islet cells in the dorsal horn that are the most common type of interneurone in lamina
II, and have rostrocaudally elongated axons. These interneurones received input
directly from primary afferents, as well as making frequent contact with other
interneurones, most ofwhich did not contain galanin 497. Galanin levels were
decreased by neonatal capsaicin treatment, particularly in laminae I-II, suggesting
some input from small primary afferent fibres 38\ Dorsal rhizotomy also decreased
levels in the superficial dorsal horn, and allowed clearer visualisation of galanin-
containing cell bodies in this area. Thoracic cord transection resulted in a small
increase in galanin levels in the lumbar and sacral areas of the spinal cord. This could
either be due to accumulation of galanin normally transported in ascending systems,
or it could be an effect due to loss of the influence of descending systems 56.
There is some disagreement about the number of primary afferent fibres containing
galanin in the normal rat, as some studies have found insignificant levels in the dorsal
root ganglia cells 16U63-425 whereas others find galanin at higher levels in dorsal root
ganglia 186. High levels have been detected in small axons in dorsal roots, even higher
than CGRP, with up to 28% of small, unmyelinated and fine myelinated axons at the
L5/S1 dorsal root level containing galanin 208. Low levels of galanin in primary
afferent fibres were also found in cats, in small to medium-sized cells in the dorsal
root ganglia, most of which also contained CGRP u. Galanin expression in adult rat
sensory neurones was also low48t>, and the central release of galanin was not affected
by stimulation of primary afferent neurones l68,292. Thus, on balance, it would seem
that galanin is not produced by primary afferent neurones to any significant extent in
the normal state.
In the primate spinal cord 214, dense collections of galanin have been found in the
spinal descending tract of the trigeminal nucleus, continuing into the substantia
gelatinosa, as well as in Lissauer's tract, the nucleus of the tractus solitarius, the
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dorsal motor nucleus of the vagus nerve and anterior horn cells in the cord. There
may, therefore, be an important functional role for galanin in the primate sensory
system, and the similarity of distribution to that found in the rat would indicate that
the rat is a suitable model for study of galanin.
Colocalisaton of galanin with other neurotransmitters
Galanin has been found to co-exist with several other neurotransmitters in the spinal
cord, including peptides. In the dorsal horn, galanin ir fibres also contained substance
P and CGRP in LDCVs probably of primary afferent terminals in laminae I-II.
Galanin-immunoreactivity (ir) was also found occasionally with CCK or NPY 496, and
in local dorsal horn neurones in LDCVs, coexisting mainly with enkephalin, but also
NPY (lamina II) and SP (deeper dorsal horn) 11,497 Galanin has been shown to coexist
extensively with GABA, in laminae I-II of the dorsal horn, but rarely with glycine.
The predominant cells in the superficial dorsal horn in which galanin and GABA
coexisted were islet cells, though to be inhibitory interneurones with long rostrocaudal
dendrites 379. In the ventral part of the motor nucleus, galanin co-existed with 5-
hydoxytryptamine (5-HT), probably as part of the descending bulbospinal system, as
the galanin-ir fibres disappeared with spinal transection 382. Although only a small
number of galanin-containing neurones were found in the lumbar dorsal root ganglia,
most of those neurones also contained CGRP, and often substance P 186. In the normal
state therefore, galanin coexists with both inhibitory and excitatory transmitters. The
functional significance of this requires further study, but any intervention that alters
the pattern of galanin co-existence with other neurotransmitters may have major
functional effects, due to alterations in the balance of substances released from
neurones.
Effects of peripheral nerve injury on galanin distribution in the spinal cord
Galanin is normally found in a few small diameter dorsal root ganglia cells, but within
24 hours after sciatic nerve transection, there was an increase in galanin mRNA and
galanin-ir in small, medium and a few large sized cells in L4/5 dorsal root ganglia,
with a corresponding increase in galanin-ir in the ipsilateral superficial dorsal horn
163,452 Thus peripheral nerve injury stimulated galanin production by many sensory
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neurones, mainly of small to medium size. There are differences between species, with
a less marked, but bilateral increase in ir-galanin in the dorsal root ganglia and spinal
cord of the guinea pig than is seen in the rat after axotomy 357. In primates, galanin
mRNA in the dorsal root ganglia and galanin in the superficial dorsal horn changed in
a similar pattern to that seen in the rat after peripheral sciatic nerve transection, with
ipsilateral increases in galanin in the dorsal root ganglia and superficial dorsal horn 495.
Different types of peripheral nerve injury, including the CCI model 29S, all resulted in
an increase in galanin-ir in rats, but a recent study has shown that partial sciatic nerve
injury resulted in a greater increase in galanin-ir, than complete sciatic nerve
transection. There was a greater increase in galanin-ir in medium and large cells in
dorsal root ganglia, as well as small cells after partial nerve transection, with both
injured and uninjured neurones being affected. After partial nerve injury, galanin-ir
was increased more in the superficial dorsal horn, with galanin-ir fibres running into
deeper levels of the dorsal horn than seen after axotomy 252. The response of
sympathetic neurones to nerve injury was also to increase galanin levels 211, but this
seems to be localised to cell bodies of uninjured axons 369. There is some evidence that
the increase in galanin found in sympathetic neurones is mediated by LIF derived from
non-neuronal cells 21°.
The factors that result in changes in peptide synthesis and distribution after nerve
injury are unclear. There may be a role for some of the neurotrophins in regulating
peptide expression in adult rats after nerve injury. Intrathecal infusion of NGF
prevents the decrease in CGRP and SP found after axotomy, but not that of
somatostatin. The up-regulation of galanin, VIP, NPY, and CCK was attenuated by
about 50% in the NGF-treated rats 424. However, when Kashiba and co-workers 195
tried to determine the effects of retrogradely transported NGF on the regulation of
galanin expression in the dorsal root ganglion, they found a lack ofNGF receptors on
dorsal root ganglia cells containing galanin, as measured by anti-NGF receptor
antibody binding. This led them to conclude that loss ofNGF was not a significant
factor in the up-regulation of galanin seen after nerve injury, and that other
peripherally-derived neurotrophic factors may be important.
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Factors other than changes in neurotrophin supply may include the central effects of
peripheral cell death on neuropeptide expression. In one study, where the primary
afferent cell death was prevented, by means of impermeable silicone tubes, there were
still alterations in peptide levels in the dorsal horn, with decreases in CGRP, SP and
CCK and an increase in VTP, as is normally seen after peripheral nerve injury. The
effect on galanin-ir was however more complex, with an apparent decrease in galanin-
ir in the medial dorsal horn, but a more widespread distribution to the lateral
superficial dorsal horn 207.
The pattern of peptide co-existence changes after nerve injury, which may have major
functional implications. In the dorsal horn of primates, there were changes in levels
and coexistence of galanin and CGRP after L7 spinal nerve ligation, with an increase
in galanin and a decrease in CGRP in the ipsilateral dorsal horn. However, neither the
number of galanin-ir synapses nor the number or diameters of the LDCVs in which
galanin was stored in the primary afferent synapses had actually increased. Instead, the
increase in galanin-ir was found to be due to a significant increase in galanin-ir
positive glial cell bodies. A significant decrease in CGRP-containing synapses was
found, resulting in less co-localisation of CGRP with galanin 52.
After sciatic nerve transection, large type dorsal root ganglia neurones, that normally
have almost undetectable staining for NPY and galanin showed coexistence of both
these peptides, and also some weak staining for CGRP 194. There was also a change in
co-localisation with the immediate-early gene, c-jun, as prior to nerve injury there was
no detectable co-localisation, whereas 48 hours after peripheral sciatic nerve
transection, about 35% of dorsal root ganglia cells displayed galanin-ir and c-jun-ir
161. There may be a link between these events, or the changes in c-jun levels may be
quite non-specific.
Although earlier studies found no effect on galanin binding in the spinal cord after
sciatic transection 27i4525 m0re recently, galanin binding sites were found to be altered
by peripheral nerve injury, with a marked decrease in the ipsilateral superficial dorsal
horn. 192. Both carrageenan induced inflammation and axotomy resulted in a down-




The results of the studies of galanin distribution in the spinal cord and dorsal root
ganglia are summarised in Table 3. There is some minor variation between studies on
the distribution of galanin in the dorsal horn, and more marked disagreement about
levels in the dorsal root ganglia. However, there seems to be general agreement that
after peripheral nerve injury, there is a marked increase in galanin production by
primary afferent neurones.
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Table 3. Galanin distribution in spinal cord and dorsal root
ganglia
This shows the results from a range of studies on galanin distribution in the central
nervous system. Abbreviations used:
drg = dorsal root ganglia
iml = interomediolateral
NA = not applicable (usually not studied)
i.t. = intrathecal
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1.3.6 Galanin-functional effects
The role of galanin in the processing of somatosensory information in the normal rat is
unclear as functional studies give variable results depending on the preparation and
dose used, and the effect studied. This is summarised in Table 4.
The behavioural effects of galanin applied to the spinal cord are inconsistent. Low
dose intrathecal (i.t.) galanin (0.03nmol) alone had no effect on the paw licking
latency in the hot plate test, but it significantly potentiated the antinociceptive effects
of morphine in rats 452-454. As the dose increased (3nmol), i.t. galanin, alone, caused a
modest increase in paw licking latency in response to a hot plate, indicating weak
mechanical hypoalgesia 455. Henry's group, 19 8 8 79 reported that galanin caused a
dose-dependent( 0.65 - 6.5 nmol) increase in withdrawal latency in the tail flick reflex,
but at higher doses (6.5nmol) vocalisation to previously innocuous touch was
observed, as tested by von Frey hairs. Wiesenfeld-Halllin's group found no evidence
of hyperalgesia, although it should be noted that a smaller maximum dose was used
than in Cridland and Henry's study (3 v 6.5 nmol). Using similar tests for thermal
nociception in mice it was found that galanin had an analgesic action (0.3-3 nmol) 34°.
In spinalized, decerebrate rats, further studies of the effect of galanin on the hamstring
flexor reflex found a biphasic action, with brief facilitation at very low doses, with a
predominantly inhibitory effect as the dose increased. Galanin strongly potentiated the
inhibitory actions of morphine, antagonising SP-, CGRP- and sural nerve-induced
facilitation of the flexor reflex 452-456. In an in vitro preparation from neonatal rats,
galanin had a concentration-dependent inhibitory action on monosynaptic and
nociceptive reflexes 486. Further evidence for inhibitory actions of galanin come from
single cell studies in the dorsal horn, where galanin appeared to hyperpolarize
membranes and decrease excitability 346.
Both galantide and M35, selective galanin antagonists given intrathecally, inhibited the
analgesic effect of morphine on noxious thermal and mechanical stimuli. When given
alone the antagonists had no effect on the response to these stimuli, and galanin itself
only showed antinociception at higher doses (2.7 nmol) 348. These antagonists also
attenuated the analgesic actions of tramodol (acts at mu-opioid receptors, inhibits
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noradrenaline re-uptake and has serotonergic effects), DAMGO (a selective mu-
opioid receptor agonist, [D-Ala2, MePhe4, Gly(ol)5]enkephalin), clonidine (alpha-2
agonist) and desipramine (noradrenaline re-uptake inhibitor) in tests using mechanical
or thermal noxious stimuli 367.
A role for galanin in the modulation of nociceptive information would certainly be
compatible with its anatomical distribution, with high levels ofgalanin-ir and galanin
binding sits in the superficial dorsal horn.
Effect of nerve injury
After sciatic nerve section, 11-24 days previously, the action of galanin on the flexor
reflex changed. It no longer had an inhibitory effect on SP actions, but instead a new
inhibitory effect on VIP-induced facilitation was found. It has been postulated that,
after peripheral nerve injury, VIP may become the predominant excitatory peptide in
place of SP 456'474. The inhibitory effect on sural nerve-induced and CGRP-induced
facilitation seen prior to nerve injury was even more pronounced 454-456-474 Further
studies also indicated an inhibitory role for galanin in the nerve-injured state, with
potentiation of the analgesic actions of morphine 454 seen to a greater extent after
axotomy 453. In addition, the high affinity galanin antagonist, M35, dose-dependently
potentiated the conditioning stimulus-induced facilitation of the flexor reflex in rats.
This action was strongly enhanced in rats that had undergone sciatic nerve transection
10-18 days previously, suggesting greater tonic inhibition by galanin after axotomy
453. M35 also significantly increased the degree of self-mutilation (assessed by
autotomy) in rats with a sciatic nerve transection 423.
From these limited behavioural and electrophysiological studies of galanin, it is still
unclear as to what its role may be in the normal rat. However, after a peripheral nerve
injury, it appears to have a predominantly inhibitory action, associated with an
increase in its production by primary afferent neurones. It may be therefore, that
galanin takes on the role of an endogenous analgesic compound in the nerve injured
state. Further studies of its functional effects, particularly in models of partial nerve
injury are required.
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Table 4. Functional effects of galanin
This table summarises the studies of behavioural or electrophysiological studies of the
actions of galanin in the spinal cord. As discussed in the text, its actions may be
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1.4 Neuropeptide Y
1.4.1 Synthesis and structure
Neuropeptide Y is a 36 amino acid peptide that was first isolated from extracts of pig
brain in 1982 408. The N and C terminals ofNPY are tyrosine and tyrosinamide
respectively, with the C terminus being needed for activity at NPY receptors. It
exhibits 70% sequence similarity with peptide YY (PYY) and about 50% with
pancreatic polypeptide (PP) 204-236. There is marked primary and tertiary structural
similarity between these peptides and they have therefore been classified into the
pancreatic polypeptide family. The primary and tertiary structure ofNPY has been
highly conserved through evolution 228. Studies from X ray crystallography have
determined the structure outlined in Figure 1.
NPY is formed from proteolytic processing of an approximately 97 amino acid long
prepropeptide 228. A signal peptide, consisting of a hydrophobic N terminal sequence
helps to direct the protein into the rough endoplasmic reticulum, where the signal
protein is cleaved and degraded. The signal peptide is cleaved after 28 residues,
resulting in Pro-NPY 284. The tertiary structure of the peptide is then formed in the
endoplasmic reticulum, with folding of the protein and formation of disulphide bonds
139 After transport to the Golgi complex 337, further modifications occur, with
amidation at the carboxyl terminal45, and packaging ofNPY into LDCVs, before
transport to the nerve terminal. The degree of transcriptional and post-transcriptional
control ofNPY production is variable, with different cell lines showing that either
protein kinase C or adenylate cyclase activation can increase transcription of the NPY
gene, or prolong the half-life ofNPY mRNA by increasing its stability 234.
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Figure 1. Structure of Neuropeptide Y and related peptides
A. The primary structure of neuropeptide Y and some related peptides in the
pancreatic polypeptide family is shown in part. Abbreviations used:
NPY - Neuropeptide Y
PYY - Peptide YY
aPP - avian polypeptide
pPP - porcine polypeptide
bPP - bovine polypeptide
B. The tertiary structure ofNPY as determined from X-ray crystallography studies.
There is an N-terminal globular structure (the PP fold) consisting of a polyproline
helix (1-8) followed by a tight hairpin loop formed by an anti-parallel amphiphilic a-
helix (13-32) and a type I a-turn, ending in a short terminal tetrapeptide amide
spatially close to the N terminal portion. The helices are held together by
interdigitating hydrophobic side chains, with the C terminal projecting away from the
loop at a 90° angle.
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1.4.2 Metabolism
NPY is resistant to degradation by non-specialised peptidases, that target a proline
residue on the penultimate N-terminal position, and is protected against degradation
by carboxypeptidases as a result of amidation of the C-terminus 272. In the brain,
astrocytes were almost always unable to catabolize NPY, whereas cultured neurones
and microglia digested NPY through cleavage after Argl9, Arg25, Arg33 and Arg35.
NPY was hydrolysed in vitro by neutral endopeptidase-24.11 (NEP) by cleaving at
Tyr20-Tyr21 and Leu30-Ile31. In vitro studies have shown that the proline-preferring
aminopeptidases, aminopeptidase-P (AP-P) and dipeptidyl peptidase IV (DPP-IV)
processed NPY at its N terminus 272,27j. DPP-IV produced NPY(3-36) that did not
have activity at the Y2 receptor on striatal synaptic membranes 245, but did in kidney
epithelial cells 341. NPY was resistant to the action of 2 other membrane
aminopeptidases (N and W) and to the action of angiotensin converting enzyme 245,268.
The relative resistance ofNPY to degradation may have functional implications. Thus
ifNPY persists for any significant length of time after its release, it may act by a form
of volume transmission, at sites distant from release 132
1.4.3 NPY Receptors
Pharmacological classification ofNPY receptor subtypes has determined multiple
subtypes, including Y-l, Y-l-like, Y-2 and Y-3 that share similarities with the PYY-
PP family of receptors. More recent molecular studies correlate well with the
pharmacological classification and have also found multiple NPY receptor subtypes.
This has been reviewed most recently by Balasubramaniam, 1997 14.
Pharmacological binding studies
Pharmacological study ofNPY receptor subtypes was reviewed by Wan, 1995 442. The
Y2 receptor has good affinity for the whole NPY molecule and the C-terminal
fragment, but the Y1 receptor requires the whole molecule 434 Thus NPY(13-36) has
activity at Y2 but not Y1 receptors. All the NPY receptor subtypes studied so far
appear to act primarily by inhibition of adenylate cyclase via a G protein, although
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subsequent intracellular events vary depending on the particular tissue and receptor
type being studied 278-318 Y1 receptor activation resulted in increased intracellular Ca2+
and neuronal excitation, whereas Y2 activation may have had the opposite effect72.
Y1 sites were found particularly in the brain cortex and postjunctionally in some
vascular beds in the rat, although in human brain, only the dentate gyrus of the
hippocampus had any significant levels of Y1 receptors 179. Y1 receptor mRNA has
also been found in small cells in the rat dorsal root ganglia491, and 5-20% of small to
medium-sized dorsal root ganglia cells bound NPY 256. The C terminal carboxyl-amide
group seems to be essential for Y1 receptor recognition. The Y2 receptor was also
activated by N-terminally truncated fragments, and was found mainly in the central
nervous system.
A comparison of the distribution of Y1 and 2 receptors in the guinea pig and rat brain
was carried out using radiolabelled subtype specific ligands. Major differences in
distribution were found between the 2 species. High levels of Y1 were found in the rat
thalamus, whereas there was very little Y1 binding found here in the guinea pig.
Conversely, Y1 binding was low in the rat hippocampus, and high in the guinea pig. It
seems likely therefore that Y1 and Y2 receptors perform different roles between the 2
species 135. The human frontal cortex appeared to have a predominance of Y2
receptors, in contrast to low levels seen here in the rat179.
The Y3 receptor was found in cardiac muscle and recognised NPY with a much
higher affinity than PYY 142. The main amino acid differences between PYY and NPY
occurred in the 13-23 segment, which must be important for receptor binding,
although the amidated C terminal was also needed 152. A further type of NPY receptor
mediated NPY-stimulated feeding , showing a broadly similar profile but with
characteristic differences from the Y1 receptor, leading to its being called "Yl-like"
23\ It has also been suggested that NPY may interact with a subtype of sigma receptor
in the rat brain, as it had very similar actions to specific sigma receptor agonists in
potentiating the effect ofNMDA in the hippocampus 290,291. However, more recent
studies indicated that the functional effect ofNPY was mediated through a different
receptor from sigma ligand 289
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The predominant receptor type on neurones seemed to be Y2. Pharmacological
studies found that the presynaptic receptor in rat hippocampus shared identical
properties to the presynaptic Y2 receptor found on sympathetic neurones 73. NPY
inhibited the release of noradrenaline in cultures of superior cervical ganglia cells, via
a pertussis toxin-sensitive mechanism, decreasing the availability of intracellular
calcium for the release process 323. NPY was probably acting at a presynaptic site to
inhibit sympathetic terminals by reducing calcium influx, possibly by selective
inhibition of neuronal N-type calcium channels 414.
Both, pre and postjunctional NPY receptors were found in the sympathetic nervous
system with vasoconstriction mediated by a direct postjunctional effect and
noradrenaline release suppressed by a prejunctional action 434. There are species
differences in the subtype of receptor found. Thus, rat and rabbit vas deferens appear
to have two different prejunctional receptor subtypes - Y1 in the rabbit and Y2 in the
rat. NPY and [Leu31,Pro34]NPY were potent agonists, whereas the C terminal
fragments NPY(13-36) and NPY(18-36), both Y2 agonists, inhibited evoked
twitches, but at differing doses in the rat and rabbit94.
Molecular studies of NPY receptors
There have been several NPY receptors cloned, all with seven transmembrane
domains, as occurs with members of the G protein family of receptors, confirming
pharmacological studies. The cloned human Y1 receptor is coupled to both cAMP
and calcium2 2, and has been found in the colon, vascular smooth muscle cells,
kidney, adrenals and heart. A human Y2 receptor has been cloned, showing about
30% sequence similarity with Y1 and also coupled to cAMP and calcium 227.
Although a bovine Y3 receptor was cloned, human and rat counterparts did not show
any detectable interaction with NPY or related peptides, making it unlikely that this is
a true NPY receptor subtype 152 Further members of the PP family of receptors have
been cloned with a putative Y4 receptor (or PP1 receptor) cloned in human, rat and
mouse 249. Most recently, a Y5 receptor has been cloned, with several variations,
and it is proposed that this might be the "Yl-like" receptor concerned with
feeding 171-321
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In studies on a human neuroblastoma cell line expressing Y1 receptors, four
monoclonal NPY antibodies, each directed against different epitopes on NPY, were
used to examine receptor interactions. For NPY binding and subsequent inhibition of
cAMP production by forskolin, sequences 11-24 and 32-36 were required. Those
antibodies directed against 27-34 and 1-12 had little effect on NPY binding except at
very high concentrations 149. Also in a human neuroblastoma cell line, NPY and a
cyclic analogue ofNPY were both shown to inhibit calcium currents, via a pertussis
toxin-sensitive mechanism. The inhibitory effects were additive with nifedipine,
probably involved N-type calcium channels, and were even more marked with the
cyclic NPY analogue with an agonist action 262.
The cloned Y2 receptor is also a 7-helix, G-protein coupled receptor that inhibited the
activation of adenylate cyclase lj8. Y2 receptor mRNA was discretely localised in rat
brain in a distribution consistent with the radioligand binding studies. In the brain, Y2
receptors were restricted to specific regions of the cortex, hippocampus, amygdala,
thalamus, hypothalamus, mesencephalon and pons. The most intense labelling was in
the CA3 region of the hippocampus, the arcuate nucleus of the hypothalamus and
layer 3 of the piriform cortex, with less intense labelling in the trigeminal nucleus and
the dorsal motor nucleus of the vagus 155.
The multiplicity ofNPY receptor subtypes, both from molecular and pharmacological
studies suggests diverse functional effects, many of which have been studied in the
nervous, endocrine and cardiovascular systems. Additionally, it should be possible to
develop drugs in such a way as to target specific subtypes of receptor, and thus gain
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specificity of action with minimal side effects
1.4.4 NPY antagonists
A variety ofNPY antagonists have been developed, and are discussed in detail in
several recent reviews 14'247. Many of the antagonists developed lack sufficient




Fragments ofNPY have been synthesised that showed antagonist properties at one or
more NPY receptor subtypes 450. For example, NPY(18-36) acted as a competitive
antagonist in rat cardiac ventricular membrane 15'282 and antagonised the potentiating
effect ofNPY on NMDA activity in rat hippocampus 291. However, NPY(18-36) also
acted as a partial agonist in some preparations with Y1 receptors and a full agonist in
Y2 systems 117-277.
Other antagonists include PYX1 and PYX2, developed by Tatemoto 409, but again
there is debate about their specificity33These agents were based on the C-terminal
end of the peptide, with at least the first 10 amino acids of the NPY structure being
incorporated. Both PYX1 and PYX2 inhibited NPY-stimulated intracellular calcium
release, in a human erythroleukaemia cell line, and displaced radiolabeled NPY from
rat brain membrane 409. There was also evidence that PYX2 can selectively antagonise
NPY-induced feeding 23\ Unfortunately, these compounds were only effective at very
high doses 25'117, but they have at least been useful in demonstrating that the C-
terminal decapeptide moiety was suitable for the development of antagonists. More
recent antagonists that used a d-Trp substitution at the C-terminal end, antagonised
the feeding effects ofNPY 16, but acted as agonists at the receptors involved in
antinociception 47.
In order to characterize the many NPY receptor subtypes properly, it was necessary
to develop multiple compounds 277. A range of modified NPY fragments was
therefore synthesised to produce Y1 selective compounds. Des-Asn29[d-
Trp28,32]NPY(27-36) was found to have no agonist activity at Y1 receptors, and
bound with higher affinity to Y1 than Y2 receptors. It antagonised NPY induced
effects on cAMP and Ca2+ mobilisation 18. Further non-selective analogues have been
developed, with moderate antagonist properties differing between receptor subtypes
17 229
. 1229U91, a new peptide antagonist, was produced, with actions at postsynaptic
vascular receptors in the rat. It was a cyclic, dimeric nonapeptide with no agonist




A number of nonpeptide antagonists have been used. Benextramine 58, an irreversible
alpha adrenoceptor antagonist and HE90481 2795 a guanethidine based HI and H2
histamine receptor antagonist were shown to have antagonist actions. Major
disadvantages included lack of specificity, low affinity and irreversibility 117>433.
Benextramine had antagonist actions, but they were irreversible, limiting its
usefulness, and there was some debate about its efficacy33\ However, a series of
benextramine analogues was produced, that had competitive antagonist activities at
NPY Y1 and 2 receptors in rat brain and femoral artery, which may be more useful58.
A substance with a similar molecular formula to a recently isolated substance P
inhibitor (TAN-1612), BMS-192548, was found to be an antagonist at NPY
receptors, 377. Two further compounds may be useful, particularly as they are non¬
peptide agents - BIBP3226 4I5'451 ancj SR120819A 368, that competitively and
selectively antagonise Y1 receptor-mediated effects in some preparations.
Thus, recently developed antagonists for Y1 and Y2 receptor subtypes are more
selective and specific, and the development of nonpeptide agents may be potentially
useful in the treatment of a number of conditions 95'148-471; since these may be more
likely to penetrate the blood brain barrier and may be degraded more slowly.
1.4.5 Distribution
NPY is one of the most abundant peptides found in mammalian central and peripheral
nervous systems 6'7.
Brain
In the rat brain, NPY was extensively distributed in periventricular areas, forebrain,
with widespread projections throughout the brain. NPY-ir was also found in all areas
associated with olfaction in the rhinencephalon, as well as in the basal ganglia,
thalamus, cortex (especially layer II/III and VI), hippocampus, amygdaloid and
hypothalamus. It also coexisted with catecholamines in cells in the locus coeruleus
and brainstem, projecting to the spinal cord 85. Efferent projections ofNPY-
containing neurones from the locus coeruleus went mainly to the hypothalamus, but
also to the spinal cord and cerebral cortex 166. In rat, guinea-pig and cat, more than
90% of the NPY-ir found in the ventrolateral medulla was rostrally situated. There
was significant overlap with those neurones containing tyrosine hydroxylase, and
remarkable consistency between species 156. Studies using 6-OHDA lesions of the
rostral ventrolateral medulla confirmed that most of the catecholamine and NPY-
containing terminals in the interomediolateral column originated in the rostral
ventrolateral medulla. This is an area of the brain known to play a critical role in
maintaining vasomotor tone and controlling vasomotor reflexes 418.
Spinal cord and primary afferents
In the rat spinal cord, NPY-ir was found in the substantia gelatinosa, the dorsolateral
funiculus and the dorsal grey commisure in the lumbosacral cord. NPY-ir was also
detected in fibres in an area of the cord concerned with autonomic function - around
the interomediolateral preganglionic sympathetic neurones in thoracic cord and
parasympathetic neurones in sacral cord 85. Immunocytochemical techniques were
used to study the ultrastructural arrangements ofNPY-containing terminals in the
dorsal horn of the cat. There was heavy staining in the superficial dorsal horn (laminae
I-II) with axons and varicosities being stained. There was a much lower level in the
deeper dorsal horn (laminae III-VI).The majority ofNPY-ir was contained in axon
terminals, most of which formed synaptic connections. Within these terminals NPY-ir
was scattered throughout the cytoplasm as well as being associated with numerous
LDCVs. NPY-containing terminals formed post synaptic connections of the axo¬
dendritic or axo-somatic type, although a few formed axo-axonic connections. Some
NPY-containing boutons were presynaptic to unlabelled terminals in laminae II,
having the appearance of primary afferent terminals. From the localisation of NPY, it
may have both postsynaptic effect on local interneurones in the spinal cord as well as
a presynaptic action on primary afferent fibres terminating in the superficial dorsal
horn 99'100.
In the absence of any peripheral injury, NPY is not stored in the central terminations
of primary afferents, but it is found mainly in intrinsic neurones of the dorsal horn 14°,
where it may coexist with galanin in a small number of intrinsic neurones in laminae II
497. A proportion of GABAergic neurones in laminae I-III of the dorsal horn of the rat
were found to contain NPY. In fact, all of the NPY containing neurones also
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contained GABA, although very few showed any glycine or met-enkephalin staining
222,355
NPY is not normally contained in primary afferent neurones in any significant
amounts. NPY mRNA was virtually undetectable in normal dorsal root ganglia
(<5%), as were signals for galanin and VIP. After capsaicin treatment, there was no
change in NPY mRNA levels, but there was an increase to about 10% for galanin and
VIP. This differential effect may be due to different subpopulations of neurones being
affected by the capsaicin 197
Sympathetic nervous system
Very high levels ofNPY were found in sympathetic ganglia and in tissues with dense
sympathetic innervation in guinea-pig, cat, pig and man 248. In many of the cell bodies,
NPY co-existed with tyrosine hydroxylase and dopamine-P-hydroxylase in large
cytoplasmic granules 182. These very high levels ofNPY in the sympathetic nervous
system suggest an important role in regulation of sympathetic tone 248. NPY was also
found in the majority of peripheral terminals of sympathetic neurones, mainly co-
localised with tyrosine hydroxylase in LDCVs. NPY was released peripherally after
stimulation of the sympathetic nerves 246. In the dog spleen and vas deferens, it was
found that the N-type calcium channel blocker, co-conotoxin, reduced the release of
both NA and NPY in an almost identical and dose dependent manner, whereas the L-
type calcium channel blocker, nifedipine, had no effect. Additionally, if exhaustive
stimulation was used, released NA was predominantly from small dense core vesicles,
as the store of LDCVs became drastically depleted, and the amount ofNPY released
was significantly decreased 82. From its distribution, it would seem likely that NPY
does have a role to play in the sympathetic nervous system. The functional nature of
this requires further study.
Effects of nerve injury on NPY in sensory and sympathetic neurones
After a peripheral nerve injury there are major changes in NPY levels in the dorsal
horn, and also in its production by primary afferent neurones. There was no significant
difference in the degree ofNPY induction between different types of nerve injury,
with axotomy, CCI and crush, inducing similar changes. There was an increase in
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laminae III-V axons and varicosities and induction ofNPY-ir in many large or
medium diameter primary afferent neurones, with less than 2% having a diameter <25
jam 435. Sciatic axotomy resulted in a marked increase in NPY levels in the dorsal
horn, especially in laminae III and IV 492 and in the gracile nucleus, reaching a
maximum at twenty-eight days. As simultaneous dorsal rhizotomy prevented the
response in the spinal cord, it seems likely to be due to changes in primary afferent
neurones 325.
In the CCI model, after twenty-eight days, there was a significant decrease in lectin
IB4 (used as a C fibre marker) in laminae I-II, with a corresponding decrease in SP
levels. Although NPY showed no change in laminae I-II, there was a marked increase
in laminae III-IV 29s, that was still present even at 100- 120 days after injury 299. There
was a corresponding increase in NPY mRNA levels in the dorsal root ganglia from
previously undetectable levels to high levels. This was seen in mainly medium to large
sized dorsal root ganglia cells, such that 20-30% of all dorsal root ganglia neurones
contained NPY mRNA. Capsaicin treatment caused only a small reduction in NPY
mRNA levels (10%), suggesting that it is found mainly in myelinated fibres 194,316.
In the dorsal root ganglia of normal rats, NPY receptor mRNA was mainly in small
type cells also containing SP and CGRP. After axotomy, the number of small
neurones labelled increased, but labelling intensity decreased. There was also an up-
regulation ofNPY Y1 receptor mRNA in large neurones 164. Despite this increase in
NPY receptor mRNA, it may not be translated into functional receptors, as neither
cuff-induced neuropathy (4 loose cuffs of polyethylene tubing) or axotomy altered
NPY binding in the dorsal root ganglia. Pharmacological binding studies indicated that
the predominant receptor type was Y2 256.
In the normal situation, neuropeptides are rarely found in large neurones in the dorsal
root ganglia. After axotomy, intense NPY-ir was seen in LDCVs budding off from the
Golgi complex in large neurones. Some of these neurones had evidence of central
transport and secretion ofNPY, possibly by both regulated and constitutive pathways,
although actual release ofNPY was not studied 24'490.
In the trigeminal ganglia, changes similar to those seen in the dorsal root ganglia after
axotomy were seen. Normally, about 5% of neurones were NPY mRNA positive and
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19% were NPY receptor Y1 mRNA positive, mainly in small sized cells. After
axotomy, 54% of mainly large sized cells were NPY mRNA positive 494. Injury to
branches of the mandibular nerve resulted in -35% of cells (mainly of medium to large
diameter) developing NPY-ir 438, with NPY-ir appearing in numerous thick nerve
fibres, also containing the calcium-binding protein, calbindin 439i44°. After tooth
extraction, NPY-ir also appeared in large to medium sized cells of the trigeminal
ganglia 177
The situation in sympathetic ganglia is unclear, as axotomy of the carotid nerves,
close to their origin from the superior cervical ganglion decreased NPY-ir in cell
bodies, but increased levels in nerve fibres. NPY mRNA decreased, although the
numbers of cells containing it remained constant 215. In LIF null mutant mice, there
was a smaller decrease in NPY mRNA levels than in wild type mice, after axotomy.
LIF mRNA expression was increased starting at 1 hour and peaking at 6 hours after
axotomy. LIF may be one of the key regulators ofNPY production in the sympathetic
ganglia 402
In the CCI model, NPY-ir decreased in vasoconstrictor efferents to the injured
hindpaw, associated with a gradual loss of these sympathetic efferents 436. Thus, nerve
injury produces a loss of NPY in neurones which normally contain it, but de novo
synthesis in a proportion of primary afferent neurones.
The stimulus for NPY production in primary afferent fibres after nerve injury is not
known. However, as with galanin, peripherally derived neurotrophins may be
important. Intrathecal NGF given for 7 days, 2 weeks after sciatic axotomy attenuated
the expected increase in NPY by about 50%, as well as preventing a decrease in
neurones expressing SP and CGRP, but not somatostatin, and attenuating the increase
in VIP, CCK and galanin 424. LIF seems to have less of a role in sensory ganglia than
sympathetic ganglia, as LIF-deficient mice still showed an increase in NPY in primary
afferent neurones after sciatic axotomy, although this was slightly less pronounced
than that seen in the wild type mice 77. Neurotrophin-3 (NT-3) may have a more
important role in the control ofNPY in primary afferent neurones, as after a bilateral
axotomy, the transganglionic response of an increase in NPY in the gracile columns
was prevented by exogenous NT-3 32<s. NT-3 seems to be important in development
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and maintenance of the large type sensory neurones that start to produce NPY after
injury 239,3845 and lack of it after injury may be one of the stimuli resulting in NPY up-
regulation. Both BDNF and NT3 have been shown to be of importance in the
phenotypic maintenance ofNPY-containing neurones in neonatal animals 54,31°.
1.4.6 Functional effects of NPY
The ubiquitous nature ofNPY indicates widespread effects in several systems. Thus it
has actions in the nervous system, with effects on nociception, anxiety; memory and
sympathetic tone 78>301; the cardiovascular system, with actions on blood pressure,
coronary perfusion and vasoconstriction 433; and effects on the regulation of food
intake and metabolism 268. Most of this section will concentrate on the neuronal
actions ofNPY, particularly in the control of nociception.
NPY actions at the membrane and interactions with other neurotransmitters
The functional effect ofNPY depends on the receptor activated. Several receptor
types were found on sensory neurones in culture, and electrophysiological studies
showed that receptor activation led to hyperpolarization 491 and a reduction in calcium
currents 76,323. Generally, activation of Y1 receptors results in an increase in Ca2+
availability, with subsequent neuronal excitation, whereas Y2 receptor activation may,
instead, reduce Ca2+ availability and inhibit neuronal function 458. However, Y1
receptors do not always result in neuronal excitation, as they have been shown to
result in hyperpolarization of small primary afferent neurones 491. There are many
studies that provide further evidence for an inhibitory action ofNPY. NPY inhibited
or suppressed the response produced by electrical field stimulation of capsaicin-
sensitive sensory neurones in guinea pig left atrium or bronchi via a prejunctional
mechanism 141. NPY inhibited calcium currents and modulated transmitter release by
highly selective mechanisms. It inhibited both SP and acetylcholine release from
sensory neurones in culture 72, and SP release into the substantia gelatinosa of the cat
following stimulation of unmyelinated primary sensory neurones no.
As well as a direct action on neurones, NPY may also modulate the effects of other
neurotransmitters. NPY inhibited the release of several neurotransmitters in different
systems. In rat hippocampal slices, NPY, PYY and NPY(13-36) (Y2 agonist) all
56
inhibited glutamate release, whereas the Y1 agonist ([Leul3,Pro34]NPY) had an
insignificant effect 147. However, in vivo studies, found that NPY potentiated the
response of hippocampal neurones to NMDA 290 via a receptor subtype that was
pharmacologically different from the already defined NPY receptors 291. The
potentiation was prevented by pre-treatment with pertussis toxin, indicating the
involvement of a G-protein in mediation of this NPY effect 289 NPY had effects on
glutamate in areas other than the hippocampus, with inhibitory effects on both
presynaptic glutaminergic neurones and presynaptic GABA-containing neurones in
the suprachiasmatic nucleus 59'421. NPY has also been shown to interact with both with
catecholamine release 221 and metabolism 101.
Nervous system
NPY is likely to be involved in the modulation of nociceptive transmission in the
spinal cord, a role that may be more important after nerve injury. When given
centrally, it seemed to be mainly analgesic 172, but the exact effect may depend on the
receptor subtype involved.
Intrathecal NPY had a dose-dependent biphasic effect on the spinal nociceptive flexor
reflex in decerebrate, spinalized rats that developed with time. Low doses ofNPY
(10-100 ng) caused a brief facilitation, changing to inhibition at higher doses (1,10 p.
g), with intense and prolonged depression. This action was not reversed by naloxone
or the a2-adrenoceptor antagonist, atipamezole. Sixteen days after axotomy, the
facilitation by NPY was significantly enhanced, but the depressive effect was
unchanged. However 31 39 days later, the inhibitory effect was more pronounced and
seen at lower doses 476. This effect may be related to changes in the types ofNPY
receptor expression after nerve injury. Behavioural studies confirmed the inhibitory
effects ofNPY, as it induced analgesia to thermal stimulation, and its C terminal
fragments induced analgesia to mechanical stimulation 172.
Although there is evidence of a central analgesic action ofNPY 172-476>478j ;n a study
giving NPY intrathecally for 14 days, it has appeared to be hyperalgesic 448, with
behavioural signs of hyperalgesia correlating with the peak ofNPY levels in the spinal
cord 298. There may also be a peripheral effect, as subcutaneous NPY into the
hindpaw resulted in hyperalgesia. This was mediated by a Y2 receptor, with Y1
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agonists being analgesic4l7. Surgical sympathectomy also relieved the hyperalgesia
and the effects ofNPY, possibly indicating a role for NPY in the sympathetic nervous
system. It is co-released with noradrenaline from sympathetic neurones, depending on
the pattern of stimulation 82'416.
After peripheral nerve injury, a major increase in NPY production by the large
diameter primary afferent cells 316 was associated with concurrent changes in NPY
receptor distribution after nerve injury, such as decreased Y1 receptor mRNA in small
dorsal root ganglia cells 491>498. it has been suggested that the changes in NPY may be
related to the development of spontaneous discharges in large myelinated fibres and
the development of hyperalgesia, although the use of appropriate NPY antagonists
would be useful to investigate this further 298'300. In the long term, however, when the
behavioural evidence of hyperalgesia had resolved, there was still an increase in NPY
levels in laminae III-IV of the dorsal horn 299.
NPY was shown to have an antinociceptive action in the mouse writhing test47,
although in the hot plate test, NPY decreased the withdrawal threshold. In the
formalin test, there was a decreased licking response in phase 1 with no effect on
phase 2. As the dose was increased there ceased to be any effect ofNPY in the tests
studied 270.
Other actions of NPY
Apart from a possible role in the modulation of nociceptive transmission, NPY has
been implicated in many homeostatic functions 302, including the control of blood
pressure 151'433; stimulation of feeding 171-268-391 ancj effects on memory 129 and anxiety
46,118,157 302
NPY has a role to play in the regulation of feeding. It simulated feeding, even in obese
rats 171'268'391; and reversed the anorexic effects of some agents 386. The effects on
feeding seem to be mediated by the atypical Yl-like receptor (from pharmacological
studies) that has recently been cloned, as the Y5 receptor321. NPY may have actions
on energy expenditure, by effecting metabolic rate in brown adipose tissue. There is
also evidence that NPY production is increased by the protein product of the Ob
gene, resulting in an increase in calorie intake 392. Interestingly, NPY does not seem to
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be an essential component of regulation of feeding, as NPY knockout mice did not
show any abnormality in weight gain or feeding behaviour 119
Other possible functions ofNPY include a role in the control of seizures. NPY
knockout mice showed an increased propensity for developing seizures n9. After
kindling-induced epileptic seizures, there were long term increase in NPY, in mossy
fibres of the hippocampus, that may be related to a generalised role in decreasing
neuronal excitability251. NPY, acting via a Y5 type of receptor, strongly inhibited
kainic acid induced seizures 463.
There is evidence that NPY can act as a growth factor itself, as it has been shown to
increase DNA synthesis in vascular smooth muscle cells and increase smooth muscle
cell proliferation 122,373. In neuronal cultures, NPY in the presence of spinal cord





The ultimate aim of the present studies was to contribute to the understanding of the
pathophysiological changes occurring in response to a peripheral nerve injury, that
result in the development of neuropathic pain. A major feature of the central response
to nerve injury is the up-regulation of certain neuropeptides that are normally found at
very low levels in primary afferent neurones. Galanin and neuropeptide Y are two of
these peptides, and both display evidence of inhibitory actions in the spinal cord. It is
important to correlate functional events with anatomical changes, and it was for this
reason that the central release pattern of these peptides has been studied during
experimental peripheral nerve injury. To do this a well validated animal model of
neuropathic pain has been studied, and the stimuli that alter release of these peptides
in the spinal cord have been determined in vivo.
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Chapter 2. General Methodology
2.1 Antibody Microprobe Technique
2.1.1 Basic principles
The antibody microprobe technique has been used extensively to study neuropeptide
release in the brain and spinal cord of both the cat108'226-293-459'460 ancj rat 111,168,352
technique was described in detail by Duggan 104,107.
The basic principle of the technique is that a series of processes are used to immobilise
a specific and sensitive antibody to the compound being studied, onto the whole of the
outer surface of fine glass microprobes. This allows the relatively atraumatic study of
the in vivo release patterns of neuropeptides of interest, as the tip diameter of each
probe is only about 5- 10p.m. Microprobes are inserted into the spinal cord to a known
depth and left in situ for a predetermined duration, to allow adequate binding of a
proportion of endogenous peptide released into the extracellular space. The peptide
binds to the antibodies coating the outer surface of the probe at localised sites of
release. After a set length of time, the probes are removed from the cord, washed and
incubated in radiolabelled peptide for 24 hours. This allows the radiolabelled peptide
to bind to any unoccupied antibodies on the microprobe. A second wash is carried out
then the tips of the probes placed next to X-ray film in order to produce an individual
autoradiographic image for each probe. Deficits in binding of radiolabelled peptide
represent areas where endogenously released peptide has bound. This is detected by
an image analysis system, that measures variations in optical density along the length
of the probe. A sorting programme can then be used to compare the means of defined
groups of microprobes, and determine differences in release at specific sites within the
spinal cord. The principles of this technique are outlined in Figure 2.
This technique therefore allows the study of the in vivo release pattern of particular
neuropeptides, and the effect of peripheral stimulation or other manipulations of this
release. In addition, release can be localised to specific areas in the spinal cord, which
is not currently possible by any other technique. Techniques using surface perfusion
do not localise the release of neuropeptides to specific areas within the spinal cord,
and require a relative excess for peptide detection. Techniques using cannulae inserted
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into the cord do give some degree of localisation, but the diameter of these cannulae
is of the order of 300 - 500 pm, and thus cause considerable trauma and cell damage
in the area of insertion 338,419
The accuracy of spatial localisation depends on the accuracy of probe placement in
the spinal cord and the resolution of the image analysis system. Maximum accuracy
would be achieved by ejecting dye from each probe used at its insertion site in the
cord. However, if several probes are used during the course of an experiment, it
becomes difficult to relate the relevant dye spot to a specific probe. Accuracy of
probe placement was improved by use of stepping motor micromanipulators, using an
operating microscope to visualise insertion. Additionally, at the end of each
experiment Pontamine Sky Blue was ejected from a microprobe inserted to a known
depth and this was measured in post mortem cord sections. The image analysis system
is capable of density measurements at 10 pm intervals, but comparisons between
groups are carried out at 30 pm intervals, since a biological resolution of 10 pm is
probably not possible 104,10<5.
The amount of neuropeptide that can be detected by this technique is very small. A
complete inhibition of binding of 12iI SP over a length of 100 pm approximates to 3 x
10"8 moles of the tracer not being bound. The amount of endogenous SP producing
such inhibition is likely to be of the same order of magnitude. More important is the
concentration of endogenous ligand in the environment producing such inhibition 104
With the majority of studies performed, in vitro studies assessing sensitivity
demonstrate at least 50% inhibition of binding of the radiolabeled peptide by the
corresponding unlabelled form of the peptide in a concentration of 10~7M 103. By
relating the images of in vitro probes exposed to a known concentration of peptide, to
in vivo images of probes inserted into the spinal cord it is possible to estimate
concentrations at release sites 294. The physiological relevance of this estimate is
unclear, as it does not indicate peptide-receptor interaction or function.
It has been found that the duration for which each microprobe must be left in the
spinal cord varies between peptides depending on variations in the antibody used.
Substance P release can be detected by probes left in the spinal cord for 5 minutes
during a specific peripheral stimulus 1I2. Before beginning to study a particular peptide
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using this technique, it is first necessary to determine the duration required for
microprobes to stay in situ, for adequate binding for each peptide.
Additional problems occur with detection of release if the substance being studied is
either inactivated very rapidly, or subject to rapid re-uptake into the cells. Both NPY
and galanin are relatively resistant to degradation, and neuropeptides in general, have
not been shown to taken up into cells after release 26j. However, as these peptides are
not degraded rapidly there will be a degree of diffusion from site of release, with
microprobes likely to show some spread outwith the actual site of release. Thus,
although the peak of the detection area is likely to be in the zone of release, the spread
around this may reflect diffusion of the peptide rather than other sites of release.
The detection of released peptide is referred to as "immunoreactive" (ir)-peptide
release as the polyclonal antibody used binds to only one terminus of the peptide
being studied. When using the microprobe method, interpretation of the significance
of "ir-neuropeptide" is greatly aided by knowledge of the siting of the amino acid
sequence to which the antibody binds, and whether degradation products also contain
this sequence intact. Precursor molecules do not generally cause a problem as they do
not tend to be released, but remain intracellular during processing of the peptide. If
antibodies to both C and N terminus of the peptide are available, then this can be used
to increase the likelihood that the substance being detected is in fact the peptide being
studied. Substance P gives similar results with use of either C- or N-terminus directed
antibodies 363. However, with Bolton-Hunter labelled peptides, the binding of
antibody to this portion of the molecule is hindered, thus making detection inaccurate.
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Figure 2. Principles of the antibody microprobe technique
This is illustrated using a microprobe coated with galanin antibody as an example.
A. The antibody microprobe technique uses a series of treatments to the glass
microprobes which are described in detail in the text. This results in immobilisation
of galanin antibody (Y) on the outer surface of the microprobes. For clarity only
one side of the microprobe is shown as having a coating of galanin antibody.
B. The coated microprobes are inserted into the spinal cord to a known depth and
endogenous galanin binds to the specific and sensitive galanin antibody, at localised
sites of release in the spinal cord.
C. The microprobes are then removed from the cord, washed and then incubated in
radiolabeled 125"I galanin ( at 4°C for 24 hours. This allows binding of the
radiolabeled galanin to any unoccupied antibody sites on the microprobes.
D. After washing, the microprobe tips are placed on card and an autoradiographic
image of each microprobe is obtained by exposure for 8-10 days on X-ray
monoemulsion film. Areas where endogenous galanin has bound are represented by
deficits in binding of radiolabeled galanin, and thus areas of lower silver grain
density. This can be analysed using an image analysis system and then related to the
actual site of release within the spinal cord.
E. This is a diagram of the structure of the IgG antibody that is used. It consists of 4
peptide chains linked by disulphide bonds: two heavy and two light chains. The
arms of the molecule - the Fab-fragments contain the antigen binding site, whereas
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The particular antibodies used will be described in the appropriate chapter, but all
were polyclonal antibodies raised in rabbit, against rat peptide sequences. As the
antisera were polyclonal, other immunoglobulins ofvarying affinity and specificity
were also likely to be contained in the freeze dried lyophilisate supplied by the
manufacturer, and the degree of purification of this lyophilisate was unknown. The
series of processes involved in antibody immobilisation serve to concentrate the
specific and sensitive antibody of interest on the outer surface of the probe. All the
antibody used for the NPY studies was obtained from Peninsula Laboratories, Inc,
Belmont, Ca, USA. The galanin antisera were obtained from two sources - Peninsula
Labs, as for NPY and Advanced Chemtech, Louisville, Kentucky, USA. The
lyophilisate already contained buffering salts and bovine serum albumin, and was
therefore dissolved directly in a small volume ofMillipore filtered distilled water to
the appropriate titre. This was then aliquoted out into Eppendorfs and frozen at -20 or
-70 °C until used for microprobe coating. Once the antiserum was made up in solution
it was never refrozen, but used straight after thawing, with any unused portion being
discarded. The titre used for each antibody was kept constant during each series of
experiments, and regular in vitro testing was carried out in parallel with the in vivo
use of the antisera to ensure continued sensitivity and specificity at the titre used,
during the time course of the experiments. One problem with using polyclonal serum
was that the sensitivity of the antibody tended to vary between different lot numbers.
These commercially produced antibodies varied to a slight extent in the antigen
binding site resulting in a mixture of IgG molecules with high and low affinity for the
inoculated peptide, as the response to antigenic peptide differed between animals.
High affinity antibodies are needed for microprobes, since the labelled neuropeptide
must not displace bound endogenous ligand to any significant extent. In those cases
where the in vitro testing indicated a major change in sensitivity for any batch of
antisera, this was discarded and not used for in vivo work.
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Peptides
A range of peptides were used for in vitro testing of each antiserum to ensure
specificity and test sensitivity. All peptides were obtained from Sigma Chemical Co,
UK in freeze dried form, and reconstituted in phosphate buffered saline (PBS). All
handling of peptides was done using silanised (Sigmacoted) containers, and the
aliquots were stored at -20 or -70 °C until used for in vitro testing. Sigmacoting was
used to prevent the peptide being adsorbed to the surfaces of any plastic material,
which would reduce the accuracy of the in vitro testing. Any remaining peptide was
discarded.
Radiolabeled compounds
Commercially prepared 125I-labelled peptides were purchased in 10 pCi batches either
from Amersham, UK or from Peninsula, Ca, USA labelled with Bolton and Hunter's
reagent. This reagent is [N-succinimidyl 3-(4-hydroxyphenyl) propionate] a molecule
by which iodine can be coupled to the peptide via the phenol group. The molecule is
linked to the peptide by its carboxyl group, either directly to free amino groups on
lysyl or to the NH2- terminal of the peptide 41. Freeze dried 125I-Bolton-Hunter
peptides were dissolved in Millipore filtered distilled water with bacitracin. The
bacitracin has been shown to improve the stability of the peptide in solution 225. The
resultant solutions were then divided into 2.5-10 pi aliquots, frozen and stored in a
dedicated, lead-lined freezer at -20° C. For in vitro or in vivo work, the ligands were
thawed then made up in a solution of PBS/azide containing either 0.5% bovine serum
albumin (BSA) or 0.5% casein. These general binding agents served to reduce levels
of non-specific binding to proteins, and non-specific binding to surfaces was
decreased by Sigmacoting all surfaces in contact with the radioactivity. Previous work
in the laboratory, and elsewhere 150 had shown that for NPY, 0.5% casein in the
solution decreased levels of non-specific binding and improved the sensitivity of the
assay to a greater extent than BSA. The final dilution was such that the concentration
used gave a count of 2000 cpm/pl, using a gamma-counter. A1 radiolabeled materials
were stored on ice until immediately before use. The half life of 125I is approximately
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60 days, therefore each batch of radiolabeled peptide was used for a maximum of 6
weeks.
2.1.3 Production of antibody microprobes
Preparation of glass microprobes
The microprobes were made from non-filamented, hollow borosilicate glass tubing
with an outer diameter of 3 mm, inner diameter 1.62 mm (GC 300-10, Clark
Electrochemical Instruments, UK). Although the glass was supplied pre-washed, it
was important that the silane based coating needed for the antibody immobilisation
was completely uniform, and for this reason all glass was washed as follows:
Batches of approximately 50 glass tubes were incubated in xylene for a minimum of
24 hours, then washed in absolute alcohol for 30 minutes. This was followed by 2
further alcohol washes, then each batch was covered and left to dry in a clean oven at
200°C for two to three weeks before being used in the manufacturing process.
Using a vertical microelectrode puller (PVS, University ofEdinburgh) individual
microprobes were pulled. Unlike microelectrodes, where it is desirable to have an
abrupt taper in order to minimise electrical resistance a quite different shape is needed
for this technique. An even, gradual taper was needed to produce a very fine probe tip
in order to minimise trauma to the spinal cord during in vivo use, and allow breaking
of the terminal 1cm without shattering. Additionally, it was essential that groups of
microprobes that were to be compared to each other had a similar shape, otherwise
differences in the physical shape would have prevented interpretation of differences
between groups due to biological causes. For this reason a standard setting was used
for the heat of the platinum coil and magnetic force exerted by the puller. To obtain
the long thin taper it was necessary to melt a fairly large area of glass - thus a 1 cm
length of platinum coil was used. Platinum has a high specific heat capacity and low
resistance, thus allowing a high enough temperature to be reached. A diagram of the
microprobe puller used and the microprobe shape produced is shown in Figure 3.
After the probe had been pulled, several methods were used to ensure standardisation
of shape. Visual inspection of every probe in comparison to a standard was used as an
initial screen. From each batch of probes pulled a selection were chosen at random
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and analysed in the computerised image analysis system to ensure consistency of
shape. Subsequently, the thick end of the probes were heat sealed in a gas flame, and
the thin end of the probes were sealed by briefly touching the tip against a heated
micro-coil (PVS, University of Edinburgh), using a micromanipulator (D10
Positioner, Research Instruments, UK) and binocular microscope to position the
probe for heat sealing. At this time a further visual inspection was carried out on each
probe, using a graticule with 10 pm divisions to measure probe diameter at the tip and
at 2.25 mm from the tip, where it was approximately 40 pm.
After tip sealing, probes were placed into specially designed glass carrying buckets,
holding up to 20 probes, with perforations in the base to allow drainage of any of the
liquids used in the treatment process. Probes were washed in 50% nitric acid for 30
minutes, in order to promote the formation of silanol groups on the surface 446. To
remove the residual acid, probes were then washed in Millipore filtered distilled water
for three times ten minute washes. Probes were dried for a minimum of four hours in a
clean oven at 200°C. The aim of this process was to produce uniformly shaped
microprobes with some degree of surface etching, on which the further reactions
needed for good immobilisation of the antibody could occur.
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Figure 3. Manufacture of glass microprobes for antibody
coating
A. This diagram represents the basic principles of the probe puller used to produce the
finely tapered microprobes required for in vivo work. The capillary glass is held
firmly between the two holders (1 & 2), running through the platinum coil (3), at
the midpoint of the length of the glass. It is important to ensure that the glass is
exactly in the centre of the coil so that it is heated evenly. The coil is attached to a
device allowing minor adjustments in position in relation to the capillary glass. The
lower holder (2) is attached to a solid iron weight (4) by a strong metal cable. The
heater to the coil is switched on and heats the coil, which in turn melts the glass
within the area of the coil. The heated glass stretches and the lower holder
gradually drops until a switch (5) is activated. This triggers a strong
electromagnetic field (6), that rapidly pulls the weight and attached holder down to
the base, drawing out the molten glass. This reaches a very gradual taper and
separates at the tips to produce two microprobes. The taper can be varied by
altering the heat of the coil, the distance to drop before the switch is activated and
the strength of the force exerted by the electromagnetic field.
B. This shows the desired shape of a microprobe, with a long, fine taper. All probes





The next step in preparing the microprobes for antibody immobilisation was to evenly
coat the outer surface of each probe with a siloxane polymer bearing free amine
groups. This process was carried out in sealed glass boiling tubes, each containing one
bucket with approximately 20 probes. The mixture required for coating consisted of
30 ml of reagent grade toluene (Aldrich, UK), plus 10ml of gamma-
aminopropyltriethoxysilane (APTES) (Aldrich, UK), plus 4-7 pi of distilled water.
The amount of water was varied in order to control the amount of siloxane
polymerisation at the surface of the probes and thus the thickness of coating. If a
greater thickness was needed the amount of water was increased. The toluene
solution had previously been treated with molecular sieves (150 g sieves/ 2.5 1
toluene) for a minimum of 24 hours, in order to remove as much water from the
mixture as possible. Water is critical in the coating process, as any excess results in
siloxane polymerisation in the solution and not on the surface of the probes.
The buckets of glass microprobes were removed from the oven and lowered into the
toluene / APTES mixture, in a fume cupboard. The stoppered tubes were then
centrifuged (Mistral 2L, MSE Science Instruments, UK) at 6°C, 2000 rpm for 1 hour
in order to increase the thickness of siloxane coating, by removal of small particles of
debris or free water away from the probes, and increasing polymerisation on the
probes rather than in the solution. After 24 hours at room temperature, the probes
were removed from the boiling tubes and placed in an oven at 200°C for at least 24
hours. Heat curing of the probes in this way resulted in a stable, water-insoluble
siloxane polymer coating on the microprobes' surface, and maximised the number of
free amine groups available without steric hindrance61.
After heat curing, each microprobe was examined under a binocular transmission light
microscope at x 125 magnification to assess the coating. A good coating appeared as a
fine granular layer on the surface of the microprobe. This must evenly cover the probe
for at distance of at least 4 mm from the tip. Any probes with patchy areas of coating
or focal aggregations of polymer were discarded. Probes with too thin a coating were
put through the coating process for a second time. Microprobes were stored
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horizontally in specially designed boxes to protect from dust contamination and to
protect the probe tips. After heat curing microprobes can be kept for at least six
months prior to being coated with antiserum. Probes were sorted into those with
heavy or medium coating and only those with similar density of coating used in any
one experiment. As well as providing a chemical base for the next step in the process,
the coating significantly increased the surface area on the probe eventually available
for antibody immobilisation 108.
Antibody immobilisation to siloxane coated microprobes
This step of the process was carried out immediately before in vivo or in vitro use of
the microprobes, as once the microprobes were coated in antibody they had a limited
time during which they could be effectively used. This process took a minimum of 48
hours, therefore the preparation of peptides and radiolabeled compounds, and animals
for in vivo studies had to be co-ordinated to prevent wastage of probes. This process
was designed to immobilise the specific antibody of interest onto the outer surface of
the probe. Despite this, when results from testing antibodies in vitro assays did not
meet the criteria for specificity and sensitivity required for in vivo use, comparative
assays using radioimmunoassay did not detect problems with the antibody. Although
the process of antibody immobilisation may have interfered with the antibody affinity
in some way, this discrepancy between radioimmunoassay and assays using
microprobes with the same antiserum may be due to the fact that in RIA, tracer and
endogenous ligand compete for the binding site at the same time. In the antibody
microprobe technique, the antibody has to have a high affinity for the endogenous
peptide, as the probes are sequentially incubated, first in vivo, with endogenous
peptide, then in vitro, with labelled peptide.
The first stage of antibody immobilisation involved treatment of microprobes with
glutaraldehyde. This was used as a cross-linking molecule, reacting covalently with
the free amine groups of the siloxane polymer and the amine groups of protein A
which is used subsequently. Buckets of 10-12 probes were immersed in a 2.5%
glutaraldehyde solution (BDH Laboratory Suppliers, UK) for 30 minutes. This was
followed by three 10 minute washes in distilled water.
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Protein A (Sigma Chemicals) was then used, diluted in phosphate buffered saline
containing 0.1% sodium azide (PBS-A) to a final concentration of 0.1 mg/ml. Protein
A is a component of the cell wall of Staphylococcus aureus, and selectively binds to
IgG fractions of the antisera. The protein A effectively excludes many unwanted
proteins, and allows concentration of the specific antibody onto the outer surface of
the probes. The Fc portion of immunoglobulins of the IgG class are bound by protein
A whilst leaving the peptide binding sites free 143.
The tip of each microprobe was carefully inserted into a glass capillary filled with 5 pi
of diluted protein A, visualised under a dissecting microscope. Any probes with
broken tips were discarded. The microprobes were then placed horizontally on a
perspex rack and stored at 6°C for a minimum of 24 hours in a covered plastic tray
containing PBS-A, to prevent drying out of the capillaries by evaporation.
The final stage in the preparation couples the antibody to the protein A now coating
the microprobes. The protein A containing capillaries were removed from the tip of
the microprobes and discarded. The microprobes were placed in glass tanks
containing sodium borohydride (Sigma Chemicals, UK) 2.5% w/v in borate buffer for
5 minutes, during which time they were repeatedly moved in order to disperse
hydrogen bubbles forming on their surface. This process reduced Schiff bases
produced by aldehyde coupling to amino groups on protein A, and stabilised the
binding of protein A. Batches of 10-12 microprobes were then put into buckets, and
given three 10 minute washes in PBS-A solution. Glass capillaries (20p.l, Camlab,
UK) were then filled with antibody solution and the tip of each probe inserted as
described for the protein A process. Microprobes underwent a minimum of a 24 hour
incubation period in the antibody at 6°C.
2.1.4 In vitro testing of antibody coated microprobes
The end result of the series of processes just outlined was to produce fine glass
microprobes with the antibody of interest immobilised onto the outer surfaces. Before
being used to study the in vivo release pattern of neuropeptides, it was essential to
check the manufacturer's data on antibody specificity and to determine the sensitivity
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of each antibody after immobilisation. Additional checks were carried out to ensure
consistent coating with antibody and to determine levels of non-specific binding.
Each new batch of antibody was tested extensively prior to any in vivo use, and in
vitro testing was carried out concurrently during in vivo experiments to ensure that
the sensitivity and specificity of the assay was maintained.
For the in vitro tests, batches of 5-10 prepared microprobes were washed in PBS-A
for 15 minutes. The subsequent treatment depended on what group each probe
belonged to, but any incubations with other peptides, for cross reactivity studies, were
carried out in 5 p.1 capillary tubes. All handling materials for peptides were
Sigmacoted to prevent the peptides adhering to the glass or plastic surfaces.
Microprobe tips were inserted into capillary tubes with the aid of a binocular
microscope to minimise damage to probe tips.
The specificity of the immobilised antibody was checked by measuring the degree of
inhibition of 125I peptide binding by related peptides, using a gamma counter. A
control group was used to check binding of the radiolabeled peptide to the antibody
in the absence of any other peptides. This interaction depends on adequacy of
antibody microprobe coating, binding affinity of antibody-peptide, and the correct
binding of 125I label to the peptide, as supplied by the manufacturer. Further groups of
microprobes were incubated in 10"5 M solutions of a range of peptides for 30 minutes
at 37°C then washed in ice cold PBS-Tween , followed by incubation in 125I peptide
for 24 hours at 6°C. After this, probes were washed in PBS-Tween for 15 minutes,
the terminal 1 cm of the tips broken off and stuck to small pieces of card. Each piece
of card was labelled according to the incubation process undergone by that probe,
then placed in individual counting tubes for counting in the gamma counter. After
counting, the cards were placed on X-ray monoemulsion film for 6-10 days to
produce autoradiographic images for each probe. This was done as a check to ensure
that there was uniform binding of the tracer to the surfaces of the microprobes.
The antibodies used were all C-terminus directed. The peptides used in cross
reactivity studies are found in the dorsal horn, and included galanin, neuropeptide Y,
VIP and substance P. Sensitivity tests were used to measure the degree of suppression
of binding by a range of concentrations of the peptide being studied from 10"5 M to
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10"9M. The procedure followed was similar to that described for cross reactivity
testing. An outline of a typical assay for galanin is given in Figure 3.
Every time a new batch of antibody was purchased, in vitro testing was carried out to
ensure that:
1. Control counts were sufficiently high for that peptide to indicate adequate binding
of labelled peptide to antibody. This varied depending on the peptide being studied,
but was normally in the range of 1000 to 2000 c.p.m. for each control probe.
Provided the assay met other criteria it was possible to use antisera-peptide
combinations with low control counts, but the duration of exposure to develop
autoradiographs that could be analysed was significantly increased. Unlike a
conventional radioimmunoassay the antibody is exposed to the unlabelled peptide
first, then incubated in the radiolabelled form A high affinity antibody is therefore
required to ensure that bound unlabelled peptide remains bound to the antibody.
2. Incubation of probes in 10"5 M of the relevant non- radiolabelled peptide, prior to
incubation with the radiolabelled form, gave at least 90% suppression of control
counts, and 10'7 M gave approximately 50% suppression. Previous studies on
tachykinin release have shown that this degree of suppression in in vitro assays was
effective in detecting release in the spinal cord 112.
3. A range of concentrations of cold peptide, e.g. 10'5 M to 10"9M, gave a
corresponding range of suppression of control counts.
4. Levels of non-specific binding to the probes themselves ( coated only with protein
A) were less than 10%. A general binding agent such as BSA or casein was used to
help reduce non-specific binding, and each stage was followed by washing in
detergent (Tween 20 or 80), with the final wash for in vivo probes being carried
out under suction.
5. If there was any doubt as to the adequacy of the coating procedure, antibody
coated probes were incubated in l25l F(ab)2, which is raised against the Fc region
of the IgG of the species in which the original antiserum was raised. Counts equal
to or greater than those for control probes should be obtained, with
autoradiographic images showing dense even binding along the length of the probe.
This demonstrates that there is a good coat of antibody on the probe surface.
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6. Cross- reactivity with other peptides was less than 10%, except for porcine forms
of the peptide that would be expected to show higher cross reactivity.
Once these criteria had been met, the antibody could be used for in vivo work. During
the course of a series of experiments (usually lasting about 6 weeks, as this was the
useful life of the radiolabeled peptides ), parallel in vitro testing was carried out each
week to ensure that the assay continued to give acceptable results.
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Figure 4. Typical in vitro assay for galanin
This diagram illustrates the procedure followed for an in vitro assay for a peptide,
such as galanin, prior to in vivo use. The results obtained from such an assay allow
confirmation of specificity from manufacturer's data, and give an indication of
sensitivity under the conditions that will be used in vivo. The procedure is described in
detail in section 2.1.4.
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15 min wash PBS-A
Microprobes coated in galanin antibody
(50 probes))
SENSITIVITY GROUP SPECIFICITY GROUP
10"5M -> 10"9M Galanin 10 5M NPY/ VIP/ SP/ CCK
(5 probes/group)
24hr incubation in 125I Galanin at 6°C
15 min wash Tween-80
Count terminal 1cm of each microprobe
in gamma counter
Tips placed on X-ray monoemulsion film for 8-10 day;
to produce autoradiographic image ofprobe tips
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2.1.5 In vivo use of antibody coated microprobes
The process described in section 2.1.3 was followed to produce batches of
approximately 30 antibody coated microprobes for each in vivo experiment. The
experimental set-up used for the rat is described in detail in section 2.2.2.
On the day of experiment a fresh aliquot of radiolabeled peptide was made up in
PBS-0.1% BSA or PBS-0.1% casein to result in a dilution of 2000 c.p.m./pi
Shortly before use, microprobes were removed from the cold room, the antibody
containing capillaries were discarded and the probes placed in buckets in PBS-A. The
sealed, non-drawn out end of the probe was carefully removed using a glass saw. This
allowed subsequent washing procedures to be carried out. Each probe tip was then
examined under the binocular microscope at x 125 magnification, with a calibrated
graticule, and the tip size checked. If the tip was greater than 10 pm, indicating
breakage during preparation, it was discarded. If the tip size was less than 10 pm,
then it was gently broken back to this size against the metal coil previously used for
heat sealing of the probes. Thus the tip of the probe was now open. This was why the
final washing procedure was carried out under suction to remove any residual debris
at the probe tip.
The peptide release experiments are described in section 2.2.2, but basically involved
insertion of microprobes to a known depth into the spinal cord of the rat. This
allowed binding of any endogenous peptide at localised release sites in the spinal cord.
After washing, 24 hour incubation in radiolabelled peptide, and a final wash under
suction, the tips of the probes were placed on card, next to X ray monoemulsion film
(Kodak), with the emulsion side of the film in contact with the probes. The film was
exposed to the probes for 6-10 days, depending on the intensity of image required and
the peptide being used. After this time, the film was developed and an individual
autoradiographic image was obtained for each microprobe.
80
2.1.6 Analysis of antibody microprobes 160
A computerised image analysis system was used to analyse the autoradiographic
images obtained from microprobes inserted into the spinal cord. In vitro microprobe
images for each experiment were also analysed as controls. Binding of endogenously
released peptide resulted in deficits in binding of ,25I-labelled peptide that were
detected as a decrease in optical density by the analysis system. An simplified outline
of the set-up used is shown in Figure 5.
For analysis, an autoradiographic image with a density well above the background
silver grain density, but below the maximum density for the film, was required. If the
image was too faint, then background subtraction could introduce errors. If the image
was developed to the maximum density, then any variations in density from peptide
binding would be obscured. The exposure length required varied between peptides,
but for galanin, 8-10 days gave a good image, and for NPY, 6-8 days were sufficient.
A clear image was achieved by having as close an apposition as possible of the probe
tip onto the film, and ensuring no movement of the film against the card to which the
tips were attached during the exposure period. If the tip was too far from the card,
then an unfocused image was obtained, and if the film moved during exposure, then a
double image was obtained. For each experiment it was usual to obtain two films of
differing exposure times from each set of probes, so that if single probe images were
unsatisfactory on one film, they could be used from the second film, thus allowing
analysis of the majority of probes.
An Imaging Technology PC Vision Plus frame grabber board operating in a Data
Control Systems 286e computer was used. The film was cut up into individual
autoradiographic images, that were labelled and wiped clean with lens tissue before
analysis. Single images were placed onto a microscope stage in a light proof box and
illuminated from beneath through a narrow slit just wider than the image. The light
source (2 X 25W microscope halogen bulbs) was mounted in a light box fitted with
diffusion plates to give uniform distribution of light. A stabilised DC power supply
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(Farnell) was used to power the light source and ensure an even and constant light
supply.
A charged coupled device black and white camera (CCD, Panasonic) scanned the
distal 5mm of each image, to give a video image for each microprobe tip, displayed on
a colour monitor connected to the output of the image processing board. The
automatic gain control function of the camera was disabled to allow use of the camera
as a densitometer, by ensuring that the digitised video image was linear with respect
to the autoradiographic density. The field of view of the camera produced a 512 x 512
pixel map, that was stored in the memory of the image board. Thus, each pixel
corresponded to approximately 10x10 pm. The image board converted the video
image to an optical density assigning an arbitrary grey scale from 0 to 255 to each
location on the board, which was inverted by the processor for display, such that 0 =
maximum light and 255 = complete blackness. If the light intensity from the light
source was increased to greater than 255, linearity was lost from the greyscale. To
avoid this, the light intensity was set at 1 when no film was present on the microscope
stage, and the amount of light reaching the camera kept constant by varying the
current of the light source.
Prior to analysis, incident light was subtracted using the average of two values of
background density from unexposed areas on the film, and the focus adjusted such
that a pre-calibrated scale bar equalled 1mm on the monitor screen. The first
microprobe image, defined by a unique code, was then placed on the stage such that
the probe was horizontal to the grid marked on the screen. Background subtractions
were carried out by the computer, with the value of the background reading at each
point being subtracted from the value for each pixel in the microprobe scan. The
corrected image was displayed on the monitor in 16 false colours corresponding to 16
groups of grey scale values. Transverse integration of optical density were carried out
to give a final resolution of 30 pm for each vertical column of pixels across the
restricted part of the field containing the microprobe image 104. For each microprobe
image a plot of optical density (grey scale) against probe length was obtained. Areas
where endogenous peptide had bound to the microprobe were shown by areas of low
optical density.
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Before comparing groups of probes it was necessary to correct for any variations in
density simply due to variations in film exposure. This was done by choosing an area
outwith the cord (thus avoiding the effects of endogenous ligand binding), and
normalising all the probes to the chosen grey scale points over a length of 500 pm.
Any images with obvious artefacts or damage were discarded from the analysis.
Using a sorting program, it was possible to compare the means of defined groups of
microprobes, at 30 pm intervals along the length of the probes. Mean image analyses
were obtained from each group by plotting the mean grey scale value for each 30 pm
interval along with the standard error of the mean, against the depth within the spinal
cord. Pairs of mean image analyses representing different experimental manipulations,
were compared statistically at 30 pm intervals, by calculating the difference between
the two groups at each point. Each site on the probe was treated as being independent
of other sites and thus comparisons between each site could be made. Statistical
significance was assigned to each site using Student's unpaired t-test, and the t values
thus obtained plotted against depth within the spinal cord. The t-test was used as the
data at each point had previously been shown to be normally distributed, although
analysis of variance could also have been used, with similar results. Both the
difference between the two groups and the t values obtained were plotted against
depth within the spinal cord.
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Figure 5: Image analysis set-up
A. The colour monitor displayed the microprobe when it was aligned under the
camera, and illuminated from below. The tip of the probe was seen at the left hand
side of the screen, which was marked off in 1 mm intervals.
B. The light box was powered by a stabilised DC power supply to illuminate each
image with a constant intensity of light.
C. The enclosed camera box was where the microprobe was placed, on top of the
internal stage. The camera was then focused and the image appeared on monitor A.
Probe position was adjusted so that the tip lay on the zero mm mark on the left
hand side of the screen. The door of the box surrounding the camera arrangement
was then closed to reduce levels of incident light and the analysis of optical density
carried out along the length of the probe.
D. The computer monitor displayed the analysed image, The optical density was
represented as a grey scale on the Y axis against the length of the probe on the X
axis. Decreases in grey scale represented decreases in optical density and hence
areas of endogenous peptide binding. The example shown here was typical of a
control in vitro probe that has not been inserted into the cord and thus gave an
indication of the underlying probe shape. The analysis programme could then sort
groups of microprobes, that were plotted out as the mean (+/- s.e.m.) for each
group on a plot similar to that illustrated.
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Figure 5. Image analysis set-up
2.2 Animal Preparation
2.2.1 Preparation of Neuropathic Model
Male Wistar rats (200-320 g), Charles River Ltd, UK) were housed for at least two
days before any handling in order to minimise the effects of stress secondary to
transportation or change of environment. In those rats that were to be subjected to a
nerve injury, behavioural testing was not carried out for the first two days after arrival
in the animal unit.
A peripheral neuropathy was induced using the technique described by Bennett and
Xie, 1988 33. Each rat was anaesthetised with 40-50 mg/kg of intraperitoneal sodium
pentobarbitone, and maintained with supplemental halothane in oxygen, as required,
supplied via a facemask. Full aseptic technique was used for this procedure, which
was carried out in an operating theatre. Apart from the operation site, the rat was
wrapped in insulating material to reduce heat loss. The skin area of the incision was
shaved and thoroughly cleaned with a solution of Hibiscrubb in alcohol (Hospital
Management & Supplies, UK). The sciatic nerve was exposed by an incision at mid
thigh level and gently dissected free of surrounding connective tissue. The nerve was
visualised under an operating microscope at x40 to ensure that four 4/0 chromic gut
sutures were placed loosely around the sciatic nerve, proximal to its trifurcation. The
ligatures were just tight enough not to slide freely on the nerve, but not as tight as to
compromise epineurial blood flow. The tissue was closed in two layers with 4/0
Vicryl® (Ethicon, UK), to reduce tissue reaction to the suture material itself. A
subcuticular stitch was used for the skin in order to try and minimise any gnawing at
the wound or premature removal of stitches. The skin was then cleaned again with a
solution of Elibiscrubb in alcohol. There were no cases of overt wound infection. Rats
were allowed to recover in special cages with solid floors and no sawdust, under a
heat lamp.
After the rats were fully awake, they were housed in solid floor cages in small groups
of three to four, with free access to food and water, under controlled conditions of
light and temperature. The guidelines for the care of experimental animals of the
International Association for the Study of Pain were followed carefully 502. Regular
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monitoring of the rats to ensure that there was no evidence of excessive stress or pain
was carried out daily in the post-operative period. If autotomy of greater than one
proximal phalanx developed the rats were generally euthanased or used in an
experiment that day. Regular behavioural testing was carried out to ensure that all the
animals used in the release experiments did indeed have evidence of neuropathic pain.
This is described in detail in section 3.1. At 10-14 days after ligature placement rats
with behavioural evidence of neuropathic pain were used to study peptide release in
the lumbar spinal cord, as described in Chapters 4 and 5.
2.2.2 Set up for peptide release experiments
Monitoring
Rats were anaesthetised with intraperitoneal urethane (1.25 g/kg) (Sigma Chemicals,
UK). A 25% solution was used, and an induction dose of 0.5 - 0.7 ml/kg was given,
followed by intermittent 0.25 ml increments as clinically indicated. Depth of
anaesthesia was monitored by assessment of blood pressure, respiratory rate, absence
of corneal blink reflex, movement of whiskers and hindpaw withdrawal reflex. The
depth of anaesthesia was monitored regularly and further injections of urethane given
as required. Vital signs were maintained in the physiological range. Continuous
monitoring of blood pressure was commenced after the carotid artery was cannulated
and connected to a pressure transducer, with an intermittent flush system using sterile
Ringer's solution and 0.1% heparin. An external jugular vein was also cannulated to
give intravenous access for warmed maintenance fluids or drugs. Several measures
were taken to reduce heat loss and maintain body temperature between 36-38°C.
Ambient temperature was increased by the use of additional heaters, and the rat was
covered with insulating material. Body temperature was monitored continuously with
a rectal probe, connected to a warming blanket. Any fluids given, including those for
irrigation of the spinal cord were warmed to body temperature. Humidified
supplemental oxygen was given via a T-piece inserted into the trachea, which aided
unobstructed breathing, and allowed removal of excess secretions. If the rat deviated
in any major way from normal physiological cardiorespiratory parameters, or body
temperature dropped below 35°C, the experiment was terminated.
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Surgical preparation
After intravenous and intra-arterial lines had been inserted, the injured sciatic nerve
was exposed by an incision at mid-thigh level and gently dissected free of surrounding
connective tissue. Once the rat was stabilised in the stereotaxic frame, a pool of
warmed paraffin oil was formed around the nerve which was mounted on a platinum
stimulating electrode, proximal to the nerve injury site.
With the rat placed in ventral recumbency, a midline skin incision was made from
thoracic to sacral region of the spine, and the connective tissue and muscle layer from
Til to L5 dissected free of the vertebrae. The animal was supported and stabilised in
a metal frame using bilaterally placed swan necked clamps below three pairs of
transverse processes and ear bars from a separate neck support. The middle clamp
was placed at the level of T13, as determined by the position of the floating rib, with
the upper clamp one level rostrally and the lower clamp two levels caudally. This
arrangement effectively immobilised the spinal cord, allowing accurate probe
placement. Using an operating microscope, a laminectomy from T12 to L2 was
performed to expose the lumbar spinal segments, L2 - L6. The cord was covered
temporarily with cotton wool soaked in warmed sterile Ringers solution. Any bleeding
points from the side of the laminectomy were packed with sterile haemostatic gauze
(Spongel, Houde Laboratories). A pool was formed by suturing the four corners of
the wound to bars on the corner of the frame, and filling with a thin layer of agar in
Ringer's solution (4% w/v, Unipath Ltd, UK). A window was made in the solidified
agar solution over the area of the cord under study, and the dura removed using
sterile watchmaker's forceps. This pool was then irrigated with warmed sterile
Ringer's solution at 37°C, this being removed by intermittent or continuous gentle
suction, thus preventing drying out of the exposed cord, and minimising collection of
any inflammatory exudates at sites of microprobe insertion.
The hindpaw with the dissected sciatic nerve was elevated and immobilised. The nerve
was mounted on platinum stimulating electrodes as described above. The optimal sites
for microprobe insertion in the spinal cord were determined by stimulation of the
sciatic nerve at low intensity (1.5-2T, 1Hz, 0.1ms), and measuring the resultant cord
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dorsum potential at several rostrocaudal sites, using a ball electrode. Microprobes
were then inserted into the area where the largest field potential was measured.
Peptide release
Pairs of probes were inserted into the spinal cord, using two stepping
micromanipulators (PVS, University of Edinburgh). Using the dorsal vein as an
indicator of the centre of the cord, probes were inserted 500 jam from the midline, to
a depth of 2.25 mm. This allowed study of peptide release throughout the dorsal and
ventral horns in the rat. Previous studies in the laboratory have shown that for both
NPY 258 and galanin 168, probes have to be left in the cord for 15 minutes to allow
sufficient peptide - antibody binding to occur at release sites. To minimise the
possibility of cord damage, probes were not inserted into exactly the same spot every
time, but sites over the area measured were sampled during the course of the
experiment. A maximum of ten probes was inserted into any one side of the cord for
each rat. Damage to the spinal cord from excess probe insertion could result in
extracellular release of enzymes from damaged cells, that might cause damage to the
probes. By incubating probes in 125"I F(ab)2 it was possible to demonstrate the
integrity of the antibody coating on the probe surface. It was shown that there was no
evidence of antibody damage using up to ten probes in each side of the cord.
Probes were inserted into right and left sides of the cord alternately. After 15 minutes,
probes were removed from the cord and washed in ice cold PBS-Tween-20 or -80
(depending on peptide) for 15 minutes. Each probe was then inserted into a 5p.l
Sigmacoted capillary tube containing the relevant 1251 peptide, then placed on a tray in
a sealed container, containing PBS-A in the bottom to reduce evaporation, and
prevent the probes drying out. The probes were incubated in the 125"I peptide for a
minimum of 24 hours in the cold room at 4 °C. Next the probes were removed from
the capillary tubes and washed in PBS-A Tween for 15 minutes under suction, in
order to remove any tissue plugs or other debris from the tips. The terminal 1cm of
each probe was then carefully broken from the rest of the probe and stuck to white
cartridge paper using a small amount of white typing correction fluid on the proximal
end. The card obtained from each experiment thus had approximately 26 probes that
had been inserted into the cord, as well as approximately 6 in vitro probes for each
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experiment. These were probes that had not been inserted into the cord, but simply
incubated in radiolabeled peptide. In every other respect they were treated in exactly
the same way as other probes used in the experiment. These probes provided an
estimate of zero endogenous peptide binding, allowing an estimate of basal levels of
neuropeptide in the spinal cord, in the absence of peripheral stimulation. They also
gave an outline of the underlying basic shape of the probes, to allow comparison of
the autoradiographic images. The card with the distal portions of the microprobes was
placed in an X-ray film cassette with a sheet of monoemulsion film (Kodak NMC) for
six to ten days to produce an individual autoradiographic image for each microprobe.
To calibrate microprobe depth accurately within the cord, a microprobe previously
filled with Pontamine Sky Blue was inserted into the cord to a known depth at the end
of each experiment. Current was passed for 5 minutes to eject the dye as an anion
from the probe tip. The rat was then euthanased with an overdose of 2.5 ml of sodium
pentobarbitone (60 mg/ml) via the intravenous cannula. The spinal cord containing the
dye spot was carefully removed and fixed in 25% formaldehyde. The exact position of
the dye spot was measured in post mortem sections of the spinal cord, thus providing
a direct measure of microprobe insertion, and a check on the accuracy of probe
placement.
In those experiments where the effects of high intensity electrical stimulation of the
injured nerve were being studied, neuromuscular blockade was necessary in order to
remove the effects of excess muscle twitching on the stability of the spinal cord. As
there is some evidence of involvement of the sympathetic nervous system in the
development of neuropathic pain, it was desirable not to use any agent that might
have either direct or indirect sympathomimetic effects. For this reason, vecuronium (1
mg/kg) was used as the neuromuscular agent of choice. This was given by repeated
bolus injection, according to Home Office guidelines, as this allowed the assessment
of depth of anaesthesia more effectively. A Harvard Animal Ventilator was used to
ventilate at a rate of approximately 80 breaths / minute to maintain end tidal C02
(Datex Capnograph) at -5%. This was monitored by sampling at the side arm of the
T-piece in the trachea, and supplemental oxygen was administered via the ventilator.
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Chapter 3. Effects of peripheral nerve injury on behaviour
3.1 Introduction
Since pain perception is subjective, there are obvious difficulties with the assessment
of pain in animals. After a partial nerve injury, behavioural signs consistent with a
chronic pain syndrome develop over time, as discussed in Chapter 1. There have been
many tests developed to try and quantitatively assess the presence and degree of pain
in such animals, with tests for mechanical, thermal and chemical allodynia and
hyperalgesia. The degree of involvement of the different modalities varies depending
on the type of nerve injury and the model being studied (see Table 2). Spontaneous
pain, mechanical allodynia and hyperalgesia have been described after a chronic
constriction injury of the sciatic nerve, and were studied here.
Spontaneous pain, arising in the absence of specific stimuli, has been assessed on the
basis of changes in hindpaw position and movement. A modification of the scoring
system used for the formalin test 102 has been adapted for use in neuropathic animals
12. Thus a normal hindpaw position is rated at 0, to a grossly abnormal position, with
the paw elevated and licked, scoring 3. A more precise description of paw posture has
also been used 12 with up to 6 different positions, including ventroflexion of the toes
and eversion of the hindpaw.
Mechanical allodynia is defined as a previously innocuous mechanical stimulus, such
as light touch, being perceived as painful. In previous studies in this laboratory the
Ugo-Basile Analgesymeter (Comerio-Varese, Italy) was used to test for mechanical
allodynia. This device exerts a force that increases at a constant rate, via a dome-
tipped plinth, to the dorsum of the rat hindpaw. It was originally developed by Randall
and Selitto, whereby the threshold for paw withdrawal was used as a measurement for
mechanical hyperalgesia 345, but has since been modified to use the threshold for
vocalisation to increasing force as a measure of mechanical allodynia This avoids
the problem of leg muscle weakness that can occur in nerve injured animals and affect
paw withdrawal ability. It has been shown that training can improve the sensitivity of
testing using an Analgesymeter 404. However, in our hands, a high degree of variability
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with individual animals was found with this device, despite training carried out prior
to the nerve injury. There was also evidence of stress in the animals probably due to
restraint, with hyperventilation, squealing and excess defaecation. For this reason,
testing of mechanical allodynia in the studies described here did not use the
Analgesymeter, but instead used a technique that could be carried out in unrestrained
animals.
Von Frey hairs are a graded series of nylon monofilaments, which allow a quantitative
assessment of sensitivity to touch, as the rat moves unrestrained on a cage floor.
These were used to assess the degree of mechanical allodynia by establishing the
lowest threshold to which the animal withdrew its hindpaw. The rats did not appear to
be unduly stressed by this technique in contrast to the response seen with the
Analgesymeter.
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Table 5 Conversion values for von Frey hairs
This shows the values used to convert the markings on the handle of each von Frey
hair to force in grams exerted by pressure on the plantar surface of the hindpaw.
Theses values are derived from manufacturer's data (Stoelting, WoodDale, 111, USA).
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Table 5 Conversion values for von Frey hairs













Mechanical hyperalgesia is defined as an exaggerated response to a normally painful
stimulus. Assessment of mechanical hyperalgesia is also possible by measuring the
withdrawal response to pin prick or noxious pinch. The effects of a repeated noxious
stimulus on response must be considered, as there is evidence that repeated noxious
stimulation can lead to changes in the spinal cord and, sub-acutely, wind up of the
response 2,464,465. The paw withdrawal duration to pin prick was used in these studies
as a quantitative assessment of mechanical hyperalgesia.
3.2 Methods
All rats that had undergone loose ligation of their sciatic nerve, as described in section
2.2.1, underwent a series of behavioural tests to ensure that study of the spinal cord
changes in these animals was carried out only in rats with definite evidence of
neuropathic pain. Prior to the nerve injury, pre-operative control values were
established. The animals were observed for the three days immediately after nerve
injury, to monitor full recovery from the residual effects of anaesthesia and surgery.
From day three onwards until the day of the acute experiment at 10 - 14 days after
ligature placement, a regular series of tests was carried out. All tests were performed
on individual rats, with the other rats being studied screened from the test area.
The rat was placed on an inverted wire cage lid and allowed to acclimatise,
unrestrained, while being observed for the characteristic changes seen in this model
12,33. The rat tended to hold the injured leg off the cage floor, hopping, with the
hindpaw everted and the toes ventroflexed. Although overt autotomy was rare, in the
first few post-operative days it was not uncommon for one or two of the nails to be
gnawed. If this progressed to damage to the phalanxes, the rat was either euthanased,
using 180 mg/kg of i.p. sodium pentobarbital, or used in an experiment that day.
Once the rats had acclimatised, von Frey hairs (Stoelting, WoodDale, IL, USA) were
used to assess the degree of mechanical allodynia. Starting with a very fine von Frey
hair, inserted through holes in the cage floor, the plantar aspect of each paw was
touched lightly up to five times on each paw or until the animal had exhibited a
withdrawal response. If no withdrawal occurred the next hair up in the series was
used in order to establish the lowest threshold at which paw withdrawal occurred. The
von Frey filaments were labelled as Log 10 of (10 * Force in milligrams). The force
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exerted by each hair is shown in Table 5. The highest value used was 5.88, as after
this the filament was thick enough to lift the hindpaw from the cage floor. The exact
force exerted does vary slightly depending on temperature, humidity and the exact
shape of the cut off end. To minimise variations, the same set of hairs was used for all
testing, which was always carried out in the same environment.
The duration of paw withdrawal to pin prick was used as a measure of mechanical
hyperalgesia 406. The plantar aspect of each hindpaw was touched lightly with a 16G
hypodermic needle, sufficient to indent, but not pierce the skin. Normally a rapid and
transient withdrawal response is elicited, which was estimated at approximately 0.5
sec. The withdrawal response that developed on the side of nerve ligation was much
more prolonged, and often accompanied by licking of the paw or squeaking. The
length of time for which each hindpaw was withdrawn above the cage floor was
measured using a stopwatch. The stimulus was delivered only once to each hindpaw
during any testing session, and the total number of testing sessions was limited. This
was done to avoid any confounding factors that might arise from repeated noxious
stimulation, such as sensitisation or tissue damage.
Statistical comparisons between right (injured) and left (uninjured) hindpaw
withdrawal thresholds and durations were made using a Mann Whitney Rank Sum
Test. Comparisons over time, from pre-operatively to 10- 14 days after nerve ligation
were made using Kruskal-Wallis One Way Analysis of Variance on Ranks. P<0.05
was taken to indicate a statistically significant difference.
Histology
Some basic histology was carried out in addition to the behavioural testing, as a
further confirmation, that in this laboratory, the histological changes expected to be
associated with this model were seen. Thus 10 to 14 days after nerve injury, following
the peptide release experiments and euthanasia of the animal, both the injured and
uninjured sciatic nerves were dissected out and placed in formalin. An example of the
gross specimen with the four loose ligatures around it is shown in Figure 6. The
histology laboratory of the Dept of Preclinical Sciences sectioned the injured and
uninjured nerves, and stained the sections for myelin with solochrome cyanin 3j0. A
typical example of this is shown in Figure 7.
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Figure 6 Specimen of sciatic nerve excised after chronic
constriction injury
This shows a typical example of a sciatic nerve that was excised 12 days after four
loose ligatures were placed around it, as described in section 2.2.1. There was
extensive fibrosis around the site of the ligatures, and when these were removed there




Figure 7. Sections from normal and ligated sciatic nerves
A. This shows a typical example of a transverse section taken from a sciatic
nerve that had not been subjected to loose ligation. With solochrome cyanin,
myelin shows up as a deep purple colour, that can been seen extensively
throughout the section.
B. This is a section taken distal to the nerve injury site, 12 days after 4 loose
ligatures were placed around the sciatic nerve. When compared to the
section from normal nerve it is apparent that there is extensive loss of myelin.
This corresponds well to the descriptions of changes occurring after this type




The characteristic changes in gait and hindpaw position were apparent in all animals
from day three after ligature placement. A limp was evident and the paw held such
that only the medial aspect touched the cage floor when walking. The foot was
everted with the toes tightly ventroflexed, and there was evidence of abnormal
grooming behaviour.
Von Frey hairs
The pre-operative control values of right and left hindpaws were virtually identical.
However, from day 3 after loose ligation of the right sciatic nerve, a highly significant
difference was detected between right and left hindpaws at each time point tested with
a Mann Whitney Rank Sum test (p<0.0001). The values obtained at each time point
are shown in Figure 8. Using Kruskal-Wallis One Way Analysis of Variance on
Ranks, there was found to be a highly significant difference (p<0.0001) between the
median pre-operative paw withdrawal threshold and each post operative time point
tested for the right side (i.e. the side of nerve injury). The values for the left side
remained relatively constant during the study period.
Pin Prick
The pre-operative control values between right and left hindpaws were essentially
identical. At the time points tested in the post -operative period, there was a highly
significant difference (p<0.0001) between right and left hindpaws as tested by a Mann
Whitney Rank Sum test, and between pre-and post-operative values for the right
hindpaw, as tested by Kruskal-Wallis One Way Analysis of Variance on Ranks. The
mean values (+/-s.e.m.) are shown in Figure 9.
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Figure 8 Response to von Frey hairs
A. The mean values +/- standard error of the mean (s.e.m.) for the paw withdrawal
thresholds to von Frey hairs (grams) is shown for right and left hindpaws during
the duration of the study period. The right side was the side of the loose ligation of
the sciatic nerve, whereas the left side was unoperated. ** indicates where
p<0.0001, for a difference between right and left sides, and from pre-operative
control values.
B. The mean values (+/- s.e.m.) for paw withdrawal threshold to von Frey hairs
(grams) are shown for each hindpaw from the pre-operative period until the day of
experiment at 10-14 days after nerve injury.
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A
Response to von Frey hairs - Paw withdrawal threshold (g)
(n=48)





pre-op(control) 68.4+/- 2.8 68.4 +/- 2.8
Day 3-4 5.5 +/- 0.4** 64.7 +/- 3.3
Day 6-8 3.0 +/- 0.3** 67.8 +/- 3.0
Day 10-14 2.3 +/- 0.1** 66.0 +/- 3.1
B
Number of days after nerve injury
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Figure 9. Response to pin prick
A. The mean values +/- standard error of the mean (s.e.m.) for the paw withdrawal
duration to pin prick (s) are shown for right and left hindpaws during the study
period. The right side was the side of the loose ligation of the sciatic nerve,
whereas the left side was unoperated. ** indicates where p<0.0001, for a
difference between right and left sides, and from pre-operative control values.
B. The mean values (+/-s.e.m.) for paw withdrawal duration to pin prick (s) are
shown for each hindpaw from the pre-operative period until the day of experiment
at 10-14 days after nerve injury.
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Figure 9. Response to pin prick
A
Response to pin prick - Paw withdrawal duration (s)
(n=48)
RIGHT: Mean +/- LEFT: Mean +/-
No. of days after nerve injury s.e.m. s.e.m
pre-op(control) 0.5 +/- 0 0.5 +/- 0
Day 3-4 14.9+/- 1.7 0.5+/-0
Day 10-14 15.7+/- 1.5 0.5+/- 0
B
Pre-op Day 3-4 Day 10-14
Number of days after nerve injury
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3.4 Discussion
A potential problem with behavioural testing is the effect of the testing itself -
confounding factors such as training, acclimatisation and differing conditions for the
test can all alter the sensitivity of the test. Those tests which are least invasive and
cause least stress in the rats would therefore seem to have an advantage over other
tests.
For tests measuring a withdrawal response the degree of motor nerve injury involved
may alter the result. For example, in the chronic constriction injury model it is mainly
large diameter fibres that are damaged, a significant proportion of which must be of
motor origin. It is known that there is a reduction in weight gain in these animals; this
could either be due to anorexia secondary to pain, or to the muscle wasting that can
be seen on the side of nerve injury. There is also evidence that in the spinal nerve
ligation model, both motor and sensory changes are involved in the abnormalities in
hindpaw position, although at least some of the behavioural changes seen have a
major sensory component, possibly related to pain j05.
Tests measuring a response to thermal stimuli may be affected by changes in blood
flow and skin temperature, as well as the thermal properties of the surface on which
the rat is placed. Thus as well as keeping ambient temperature constant during the
period of behavioural testing, factors altering vasomotor tone must be minimised 165.
There is evidence that in the chronic constriction injury model there are unpredictable
changes in skin temperature and vasomotor tone both on the side of the nerve injury
and also on the contralateral hindpaw 32-218'436; thus making interpretation of thermal
tests more difficult. Additionally, tissue damage from repeated noxious testing must
be avoided, as the response in these circumstances does not reflect the initial nerve
injury alone, but subsequent damage.
The interaction between spinal cord and higher centres may also alter the response
seen. Noxious thermal stimulation of a hindpaw can decrease the response seen in the
tail flick reflex. This seems to be mediated by a heterosegmental route, part ofwhich
is supraspinal, as it does not occur in spinalized rats 3j9. Variations in degree of
arousal can alter the baseline response, for example as occurs with stress-induced
analgesia40.
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Another problem after nerve injury is the change in peripheral receptive fields that
occurs, with the development of extra-territorial pain, thus making it harder to assess
the nerve being tested. In the chronic constriction injury model, there is evidence of
mechano-allodynia and hyperalgesia in the distribution of the saphenous (branch of
the femoral nerve) as well as the sciatic nerve, that was abolished by acute sciatic
nerve transection 406.
Despite all these factors, behavioural testing can be used to test for the development
of signs of sensory disorders after nerve injury. Additionally, depending on the test
used, quantitative assessment can be made, thus allowing comparison between animals
as well as measuring the effects of specific interventions. The purpose of carrying out
the tests described here was to ensure that the rats with loose ligation of one sciatic
nerve did indeed develop behavioural evidence of neuropathic pain. These behavioural
studies provided qualitative evidence of spontaneous pain and quantitative evidence of
mechanical allodynia and hyperalgesia. Thus, conclusions drawn from further studies
of peptide release in the spinal cord were based on rats with behavioural changes
associated with pain-related behaviour. In addition, the well-described histological
changes in the ligatured nerve were also present in those rats studied 23'297.
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Chapter 4 - Studies of the spinal release of galanin
4.1 Introduction
Previous work from this laboratory found an extensive basal release of ir-galanin in
the spinal cord of the normal rat 168. Neither innocuous or noxious peripheral
stimulation resulted in changes in spinal ir-galanin release I68'292. The likely origin of
this basal presence of ir-galanin was, therefore, either from intrinsic neurones of the
spinal cord or of supraspinal origin, rather than from primary afferent fibres. This
would correlate with results from immunohistochemical studies that have found
significant amounts of galanin in the dorsal horn 56'214'497; but low levels in primary
afferent neurones 16U63-425.
After sciatic nerve transection, galanin production increased in mainly small to
medium sized primary afferent cells of the dorsal root ganglia 164,495, with an
associated increase in galanin-ir in the superficial dorsal horn 493. In the CCI model, a
similar increase in galanin synthesis by primary afferent neurones was found 308, with a
corresponding increase in galanin-ir in the ipsilateral dorsal horn 252 The effect of
peripheral nerve injury on the spinal release of ir-galanin under basal or evoked
conditions, is not known.
The present experiments were therefore carried out to address directly the question of
what changes occur in the central release of ir-galanin in the spinal cord of rats after a
peripheral nerve injury.
Three series of experiments were carried out on spinal ir- galanin release:
1. Ir-galanin release was studied in the spinal cord of normal and neuropathic rats
under basal conditions; to determine the effect of the nerve injury itself on ir-
galanin release and allow comparison with the normal situation.
2. The effect of peripheral electrical stimulation of the injured nerve on the spinal
release of ir-galanin was studied, in order to define the necessary stimuli required
(if any) to alter spinal ir-galanin release.
3. Input from the injured nerve was blocked to determine the effect of altered input
secondary to the nerve injury, on spontaneous ir-galanin release.
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4.2 Materials and methods
4.2.1 Animal Preparation
General
The studies were carried out under Home Office Licence No PPL 60/1146, and the
guidelines for the care of experimental animals set out by the International Association
for the Study of Pain were followed carefully 502.
A total of 53 male Wistar rats (Charles River Ltd, UK), 240 g to 380 g were used in
the ir-galanin release studies. Of these, 7 did not undergo a peripheral nerve injury,
but were used as controls to determine the basal presence of ir-galanin in the spinal
cord of normal rats, thus allowing comparison of basal levels of ir-galanin between
normal and neuropathic rats.
A peripheral nerve injury was induced according to the model of Bennett and Xie 33,
as described in section 2.2.1. Following this, all rats were monitored to ensure
adequate wound healing, without infection, and underwent the behavioural tests
outlined in chapter 3. All rats used in ir-galanin release studies had behavioural
evidence of spontaneous pain and mechanical allodynia and hyperalgesia. For the ir-
galanin release experiments, carried out at ten to fourteen days after ligature
placement, the standard experimental set up outlined in section 2.2.2 was used.
Microprobes were inserted into both sides of the cord and left in place for fifteen
minutes to allow adequate binding of any extracellular galanin present in the cord, as
described in section 2.1.5. Previous studies in the laboratory have shown this length of
time to be optimal for binding of released ir-galanin 168. Following removal from the
spinal cord, microprobes were washed in cold phosphate-buffered saline containing
0.1% Tween 80 to reduce levels of non-specific binding and then incubated for 24
125
hours at 4 °C in a solution of radiolabeled I galanin. After further washing in 0.1%
Tween 80, the distal portions of microprobes were placed in an X-ray film cassette
with a sheet of monoemulsion film (Kodak NMC) for eight to ten days to produce an
individual autoradiographic image of each microprobe.
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Stimulation experiments
In those experiments where the effects of peripheral electrical stimulation on ir-
galanin release was being studied, a platinum stimulating electrode was used proximal
to the ligatures. Before any stimulus had been delivered, six to eight antibody-coated
microprobes were inserted into the spinal cord to a depth of 2.25 mm, as described in
section 2.2.2, to confirm basal levels of galanin. This was followed by peripheral
electrical stimulation in order to activate large myelinated fibres. Microprobes were
inserted during stimulation and for the following two hours to measure any
persistence of stimulus-released ir-galanin. This was followed by higher intensity
stimulation to activate small myelinated and unmyelinated fibres as well. Again
microprobes were inserted during and after stimulation for up to two hours. The
stimulus parameters used were:
1. Stimulation of large myelinated fibres at 2 Hz, 3 x threshold, 0.1 ms pulse duration,
for a period of 15 minutes;
2. Additional stimulation of small myelinated and unmyelinated fibres at 2 Hz, 50 x
threshold, 0.1 ms pulse duration, for a period of 15 minutes.
In those animals where paralysis was required, during stimulation of C fibres,
vecuronium (1 mg/kg) provided neuromuscular blockade and a Harvard Animal
Ventilator was used to ventilate at a rate of approximately 80 breaths/minute. This
minimised the effects of high intensity stimulation-induced muscle twitching on
movements of the microprobes within the spinal cord.
The initial study on basal levels of ir-galanin, outlined in section 4.3.2, showed no
effect of peripheral nerve injury on spontaneous ir-galanin release in the spinal cord
contralateral to the side of injury 74. Thus, microprobes inserted into the contralateral
side of the cord could be used as controls for microprobes inserted ipsilateral to the
nerve injury.
Blocking peripheral input
In order to investigate the effect of spontaneously firing injured primary afferent fibres
on basal ir-galanin release, electrical input from the injured nerve was blocked in two
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stages, using amethocaine gel 4% w/v (Smith & Nephew Healthcare Ltd, Hull, UK).
Prior to application of amethocaine gel, six to eight microprobes were inserted under
basal conditions to confirm previous results and give a definitive pre-intervention level
for comparison. This was followed by placement of a piece of polyethylene tubing
around the nerve, proximal to the site of the chronic constriction injury. This was cut
to 1 cm in length and had a diameter of 5 mm, with a slit down one side to allow
application around the nerve. Once the tubing was in place, ~0.1 ml amethocaine gel
was injected into the tube in order to block neuronal conduction from the nerve injury
site. The tube was used to try and minimise any effects from spread of the local
anaesthetic and systemic absorption from the muscle vasculature around the sciatic
nerve. This was left in place for a minimum of 30 minutes, before the adequacy of
conduction block was checked, as described below. Once peripheral conduction was
blocked, four pairs of antibody-coated microprobes were inserted into the spinal cord
in sequence.
Blocking input from the dorsal root ganglia
The laminectomy was extended distally and laterally to expose the dorsal roots L3-S2.
These were gently mobilised using a fine blunt probe, and a small piece ( ~0.5 x 1 cm)
of black polythene inserted under the dorsal roots. This allowed the application of
~0.1 ml amethocaine gel around the dorsal roots without any of it contacting the
spinal cord itself, so that the effect of peripheral, and not central, conduction block
could be studied. In addition, sealant gel was used around the edges of the polythene
to prevent leakage of the amethocaine gel pool from the dorsal roots onto the spinal
cord. Continuous irrigation of the cord with warmed sterile Ringer's solution was
suspended during this period to prevent washing the local anaesthetic onto the cord.
Instead irrigation was carried out intermittently with warmed sterile Ringer's solution,
and intermittent suction.
A minimum of 30 minutes was allowed after application of the amethocaine gel at
both peripheral and proximal sites. A preliminary study had been carried out to
determine the most effective type of local anaesthetic and the length of time necessary
for adequate conduction block. Amethocaine gel was found to be superior to
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solutions of 2% lignocaine, 0.25-0.75% bupivacaine and EMLA ® cream (Eutectic
Mixture of Local Anaesthetic, Astra Pharm, UK), as it produced the quickest onset of
block, and one that was sufficiently prolonged for the study duration.
Thus, prior to inserting any microprobes after conduction block, the adequacy of the
block was checked. The injured nerve was stimulated peripherally at high intensity,
distal to local anaesthetic, and the resultant activity evoked within the cord measured
using a silver ball electrode on the cord surface as described in section 2.2.2. Provided
no activity was detected, microprobes were then inserted into the cord to measure the
effect of blocking conduction from the injured nerve on ir-galanin release. If activity
was detected, more amethocaine gel was applied, and the preparation was left for a
further 30 minutes to allow adequate diffusion of the local anaesthetic to its site of
action.
By applying the amethocaine gel in two stages, it was possible to differentiate the
relative contributions, if any, of spontaneous ectopic neuronal activity from either the
nerve injury site or the dorsal root ganglia 190'407'441 to the increased spontaneous
release of ir-galanin.
4.2.2 Antibody microprobe preparation 1CH107
Materials
Using the standard technique described in section 2.1 for antibody microprobe
preparation, fine glass micropipettes, with a tip diameter of approximately 10pm,
were coated with rabbit anti-rat galanin antiserum. Such coated microprobes can bind
endogenous galanin, at localised sites of release, that is detected by subsequent
inhibition of binding of exogenous radiolabelled l25I galanin (Peninsula, CA).
Two suppliers were used for the galanin antiserum - Peninsula Laboratoreis,
California, USA supplied the antiserum used in the study of basal and stimulated ir-
galanin release, and Advanced Chemtech, Kentucky, USA supplied the galanin
antiserum used in the study of ir-galanin release after conduction block from the
injured nerve. This was because the original lot number supplied by Peninsula
Laboratories was no longer available when the conduction block study was carried
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out, and the new lot number supplied by them did not meet the requirements of the in
vitro assays (as outlined in section 2.1.4), such that this batch had to be discarded.
The galanin antiserum supplied by Advanced Chemtech did meet the requirements for
in vitro assays.
In vitro tests
Prior to commencing in vivo work, in vitro assays were carried out to determine the
specificity and sensitivity of the immobilised galanin antibody by measuring the degree
of inhibition of 125I galanin binding by related peptides or varying concentrations of
unlabelled galanin. The procedure used for in vitro assays is outlined in section 2.1.4
and Figure 4. In vitro assays were carried out for each new batch of galanin
antiserum, and continued in parallel with in vivo work to ensure no major
deterioration in the assay. Sensitivity was determined by incubating microprobes in a
range of unlabelled galanin peptide from 10"5M to 10"8M prior to incubation in 125I
galanin. Specificity values were supplied by the manufacturer's data, but these were
checked by incubation of microprobes in 10"5M to 10"6M SP, VIP and NPY.
4.2.3 Analysis of Microprobes 160
The principles of image analysis are described in section 2.1.6. Basically, a
computerised image analysis system was used to analyse the autoradiographic images
obtained from galanin antiserum-coated microprobes inserted into the spinal cord. In
vitro microprobe images for each experiment were also analysed as controls. Binding
of endogenous galanin resulted in deficits in binding of l25I-labelled galanin that were
detected as localised decreases in optical density by the analysis system. For each
microprobe, a plot of grey scale (i.e. total optical density) against depth of the probe
in the spinal cord was obtained. Thus areas where endogenous galanin had bound to
the microprobe were shown by areas of low optical density and a low grey scale
value.
A grey scale range of 50 points on the probe were chosen outwith the spinal cord as
the site for normalisation of each series of experiments. This allowed comparison of
probes that might otherwise have had minor variations in optical density due to
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exposure time, rather than biological variation. An example of the plot used to
determine the normalisation point is shown in Figure 10. The mean values for defined
groups of microprobes, were plotted as the means (+/- s.e.m.) of the grey scale values
at 30 p.m intervals against the depth within the spinal cord. Statistical significance was
assigned to each site using Student's unpaired t-test, and the t values thus obtained
plotted against depth within the spinal cord. A p value of less than 0.05 was taken as
showing a statistically significant difference between groups.
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Figure 10. Mean image analysis of microprobes prior to
normalisation
The mean image analysis (+/- s.e.m.) of all probes used to measure ir-galanin release
under basal conditions (n=268) is plotted. In order to allow valid comparisons
between groups of microprobes, is necessary that all probes are normalised to an
identical optical density outwith the cord. If this were not done, a difference in optical
density between groups of probes could be due to variations in the exposure of the X-
ray film, rather than a true biological difference in ir-galanin release. As shown at (a),
a normalisation point well outwith the cord was chosen. All probes were normalised
to the optical density measured from point (a), and for 50 analysis points from here
(i.e. 500 pm) along the probe length. All further analysis was done on normalised
data.
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4.3 Results
4.3.1 In vitro testing
The galanin antibody used was C-terminus directed and showed minimal cross
reactivity with other peptides found in the dorsal horn (according to manufacturer's
data and confirmed by in vitro testing). Sensitivity tests found suppression ofbinding
of radiolabeled galanin ranging from approximately 90% with 10"5 M galanin to
approximately 50% suppression with 10"8M galanin, indicating that the sensitivity of
the galanin antibody was adequate to detect significant areas of galanin release in the
spinal cord. Levels of non-specific binding of the radiolabeled galanin to the
microprobes were assessed by measurement of the degree of binding to probes not
coated in galanin antibody, but simply coated in protein A. The level of binding to
such probes was in the region of 10% of control counts, thus suppression at a level
greater than 10% can be assumed to de due to galanin-galanin antibody binding. To
check the adequacy of the antibody coating of the microprobes, one group was
incubated in 1251 Fab instead of1251 galanin (see section 2.1.4). Both antibodies used
showed evidence of good coating of the probes. The results of in vitro testing from
the two batches of galanin antisera ( one from Peninsula Labs and one from Advanced
Chemtech) are shown in Tables 6 and 7. Although the control counts were higher
with the Advanced Chemtech antiserum, the sensitivity and specificity of the two
different galanin antisera used did not vary significantly.
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Table 6. In vitro assay using galanin antiserum from Peninsula
Labs.
This shows the results from microprobes used in in vitro assays to ensure adequate
sensitivity and specificity of the galanin antibody coating on the microprobes. Low
levels of non-specific binding are also demonstrated, and good antibody coating of the
probes, as shown by the high counts obtained with those probes incubated in 1251 Fab.
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Control (109) 774 (+/-40)
10"5 M galanin (76) 80 (+/-9) 90
10"6 M galanin (10) 155 (+/-26) 80
10"7 M galanin (49) 298 (+/-17) 62
10"8 M galanin (34) 348 (+/-46) 55
10"5 M SP (5) 1364 (+/-80) +75
10"5 M VIP (17) 800 (+/-75) +3
10"5 M NPY (17) 886 {+1-11) +14
1251 Fab (8) 1041 (+/-73) +35
Protein A (18) 81 (+/-19) 10 (non-specific binding, %
of control)
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Table 7. In vitro assay using galanin antiserum from Advanced
Chemtech
This demonstrates similar in vitro assay to those outlined in Table 6, but using a
galanin antiserum from a different manufacturer.
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Table 7. In vitro assay using galanin antiserum from Advanced
Chemtech
Group (number of Mean corrected % suppression of
probes) c.p.m. (+/-s.e.m.) control group
Control (33) 1709 (+/-130)
10"5 M galanin (32) 182 (+/-42) 90
10"6 M galanin (15) 396 (+1-31) 77
10"7 M galanin (9) 431 (+/-117) 75
10"8 M galanin (9) 900 (+/-130) 47
10'5 M SP (6) 1923 (+/-120) + 12
10"5M VIP (9) 1777 (+1-331) +4
10'5MNPY (9) 1885(+/-305) + 10
1251 Fab (6) 1645( +/-104) 9
Protein A (8) 126 (+/-15) 7 (non-specific binding, %
of control)
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4.3.2 Basal ir-galanin release
A total of 31 rats were used to determine the basal release of ir-galanin in normal (7)
and neuropathic (24) rats. All rats used with a chronic constriction injury of the right
sciatic nerve had behavioural evidence of spontaneous pain, mechanical allodynia and
hyperalgesia on the side of nerve injury, as described in chapter 3. A total of 268
probes were inserted into the spinal cord, with a further 187 probes being used as in
vitro controls. These in vitro microprobes had been prepared concurrently with the in
vivo probes, but had not been inserted into the central nervous system. Instead, they
were washed in 0.1% Tween 80, then incubated in 1251 galanin, thus representing zero
endogenous galanin binding.
Microprobes were inserted into both sides of the spinal cord of normal rats in the
absence of peripheral stimulation (n=57). Comparison of the mean image analyses of
these two groups showed no difference in basal ir-galanin release between the right
and left side of the spinal cord. Thus both sides of the spinal cord showed extensive
basal ir-galanin release in the dorsal and ventral horns, when compared to in vitro
microprobes (n=187). The area of ir-galanin release in the spinal cord of normal rats is
shown in Figure 11. This confirms previous results in the rat from this laboratory 168
and studies from elsewhere in the cat 292, that have also shown no effect of peripheral
stimulation on central ir-galanin release. There was no significant difference between
the pattern of ir-galanin release on the right and left sides of the spinal cord in these
normal rats.
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Figure 11. Basal release of ir-galanin in the spinal cord of
normal rats.
A. The mean image analysis of two groups of microprobes are plotted with respect to
length: the in vitro microprobe group have not been inserted into the cord, but the
equivalent length to microprobes used in vivo has been analysed to allow
comparison. The optical density is represented by the grey scale (y axis), with any
decrease in optical density (as shown by an upward deflection) indicating the
binding of endogenously released ir- galanin to antibody-coated microprobes in the
spinal cord. Each line is made up of the mean image analyses at 30 pm intervals
along the length of the microprobe. The dotted line adjacent to the solid line for
each group is the standard error of these means (s.e.m.). The two groups are the
mean image analysis (-s.e.m.) of the in vitro microprobes (n=187) and the mean
image analysis (+s.e.m.) of microprobes inserted into the spinal cord for 15 minutes
without any concurrent peripheral stimulus (n=57). All microprobes were coated
with galanin antiserum (Peninsula Labs, Ca, USA).
B. The right hand side of the diagram is a plot of the t statistics derived from
comparison of the means at each analysis point in the mean image analyses shown
in A. This is related to an outline of the spinal cord (modified from Molander, 1984
287) on the left hand side, to give an indication of the sites of ir-galanin release. The
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In neuropathic rats, there was found to be no significant difference between spinal ir-
galanin release contralateral to the nerve injury, compared to ir-galanin release in
normal rats. The mean image analysis of microprobes (n^S) inserted into the spinal
cord of normal rats and the mean image analysis of microprobes (n-50) inserted into
the side of the spinal cord contralateral to the nerve injury, in neuropathic rats, were
not significantly different. Thus, the initial extensive basal release of ir-galanin seen in
the spinal cord of normal rats was unchanged in the spinal cord of neuropathic rats,
contralateral to the peripheral nerve injury. This is shown in Figure 12.
By contrast, an increase in spontaneous ir-galanin release was detected with a peak in
the superficial dorsal horn ipsilateral to the side of nerve injury, both when compared
to the release pattern found in normal rats, and to that seen in the side of the cord
contralateral to the nerve injury (see Figure 13). This area of increased basal ir-galanin
release is in the same area as the termination of the small to medium sized primary
afferent fibres, that start synthesising galanin after nerve injury 164-j08'j16'495
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Figure 12. Basal ir-galanin release contralateral to a
peripheral nerve lesion
A comparison was made between microprobes inserted into the spinal cord of normal
rats to microprobes inserted into the spinal cord contralateral to the side of nerve
injury in neuropathic rats, in the absence of any active peripheral stimulation.
A. The mean image analysis (- s.e.m.) of microprobes (n=58) inserted into the spinal
cord of normal rats and the mean image analysis (+ s.e.m.) of microprobes (n=l 12)
inserted into the left side of the spinal cord, contralateral to the nerve injury, for 15
minutes without any concurrent peripheral stimulus. The two groups are plotted
with respect to depth of insertion into the spinal cord, with the cord surface being
on the right hand side of the diagram.
B. The differences between the two groups of microprobes are shown as the t
statistics relative to depth in the spinal cord. At no point along the length of the
probe was there any significant difference between the two groups.
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Figure 13. Basal ir-galanin release ipsilateral to a peripheral
nerve lesion
A comparison was made between microprobes inserted into the ipsilateral and
contralateral side of the spinal cord of neuropathic rats.
A. Microprobes were inserted into the spinal cord of neuropathic rats for 15 minutes
without any concurrent peripheral stimulus. The plot shows the mean image
analyses (+/-s.e.m.) of microprobes inserted into the ipsilateral (n=121) and
contralateral (n=l 12) sides of the spinal cord relative to the nerve injury, which is
on the right side. The microprobes inserted on the ipsilateral side are displaced
above those inserted into the contralateral side, indicating a new zone of ir-galanin
release under basal conditions.
B. The differences between the ipsilateral and the contralateral groups of microprobes
are shown as the t statistics relative to depth in the spinal cord. The hatched area
shows where there is a significant increase (p<0.05) in spontaneous ir-galanin
release in the superficial dorsal horn.
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4.3.3. Evoked ir-galanin release
A total of 12 neuropathic rats (240-350 g) were used to study the effects of peripheral
stimulation on spinal release of ir-galanin. A total of 195 microprobes coated with
galanin antiserum were inserted into the spinal cord, with a further 48 microprobes
used as in vitro controls, so that basal ir-galanin release could be detected.
Basal ir-galanin release
The mean image analyses of microprobes inserted into both sides of the spinal cord in
the absence of any active peripheral stimulation were studied to confirm previous
results and give a level for basal ir-galanin release with which to compare the effects
of peripheral stimulation. The increased area of ir-galanin release, in the superficial
dorsal horn, seen previously was again found, as shown in Figure 14.
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Figure 14. Effects of peripheral nerve injury on basal ir-galanin
release.
This confirmed the previous finding (see Figure 13) of an increase area of
spontaneous ir-galanin release in the superficial dorsal horn on the side of a peripheral
nerve injury. The results are from microprobes inserted into the spinal cord of
neuropathic rats prior to peripheral nerve stimulation. This was done to ensure that
the same in crease in spontaneous ir-galanin release was found in those rats being
studied in stimulation experiments.
A. The plot shows the mean image analyses (+/-s.e.m.) of microprobes inserted into
the spinal cord, ipsilateral (n=T8) and contralateral (n=17) to the nerve injury. The
mean image analysis of microprobes inserted on the ipsilateral side is displaced
above that from microprobes inserted into the contralateral side, indicating an
increase in ir-galanin release under basal conditions.
B. The differences between the ipsilateral and the contralateral groups of microprobes
are shown as the t statistics relative to depth in the spinal cord. The hatched area
shows where there was a significant increase (p<0.05) in spontaneous ir-galanin
release in the superficial dorsal horn.
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Ir-galanin release evoked by A fibre stimulation:
Peripheral electrical stimulation sufficient to activate only large myelinated fibres in
the injured nerve did not alter the release of ir-galanin in the spinal cord. Thus, the
increased area of ir-galanin release detected ipsilateral to nerve injury was still present,
but not increased by A fibre stimulation. The mean image analyses of microprobes
inserted into the right side of the spinal cord (ipsilateral to the nerve injury) prior to
(n=18) and during (n=8) 15 minutes of electrical stimulation at 3T, 2 Hz, 0.1 ms pulse
duration, are shown in Figure 15. Thus, electrical stimulation of the injured nerve at a
stimulus strength sufficient to activate mainly A(3 fibres did not alter the release
pattern of ir-galanin in the spinal cord from that seen in the basal state.
No change in the pattern of ir-galanin release from that found under basal conditions
was seen on the contralateral side of the cord during electrical stimulation of AP fibres
in the injured nerve. This is shown in Figure 16. After electrical stimulation of the
injured nerve had ceased, further microprobes inserted into both right (n=33) and left
(n=32) sides of the spinal cord for the next two hours did not show any change in ir-
galanin release from basal levels, indicating that there was no delayed effect of
peripheral stimulation at low intensity, or change in ir-galanin release with time.
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Figure 15. Effect of A fibre stimulation on ir-galanin release
ipsilateral to peripheral nerve lesion
Microprobes were inserted into the spinal cord during 15 minutes of peripheral nerve
stimulation sufficient to activate large myelinated fibres (2 Hz, 3 x threshold, 0.1 msec
pulse duration). The stimulating electrode was placed proximal to the site of the
chronic constriction injury.
A. The mean image analyses (+/- s.e.m.) of microprobes inserted into the side of the
cord ipsilateral to nerve injury under basal conditions (n=18) and during peripheral
stimulation sufficient to activate only large myelinated fibres (n=8).
B. The t statistics obtained from comparing these two groups at 30 pm intervals along
the length of the microprobes are plotted alongside a diagram of the lumbar spinal
cord. At no point was there any significant difference between the 2 groups.
134
Depth within the spinal cord (mm)
B
135
Figure 16. Effect of A fibre stimulation on ir-galanin release
contralateral to peripheral nerve lesion
Using an electrode proximal to the nerve injury site, microprobes were inserted into
the spinal cord during 15 minutes of peripheral nerve stimulation sufficient to activate
large myelinated fibres (2 Hz, 3 x threshold, 0.1 msec pulse duration).
A. The mean image analyses (+/- s.e.m.) of microprobes inserted into the side of the
cord contralateral to nerve injury under basal conditions (n= 17) and during
peripheral stimulation sufficient to activate only large myelinated fibres (n=10).
B. The t statistics obtained from comparing these two groups at 30 pm intervals along
the length of the microprobes are plotted alongside a diagram of the lumbar spinal
cord. At no point was there any significant difference between the 2 groups. This
indicates that stimulation of the injured nerve at this strength did not have any
effect on the release of ir-galanin on the side of the spinal cord contralateral to
nerve injury.
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Ir-galanin release evoked by A plus C fibre stimulation
A minimum of two hours after A fibre stimulation, a further 15 minute electrical
stimulus was delivered to the injured nerve. This was of a much higher intensity than
used previously, sufficient to activate both myelinated and unmyelinated fibres (2 Hz,
50T, 0.1 ms). The mean image analyses of microprobes inserted into the spinal cord
without any concurrent peripheral stimulus was compared with that of microprobes
inserted during 15 minutes of high threshold electrical stimulation of the injured nerve
as shown in Figures 17 and 18. Ir-galanin release was increased by this stimulus, on
the side ipsilateral to nerve injury, with a peak in the superficial dorsal horn, with
slightly deeper spread. This occurred in a similar area to the increased spontaneous ir-
galanin release found in neuropathic rats as compared to normal rats. As this increase
in ir-galanin release occurred in the area where the small primary afferent fibres
terminate, it would be consistent with the hypothesis that the source of the new area
of ir-galanin release in neuropathic rats was from small primary afferent fibres. High
threshold peripheral nerve stimulation did not increase the basal pattern of ir-galanin
release on the contralateral side of the spinal cord. Indeed, at one point on the analysis
there was a significant decrease in ir-galanin release on the side contralateral to high
intensity stimulation of the injured nerve.
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Figure 17. Effect of A + C fibre stimulation on ir-galanin
release ipsilateral to peripheral nerve lesion
Ir-galanin release was studied during electrical stimulation of the injured nerve at a
stimulus strength sufficient to activate Ap, A5 and C fibres on (2 Hz, 50T, 0.1 ms)
were studied. Microprobes were inserted into the side of the spinal cord ipsilateral to
nerve injury for 15 minutes prior to and during peripheral electrical nerve stimulation.
A. The plot shows the mean image analyses (+/-s.e.m.) of microprobes inserted into
the spinal cord before (n=l 8) and during (n=9) electrical stimulation of the injured
nerve. At some points within the cord, the mean image analysis of microprobes
inserted during stimulation is displaced above that of microprobes inserted before
stimulation.
B. The differences between the basal and stimulus groups of microprobes are shown
as the t statistics relative to depth in the spinal cord. The hatched area shows where
there is a significantly (p<0.05) increased zone of ir-galanin release evoked by high
threshold stimulation sufficient to activate both myelinated and unmyelinated
fibres.
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Figure 18. Effect of A + C fibre stimulation on ir-galanin
release contralateral to peripheral nerve lesion
Microprobes were inserted into the side of the spinal cord contralateral to nerve injury
for 15 minutes prior to and during peripheral electrical nerve stimulation at a stimulus
strength sufficient to activate Ap, AS and C fibres on ir-galanin release (2 Hz, 50T,
0.1 ms).
A. The plot shows the mean image analysis (+/-s.e.m.) of microprobes inserted into
the spinal cord before (n=17) and during (n=10) electrical stimulation of the injured
nerve. At some points within the cord, the mean image analysis of microprobes
inserted during stimulation is displaced below that of microprobes inserted before
stimulation.
B. The differences between the basal and stimulus groups of microprobes are shown
as the t statistics relative to depth in the spinal cord. At no point did high threshold
stimulation, sufficient to activate both myelinated and unmyelinated fibres, increase
ir-galanin release on the contralateral side of the spinal cord. In fact, there is a
suggestion that there is actually a decrease in ir-galanin release, this reaching
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Persistence of evoked ir-galanin release
The mean image analysis of microprobes inserted into both sides of the spinal cord, at
15 minute intervals, for up to 2 hours after peripheral stimulation ceased, was
compared to that of microprobes inserted under basal conditions. This is shown in
Figures 19 and 20. During the time period studied there was no evidence of any
persistence of the evoked ir-galanin ipsilateral to nerve injury. This remained the case
even microprobes were split into groups of each individual 30 minute time period,
from immediately after stimulation to 2 hours later. There was a persistent point of
significantly decreased ir-galanin release contralateral to the nerve injury when the
analysis was carried out. The temporal resolution of the microprobe technique is
limited by the fact that microprobes have to be inserted for 15 minutes to allow
adequate binding to the microprobes, thus changes in ir-galanin release during this
time would not be detected. Thus, it is possible that the evoked ir-galanin could
persist for some minutes. Despite this limitation, the present results with ir-galanin are
different from other peptides studied using the same technique. Neurokinin A and
neuropeptide Y, for example, have both been shown to persist and spread to sites
• * * 109 257distant from release, sometimes for hours after stimulated release ' .
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Figure 19. Study of persistence of ir-galanin after evoked
release from high threshold stimulation.
Microprobes were inserted into the ipsilateral side of the spinal cord to nerve injury
after peripheral stimulation had ceased for up to two hours afterwards.
A. The mean image analysis (+/-s.e.m.) of microprobes inserted prior to (n=18) high
threshold stimulation (2 Hz, 50T, 0.1 msec) and those inserted during the time
period from 15 minutes to 2 hours after stimulation had ceased (n=31). The
cumulative group of all post-stimulation probes is shown, but the result was the
same when split into component groups (0-30 minutes, n=9; 31-60 minutes, n=10.
61-90 minutes, n=8, 91-120 minutes, n=4). There was no decrease in optical
density of those probes inserted afterwards compared to those inserted under basal
conditions.
B. The differences between the basal and post-stimulus groups of microprobes are
shown as the t statistics relative to depth in the spinal cord. There was no
significant difference between these 2 groups, thus providing no evidence for long-
term persistence of ir-galanin after its C fibre-evoked release.
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Figure 20. Changes in contralateral ir-galanin release after
high threshold stimulation.
Microprobes were inserted into the contralateral side of the spinal cord to nerve injury
after peripheral stimulation had ceased for up to two hours afterwards.
A. The mean image analysis (+/-s.e.m.) of microprobes inserted prior to (n=17) high
threshold stimulation (2 Hz, 50T, 0.1 msec) and those inserted during the time
period from 15 minutes to 2 hours after stimulation had ceased (n=26). There was
a minor increase in optical density of those probes inserted afterwards compared to
those inserted under basal conditions.
B. The differences between the basal and post-stimulus groups of microprobes are
shown as the t statistics relative to depth in the spinal cord. A significant decrease
was detected in ir-galanin release contralateral to nerve injury, after high intensity
stimulation of the injured nerve, as indicated by *.
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4.3.4 Effect of conduction block on ir-galanin release
A total of 12 neuropathic rats (245-350 g) was studied to determine the effect of
blocking peripheral input from the injured nerve on spinal release of ir-galanin. A total
of 261 galanin antibody coated microprobes were inserted into the spinal cord, with a
further 60 in vitro probes and 14 probes incubated in cord perfusate. This was to
check that probes inserted during intermittent rather than continuos irrigation of the
spinal cord did not show any evidence of probe damage at the insertion site.
After basal probes had been inserted, and amethocaine gel placed around the nerve the
adequacy of conduction block was assessed. Figure 21 shows a typical example of
recording cord dorsum potentials from electrical stimulation of the injured nerve,
before and after application of amethocaine gel proximal to the nerve injury site.
Microprobes inserted into right (n=42) and left (n=30) sides of the spinal cord prior to
any intervention confirmed the same increased peak of ir-galanin release occurring
spontaneously in the superficial dorsal horn ipsilateral to nerve injury, as found
previously (see Figures 13 and 14).
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Figure 21. Cord dorsum potentials before and after application
of amethocaine gel
A. The injured nerve was stimulated at 2 T, 1Hz, 0.1 ms pulse width, and the cord
dorsum potential measured on the cord surface as described in section 2.2.2. The
expected field potential was obtained .
B. The injured nerve was stimulated at a much higher intensity (50 T, lHz,0.1 ms
pulse width) 30 minutes after amethocaine gel was applied proximal to the nerve
injury site. As can be seen from the averaged field potential, no activity was evoked
in the spinal cord, confirming block of peripheral electrical input.
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Effect of peripheral conduction block on ir-galanin release
Microprobes inserted after conduction block proximal to the nerve injury site, but
distal to the dorsal root ganglia had no effect on the spinal release of ir-galanin on
either the ipsilateral (n=38) or contralateral (n=37) side of the spinal cord relative to
the nerve injury. The right to left difference between ir-galanin release was preserved
after this intervention. This is shown in Figures 22 and 23.
A control group was used where the manipulations of the sciatic nerve required for
placement of the plastic tubing around the nerve were carried out, but without
application of the amethocaine gel. Microprobes inserted after manipulation of the
nerve did not show any significant alteration in the release of ir-galanin in the
ipsilateral (n=l 1) dorsal horn. As with the contralateral effects of high intensity
stimulation, peripheral manipulation of the injured nerve resulted in a trend towards a
decrease in contralateral ir-galanin release (n=l 1). This is shown in Figures 24.
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Figure 22. Effect of blocking conduction proximal to nerve
injury site on spinal ir-galanin release
Microprobes were inserted into both sides of the spinal cord after peripheral
conduction block with amethocaine gel had been tested for effectiveness.
A. The mean image analysis (+/-s.e.m.) of microprobes inserted ipsilateral to (n=38)
the site of conduction block, proximal to the chronic constriction injury of the
sciatic nerve, and those microprobes inserted prior to this (n=42). There was no
decrease in optical density of those probes inserted after conduction block
compared to those inserted under basal conditions. The differences between the
basal and post-conduction block groups of microprobes are shown as the t
statistics relative to depth in the spinal cord, at CI. There was no significant
difference between these 2 groups, indicating no effect of peripheral conduction
block on spontaneous ir-galanin release.
B. The mean image analysis (+/-s.e.m.) of microprobes inserted contralateral to
(n=37) the site of conduction block, proximal to the chronic constriction injury of
the sciatic nerve, and those microprobes inserted prior to this (n=30). There was
no decrease in optical density of those probes inserted after conduction block
compared to those inserted under basal conditions. The differences between the
basal and post-conduction block groups of microprobes are shown as the t
statistics relative to depth in the spinal cord at C2. As there was no significant
difference between these 2 groups, peripheral conduction block did not alter
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Figure 23. Peripheral conduction block does not alter
spontaneous ir-galanin release ipsilateral to nerve injury
A. This shows the mean image analyses of microprobes inserted ipsilateral (n=38) and
contralateral (n=37) to the injured nerve, that has been previously blocked by
amethocaine gel proximal to the injury site.
B. The difference between the two sides of the cord that has been demonstrated under
basal conditions is preserved after peripheral conduction block, as demonstrated by
the hatched area showing a significant (p<0.05) increase in ir-galanin release
ipsilateral to the side of the blocked nerve.
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Figure 24. Effect of manipulation of injured nerve on spinal ir-
galanin release
Microprobes were inserted into both sides of the spinal cord after peripheral
manipulation of the injured nerve, without conduction block
A. The mean image analyses (+/-s.e.m.) of microprobes inserted ipsilateral to the
injured nerve prior to (n=42) and after manipulation of the nerve (n=l 1). The
differences between the basal and post-manipulation groups of microprobes are
shown as the t statistics relative to depth in the spinal cord at CI. There was no
significant difference between these 2 groups, indicating no effect of peripheral
manipulation on spontaneous ir-galanin release.
B. The mean image analyses (+/-s.e.m.) of microprobes inserted contralateral to the
injured nerve prior to (n=30) and after manipulation of the nerve (n=l 1). The
differences between the basal and post-manipulation groups of microprobes are
shown as the t statistics relative to depth in the spinal cord at C2. A trend towards
a decrease in spontaneous ir-galanin release contralateral to the site of nerve injury
after peripheral manipulation of the injured nerve was seen. Significant points are
indicated *.
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Effect of proximal conduction block on ir-galanin release
After all electrical activity from the injured sciatic nerve had been effectively blocked
by placement of amethocaine gel proximal to the dorsal root ganglia, further
microprobes were inserted into the spinal cord. On the side of the cord ipsilateral to
the nerve injury, there was a small area of increased ir-galanin release in the white
matter of the spinal cord after proximal conduction block (n=35). However, the
greatest effect of proximal conduction block was a marked, diffuse increase in ir-
galanin release on the side of the cord contralateral to the nerve injury (n=34). The
increase on the contralateral side of the cord was such that the previously observed
difference between the two sides of the cord, with greater spontaneous ir-galanin
release ipsilateral to the injured nerve was no longer apparent. This is shown in
Figures 25 and 26.
The effects of manipulation of the dorsal roots, as described in section 4.2.1, but
without application of local anaesthetic, on spinal ir-galanin release were also studied.
This was to ensure that the changes seen in ir-galanin release were not simply due to
the preparation required to place the amethocaine gel on the dorsal roots.
Microprobes inserted ipsilateral to the nerve injury were compared before (n=42) and
after(n=ll) manipulation, and no significant difference was found in ir-galanin release.
Microprobes inserted into the contralateral side of the cord, where the greatest change
was detected after proximal conduction block, did not show any difference in ir-
galanin release before (n=30) and after (n=12) manipulation of the dorsal roots.
In order to exclude the possibility of damage to the microprobes from exudate
collecting on the spinal cord, when irrigation was intermittent, microprobes were
incubated in 5 pi capillary tubes of this exudate, at 37°C for 15 minutes. Comparison
of such microprobes (n=14) with the in vitro microprobe group (n=60) did not show
any difference, thus excluding the possibility of enzymatic damage to the antibody
coating. This is shown in Figure 27.
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Figure 25. Effect of proximal conduction block on spinal ir-
galanin release
A. The mean image analyses (+/-s.e.m.) of microprobes inserted ipsilateral to the
nerve injury, before (n=42) and after (n=35) conduction block proximal to the
dorsal root ganglia from the injured nerve. Those inserted after conduction block
showed some increase in optical density compared to those inserted under basal
conditions. The differences between the basal and post-conduction block groups of
microprobes are shown as the t statistics relative to depth in the spinal cord at C1.
There was a significant difference (p<0.05) between these 2 groups, with a small
area of increased ir-galanin just below the dorsal surface of the spinal cord.
B. The mean image analyses (+/-s.e.m.) of microprobes inserted contralateral to the
nerve injury, before (n=30) and after (n=34) conduction block proximal to the
dorsal root ganglia from the injured nerve. There was an increase in optical density
of those probes inserted after conduction block compared to those inserted under
basal conditions. The differences between the basal and post-conduction block
groups of microprobes are shown as the t statistics relative to depth in the spinal
cord at C2. There was a large area throughout the spinal cord where ir-galanin












































Figure 26. Side to side comparison of ir-gaianin release after
proximal conduction block
A. This shows the mean image analyses of microprobes inserted ipsilateral (n=35) and
contralateral (n=34) to the injured nerve, that has been previously blocked by
amethocaine gel proximal to the dorsal root ganglia. The two groups are almost
superimposed on each other, showing that blocking all neuronal input from the
injured sciatic nerve results in eliminating the difference in spontaneous ir-galanin
release between the two sides of the cord that occurs after nerve injury.
B. The difference between the two sides of the cord that has been demonstrated under
basal conditions in neuropathic rats, is no longer present after proximal conduction
block, as no significant increase in ir-galanin release can now be detected.
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Figure 27. Effect of cord perfusate on antibody coating of
microprobes
A. This shows the mean image analysis of microprobes (n=14) incubated in 5 pi
capillary tubes of the fluid on the cord surface, during intermittent irrigation, at
37°C for 15 minutes. The microprobes were then treated as for the other
experimental probes. The second mean image analysis shows the in vitro group
(n=60) of microprobes, to allow detection of any areas along the length of the
probe that might be damaged.
B. The t statistics obtained from comparing in vitro probes with those incubated in
cord perfusate shows that there is no difference between these two groups. This
would help to confirm that decreases in optical density from in vivo probes is due
to ir-galanin release and not probe damage.
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4.4 Discussion
In summary, the findings from the study of ir-galanin release in the spinal cord are:
1. In neuropathic rats there was evidence of a new site of ir-galanin release occurring
in the absence of any active peripheral stimulation, peaking in the superficial dorsal
horn ipsilateral to the nerve injury. The pattern of ir-galanin release contralateral^
was unchanged from that normally found.
2. This new site of ir-galanin release was increased, with a peak in the same area, by
electrical stimulation of the damaged nerve only at stimulus strengths sufficient to
activate small myelinated and unmyelinated primary afferent fibres, but not at lower
stimulus strengths. The stimulus-evoked release of ir-galanin did not persist for any
significant length of time after release.
3. Blocking all neuronal input from the injured nerve resulted in little change in
ipsilateral ir-galanin release, but a significant increase in ir-galanin release on the
contralateral side of the cord. This was such that the difference in ir-galanin release
between the two sides of the spinal cord found consistently in neuropathic rats was
no longer present. Both high intensity stimulation and peripheral manipulation of
the injured nerve resulted in a significant decrease in contralateral^ released ir-
galanin at one point in the superficial dorsal horn.
4.4.1 Source of ir-galanin
It is important to consider the source of the increased ir-galanin release. Possible
sources of release include primary afferent neurones, intrinsic neurones of the dorsal
horn, or descending spinal tracts. Although it has been demonstrated both in this
study and others 168, that there was extensive basal release of ir-galanin in normal rats,
this was unlikely to be from primary afferent neurones, for several reasons. Firstly,
there were very low levels of galanin rnRNA in the dorsal root ganglia u'425j and
secondly, peripheral innocuous and noxious stimulation did not alter the basal ir-
galanin release in the spinal cord of normal rats or cats 168'292. The major difference in
the neuropathic rats was that an increase in ir-galanin release was found in the dorsal
horn ipsilateral to the nerve injury, and this was increased further by stimulation of
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high threshold neurones (A-delta and C fibres). Other studies have shown dramatically
increased galanin synthesis after nerve injury in the small to medium sized primary
afferent cells that normally terminate in the superficial dorsal horn 308'316. There is also
immunohistochemical evidence that the increase in intra-axonal galanin levels in the
dorsal horn after nerve injury arises from central transport from the cell bodies in the
dorsal root ganglia 426>49°
The results from the current studies indicate that the increased spontaneous and
evoked release of ir-galanin in the superficial dorsal horn of neuropathic rats is likely
to arise from small primary afferent neurones. It is also likely that the significantly
increased spontaneous release of ir-galanin found in the superficial dorsal horn of
neuropathic rats arises from these primary afferent neurones.
The interpretation of theses studies is made more complicated by the fact that ir-
galanin release is increased in an area of the spinal cord where several systems
interact. Thus, the small sized primary afferent neurones that start to produce galanin
terminate here, in an area where either intrinsic or descending neurones also release ir-
galanin. Although it is highly probable that the increased ir-galanin release is indeed
from primary afferent neurones, there may also be parallel effects of nerve injury on
other galanin-containing neurones, of non-primary afferent origin, in this area of the
spinal cord. The results of blocking peripheral conduction, with an increase in ir-
galanin release on the contralateral side of the spinal cord would certainly seem to
indicate the involvement of either intrinsic loops with bilateral neuronal connections in
the spinal cord 180, or bilateral effects of supraspinal systems, both of which must be
affected by ongoing neuronal input from the injured nerve. If this were the case, then
inhibition of ir-galanin release contralateral^, either by high intensity stimulation of
the injured nerve, or manipulation around the site of nerve injury could also occur by
this mechanism. This would indicate that some input from the injured nerve results in
inhibition of ir-galanin release from neurones within the dorsal horn. As this effect is
seen on the contralateral side of the cord, it seems that input from a unilateral nerve
injury has bilateral effects. This would certainly correlate with bilaterally altered
responses previously found in response to electrical stimulation of the injured nerve 75.
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4.4.2 Stimulus for ir-galanin release
If the increase in spontaneously released ir-galanin did arise from primary afferent
neurones, one explanation for this is that abnormal activity, developing in the primary
afferent neurones, provided a stimulus for release. There is an increasing amount of
evidence that after nerve injury, primary afferent neurones behave abnormally, with
the generation of spontaneous ectopic activity both at the nerve injury site 275>407>488j
and at cell bodies in the dorsal root ganglia 190'472
In the CCI model, it was found that the majority of cells showing evidence of
spontaneous activity were of the A-beta type. Spontaneous activity in C fibres did not
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appear to increase significantly until about 10 days after nerve injury . A high level
of spontaneous activity was also found in medium sized neurones 396. This high level
of spontaneous activity from primary afferents is likely to contribute to changes in
somatosensory processing that occur centrally in response to peripheral nerve injury.
Tal and co-workers 407 did find that there was a correlation between the amount of
spontaneous activity in myelinated primary afferents and the development of thermal
hyperalgesia.
As these afferents are firing spontaneously, it is possible that the central release of
neuropeptides such as galanin is due to these abnormal impulses.
Although the block of ectopic discharges was not measured directly in the
experiments using local anaesthetic to block conduction, there is evidence of ectopic
discharges being generated via TTX-sensitive sodium channels 328, that are sensitive
to local anaesthetics at much lower doses than those required for conduction block
57'260. It can be assumed therefore that by effectively blocking the measured cord
dorsum potential resulting from stimulation of the injured nerve, all ectopic discharges
were also blocked.
It is likely that the changes in ir-galanin release found after conduction block are due
to effects in a mixed neuronal population - thus ir-galanin released from primary
afferent activity ipsilateral to the nerve injury may have been eliminated, whereas the
block of all peripheral input led to disinhibition of intrinsic neurones or supraspinal
systems releasing ir-galanin. This would account for the contralateral increase in ir-
galanin, with the increase in ipsilateral ir-galanin from intrinsic neurones being
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balanced by a decrease from primary afferent neurones. Thus, as galanin is produced
in mainly small to medium sized primary afferent neurones, it may be that spontaneous
activity in these results in central ir-galanin release. However, the effects of
spontaneously firing large diameter primary afferent neurones may also have an effect
on spinal release of ir-galanin. This may, in part, explain the differential effects in ir-
galanin release from primary afferent neurones and from intrinsic or supraspinal
neurones.
4.4.3 Functional significance of galanin changes
The functional role of galanin after nerve injury is not known, but there are several
possibilities:
1. Galanin may act as an endogenous analgesic substance. The functional significance
of galanin is not clear, with evidence of both inhibitory 348,455 and excitatory 7 '217
effects, including potentiation of the inhibitory effects of morphine 454. Its presence
in the superficial dorsal horn and its increased release here after nerve injury,
implies that it may have an important role in processing of nociceptive information.
After peripheral nerve injury, behavioural and electrophysiological studies show a
greater inhibitory action of galanin. It may therefore be more important as an
inhibitor of ongoing neuronal activity only after a peripheral nerve injury has
occurred 423,453. The lack of persistence of released ir-galanin for any significant
length of time after its release, provides a further indication that it acts in or close
to its area of release, i.e. in an area of the dorsal horn thought to be important in
the processing of nociceptive inputs. Additionally, the increase in contralateral ir-
galanin release after conduction block may indicate that one reason for the
generation of spontaneous pain is that galanin release is inhibited, thus preventing
its endogenous analgesic effect - it could be that if an inadequate amount of galanin
is released, there is inadequate damping of abnormal incoming activity from the
injured nerve. Thus, the release of ir-galanin from primary afferent fibres may be
inadequate to inhibit transmission of abnormal nociceptive messages. As the
spontaneously released ir-galanin is likely to be from small to medium sized
primary afferent neurones, it may be that spontaneous firing from large primary
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afferent neurones inhibits further ir-galanin release, thus it could be that pain
develops because of an inadequate galanin response.
2. It must also be considered that galanin may in fact be involved in the development
of the central sensitisation accompanying neuropathic pain. There is a correlation
between the rate of ectopic discharge and the degree of spontaneous pain in both
humans and animals 320-347j ancj ^ may be that ectopic impulse-evoked release of
neuropeptides is related to the generation of spontaneous pain. Ir-galanin release
occurred in an area where new synaptic contacts have been formed, and could
amplify an ongoing neural input, resulting in pain. Electrophysiological studies of
the dorsal horn in animal models of nerve injury have shown both an increase in
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spontaneous activity of dorsal horn neurones ' and ascending systems ' ,
as well as bilaterally increased evoked activity 75. However, this increase in activity
has neither been related to galanin release nor to the generation of pain. More
recent evidence has shown almost complete loss of GABA-containing cells in
laminae I- III of the dorsal horn after nerve injury, with lesser decrease
contralateral^ 175. Galanin has been shown to co-exist with GABA in the
superficial dorsal horn in normal rats 379, a pattern of co-existence that must be
altered after nerve injury. Alterations in the number of inhibitory neurones and the
pattern of neurotransmitter co-existence may lead to impaired inhibitory function
and central hyperexcitability after peripheral nerve injury.
3. Alternatively, galanin may be not be acting as a neurotransmitter at all, but may be
involved in the reorganisational changes that occur in the dorsal horn after nerve
injury 68. An enhancement of central regeneration of primary afferent neurones has
been found after axotomy and nerve crush 35\ Large myelinated fibres have been
shown to sprout from deeper in the dorsal horn up to laminae I-II 232-468>469j with
some evidence of synaptic contacts being formed in these superficial areas. A
protein associated with regrowth, growth associated protein-43 (GAP-43), appears
in the superficial dorsal horn after peripheral nerve injury with a distribution similar
to that of small primary afferent terminals 51,71,467 Thus, there is anatomical
evidence of altered primary afferent connections in the same area as the increased
release of ir-galanin has been found. There is some evidence that peptides can have
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neurotrophic effects themselves. PACAP, VIP and NPY have been shown to
induce neurite outgrowth 145'1785 but galanin did not have any neurotrophic effect
212
In conclusion, the findings of increased release of ir-galanin in the superficial dorsal
horn on the side ipsilateral to a peripheral nerve injury suggest that it plays a greater
role in spinal processing in this abnormal state. The spontaneous release of galanin, as
well as increased release during stimulation of small diameter primary afferents,
indicate a role in the processing of nociceptive information. The widespread effects of
blocking conduction from the injured nerve on ir-galanin release also indicate an
important functional role in the processing of information from the injured nerve.
There is evidence for ongoing inhibition of ir-galanin release bilaterally in the
neuropathic state, which may have widespread functional consequences. The neuronal
systems involved are unlikely to be simple mono-synaptic connections, but to involve
complex interactions between primary afferent neurones, local dorsal horn neurones
and ascending and descending systems. However, galanin, or a galanin analogue, may
provide a potential new treatment for neuropathic pain syndromes, perhaps by
influencing an endogenous analgesic system similar to that found with opioid peptides.
However, further studies are required to elucidate the precise functional role of
galanin released into the spinal cord, both from primary afferent neurones and from
other sources.
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Chapter 5. Studies of the spinal release of ir-neuropeptide Y in
neuropathic rats
5.1 Introduction
In normal rats, ir-NPY was released in the superficial dorsal horn, and peripheral
electrical stimulation had no effect on this release. As NPY is not synthesised by
primary afferent neurones in the normal situation l00,4':>53 and spinalisation had no
significant effect on release, then the ir-NPY release detected in the superficial dorsal
horn was likely to be from intrinsic neurones 258. Studies of neuropathic rats, in which
I was involved, detected an area of spontaneously released ir-NPY deeper in the
dorsal horn than normally found, on the side ipsilateral to nerve injury. This new area
of ir-NPY release was increased by stimulation of large myelinated fibres and could
still be detected for some time after its release 257. As this new zone of ir-NPY release
occurred in a deeper area from that where intrinsic neurones normally released ir-
NPY, in the superficial dorsal horn, it is likely that this spontaneous release of ir-NPY
was from large diameter primary afferent neurones 257, that have started to produce
NPY after nerve injury 308>316'492
As with galanin, one possible stimulus for spinal release of ir-NPY from primary
afferent fibres could be spontaneously occurring ectopic discharges that develop at the
nerve injury site and the dorsal root ganglia, particularly in myelinated fibres. It has
been well documented that in the CCI model, spontaneous neuronal activity arises at
ectopic sites - both at the nerve injury site 187'407 and also at the dorsal root ganglia
from the injured nerve 396-472. Initially, ectopic activity was found in the majority of A-
(3 fibres, to a lesser extent in A-S fibres and least in unmyelinated fibres. The pattern
of ectopic activity developed with time, with myelinated fibres developing this activity
at an earlier time point than was seen in unmyelinated fibres 187. There was also
evidence of abnormal ectopic activity spreading to influence non-injured primary
afferent neurones, with cross-excitation occurring between both primary afferent
neurones 8 and spontaneously firing sympathetic neurones 90 in the dorsal root ganglia.
171
The abnormal ectopic activity may involve voltage sensitive Na+ channels 260 that are
sensitive to local anaesthetics at much lower doses than those required for conduction
block 57,91. IfNPY were released by this mechanism then block of ectopic discharges,
as described in section 5.2.1, would eliminate the deep zone of ir-NPY released in
response to spontaneous activity in primary afferent neurones.
Another factor that may be important in the changes in peptide synthesis and release
after nerve injury, is interruption to the supply of peripherally derived growth factors.
There is evidence that after nerve injury there is a decrease in production ofNT-3
distally, both in neurones 239 and Schwann cells 131, as well as decreased retrograde
transport from the periphery 158. It may be therefore, that lack ofNT-3 plays at least a
partial role in the changes in peptide production of at least some of the primary
sensory neurones. Lack of both NGF 424 and NT-3 326 has been shown to influence the
increase in NPY synthesis by primary afferent neurones after axotomy. Like the
primary afferent neurones that start to produce NPY after nerve injury, the NT-3
responsive neurones are also large diameter primary afferent neurones. Thus, NT-3
deficiency may be an important factor in the changes seen in NPY production in these
large diameter neurones after nerve injury. Studies ofNT-3 knockout mice have
found a marked decrease in sensory neurones in the dorsal root ganglia, particularly
large diameter sensory neurones, with associated decreases in la muscle afferents,
slowly adapting mechanoceptor and proprioceptive fibres 3-4-384 In addition, it is
mainly the large diameter primary sensory neurones that express the high affinity NT-
3 receptor, the trkC receptor 239 Mice lacking the trkC receptor show marked sensoiy
abnormalities, and a similar loss of large myelinated fibres to that seen in the NT-3
knockout mice 209'378. NT-3 itself has been shown to have antinociceptive effects 38°,
as well as attenuating behavioural and anatomical effects of a large fibre sensory
neuropathy induced by pyridoxine I58. Thus lack ofNT-3 might result in the
development of pain-related behaviour. There is also recent evidence that
neurotrophins may actually alter neurotransmitter release, possibly by altering the
levels of secretory proteins at the synapse 405, although the effect ofNT-3 on
neurotransmitter release has not yet been studied.
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To investigate the effect of a peripheral nerve injury on spontaneous ir-NPY release
further, two series of studies were carried out using the antibody-coated microprobe
technique previously described.
1. All neuronal input from the injured nerve was blocked by local anaesthetic placed
proximal to the dorsal root ganglia from the injured nerve.
2. Sub-cutaneously implanted osmotic pumps chronically infused NT-3 to the nerve
injury site, from the time of nerve injury, for 10 to 14 days, when the effect on
spontaneous ir-NPY release was studied. During the infusion period quantitative
assessment of the degree of mechanical allodynia and hyperalgesia was studied.
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5.2 Materials and methods
5.2.1. Animal preparation
Set up of neuropathic model and implanting osmotic pumps
A total of 31 male Wistar rats were used (220 g to 360 g; Charles River, UK) in the
studies of ir-NPY release. In all the rats used, the CCI model was set up as previously
described in section 2.2.1, except for those rats in which the effects ofNT-3 infusion
were being studied. In those animals, at the time of loose ligation of the right sciatic
nerve, Alzet® mini-osmotic pumps (Alza Scientific Products, Ca, USA) were also
implanted sub-cutaneously into the lower abdomen. The pump used had a reservoir
volume of 200 pi (model No 2002) and an infusion rate of 0.5 pl/hr. The pumps were
pre-filled with the filling tube supplied, according to manufacturer's instructions,
using a flow moderator attached to a 3 cm length of polyethylene tubing (PE-60). All
handling of the pumps and materials used were carried out using strict aseptic
technique to ensure that the pump and tubing were sterile, when implanted into the
rat. A diagram of the pump and an outline of the principles behind its operation 411 are
shown in Figure 28. After the pump was implanted the attached catheter was
tunnelled sub-cutaneously to the site of nerve injury, at mid-thigh level. A larger
diameter piece of tubing, approximately 1 cm in length, with a longitudinal split, was
placed around the nerve and the ligatures. To prevent this slipping down the nerve
this was anchored by a suture (4/0 Vicryl) to the end of one of the ligatures. The slit
was held shut by further sutures, and the catheter itself sutured within the tubing. This
allowed delivery of the NT-3 solution close to the nerve injury site, thus ensuring that
it received the highest concentration of the solution. It did not prevent systemic
absorption ofNT-3, thus the possibility of systemic and possibly bilateral effects could
not be excluded. For this reason, a control group of rats was used with 0.9% saline
only in the implanted osmotic pumps. After implantation of the pumps, tissue layers
were closed as described previously (section 2.2.1) and the rats recovered in the
standard fashion.
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From day 3 after ligature placement a regular series of behavioural tests were carried
out as outlined in chapter 3. These were analysed using Mann Whitney Rank Sum
tests to determine the effect ofNT-3 infusion on the development of the behavioural
syndrome. At ten to fourteen days after nerve injury ir-NPY release experiments were
carried out.
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Figure 28. Diagram of Aizet® osmotic pump
This outlines the principles of the osmotic pump. NT-3 or sterile 0.9% saline fills the
drug reservoir (a), sealed with a cap and flange (b). This is surrounded by a
compressible, impermeable reservoir wall (c ). Outwith this is an osmotic agent - a
high concentration of sodium chloride, contained within an osmotic sleeve (d), with a
semi-permeable membrane (e) separating this from the implantation site. The
difference in osmotic pressure between this compartment and the implantation site
draws in water, compressing the drug reservoir and driving delivery of the test
solution. The rate of flow is controlled partly by the flow moderator (f), and partly by
the characteristics of the semi-permeable membrane. The flow moderator is tightly
connected to the polyethylene catheter (g) that delivers the NT-3 or saline to the
nerve injury site. Diagram modified from manufacturer's data.
176











Blocking neuronal input from the injured nerve
A total of 12 rats with behavioural evidence of spontaneous pain and mechanical
allodynia and hyperalgesia were studied (see chapter 3). The standard experimental
set up described in section 2.2.2 was used. Prior to conduction block, 6-8 NPY
antibody-coated microprobes were inserted into the spinal cord to establish basal
levels of spontaneous ir-NPY release. As for the studies of ir-galanin release, after
proximal conduction block, the laminectomy was extended distally and laterally to
allow gentle mobilisation of the dorsal roots from the sciatic nerve, and a small piece
(~0.5 xlcm) of black polythene inserted under the dorsal roots. Approximately 0.1ml
amethocaine gel was applied to the dorsal roots, on top of the polythene, and
surrounded by sealant gel around the edges of the polythene to prevent leakage of the
amethocaine gel pool onto the spinal cord. Intermittent irrigation of the cord with
warmed sterile Ringer's solution was used to prevent washing the local anaesthetic
onto the cord.
A minimum of 30 minutes was allowed after application of the amethocaine gel to the
dorsal roots. As was described in section 4.2.1, adequacy of conduction block was
checked by high intensity electrical stimulation proximal to the nerve injury site. Only
after an adequate block had been established were further microprobes inserted into
the spinal cord for up to two hours after conduction block had been established.
At the end of each experiment a pair of microprobes was incubated in 5 pi capillary
tubes of cord perfusate from the surface of the spinal cord, for 15 minutes at 37°C.
These were then washed, as for in vivo probes and incubated in 125I Fab, instead of ,25I
NPY. For comparison, some of the in vitro probes from each experiment were also
incubated in 125I Fab. This allowed assessment of any damage to the NPY antibody
coating on the probe surface.
Effect of NT-3 infusion on ir-NPY release
A total of 20 rats were used in these studies, of which 13 were implanted with NT-3-
containing osmotic pumps at the time of nerve injury, and 7 were implanted with
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0.9% saline-containing osmotic pumps. Prior to study of ir-NPY release, regular
behavioural testing was carried out to determine whether or not NT-3 infusion had
any effect on the development of neuropathic pain. Tests for mechanical allodynia and
hyperalgesia were used, as outlined in section 3.2. These were carried out by a single
observer who was blinded to the contents of the osmotic pump.
Ir-NPY release experiments were carried out at 10-14 days after nerve injury and
pump placement. The standard experimental set up described in section 2.2.2 was
used. Up to 24 microprobes coated with NPY antibody were inserted into the spinal
cord under basal conditions, with the final pair of probes being incubated in 125I Fab,
to exclude probe damage secondary to enzyme release from ruptured cells. After
incubation with 125I NPY, washing and placing on X-ray monoemulsion film for 6-8
days, autoradiographic images were obtained for each microprobe.
Several methods were used to check correct functioning of the osmotic pumps, and
delivery of the reservoir contents to the nerve injury site. At the time of set up for
release experiments, correct placement of the pump and catheter were checked. At the
end of each experiment, after the rat had been euthanased, the sites of pump insertion
and catheter were examined to exclude signs of infection, the patency of the catheter
checked, and the drug reservoir was examined to ensure that it was empty.
5.2.2. Antibody microprobe preparation
Materials
NPY antibody coated microprobes were prepared as described previously (section
2.1). Only one supplier ofNPY antiserum was used (Peninsula, Ca, USA), and the
same lot number was used for all the experiments described. The basic technique used
is the same for both galanin and NPY antibody-coated microprobes, with a few
differences. When reconstituting the 125I NPY, 0.1% casein was used instead of BSA.
This was because previous studies in this laboratory had found unacceptably high
levels of non-specific binding with BSA, and much lower levels when casein was
used. The washing solution used for both in vitro and in vivo probes was always 0.1%
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Tween-20, as opposed to the Tween-80, that was used in the galanin experiments, for
the same reason.
The NT-3 was kindly gifted by Regeneron, NY, USA (Dr RM Lindsay), and was
reconstituted in sterile 0.9% saline to give a solution of 1 mg/ml. This dose was
slightly higher than that used in the study of the effects ofNT-3 in axotomy (800
p.g/ml) 326. The solution was aliquoted into sterile Eppendorfs and frozen at -70°C
until used.
In vitro tests
Prior to commencing in vivo work, in vitro assays were carried out to determine the
specificity and sensitivity of the immobilised NPY antibody by measuring the degree
of inhibition of 125I NPY binding by related peptides or varying concentrations of
unlabelled NPY. The same basic procedure used for in vitro galanin assays (see
section 2.1.4 & 4.2.2; Figure 4) was used for the NPY assays. In vitro assays were
carried out for each new batch ofNPY antiserum, and continued in parallel with in
vivo work to ensure that there was no major deterioration in sensitivity or specificity.
Sensitivity was determined by incubating microprobes in a range of unlabelled NPY
from 10"5M to 10"8M prior to incubation in 125I NPY. Specificity values were supplied
by the manufacturer's data, but these were checked by incubation of microprobes in
10"5M to 10"6M SP, VIP, galanin, PYY and PP. Levels of non-specific binding were
assessed by incubation of microprobes coated only with PrA in 125I NPY, and the
antibody coating was assessed by incubation in 125I Fab.
5.2.3. Analysis of microprobes
The same image analysis set up as that used for the galanin experiments was used, and
is described in detail in section 2.1.6. Basically, the computerised image analysis
system analysed autoradiographic images of both in vivo and in vitro microprobes.
The in vitro probes gave an estimate of probe shape and allowed estimation of basal
levels of ir-NPY release in the spinal cord. Binding of endogenous NPY resulted in
deficits in binding of 125I NPY that were detected as localised decreases in optical
density (grey scale) by the analysis system. A plot of grey scale against depth of the
probe in the spinal cord was obtained for each microprobe.
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All analysis was carried out on normalised data, as described in section 2.1.6. This
allowed comparison of probes that might otherwise have had minor variations in
optical density due to exposure time, rather than biological variation. The mean values
for defined groups of microprobes, were plotted as the means (+/- s.e.m.) of the grey
scale values at 30 pm intervals against the depth within the spinal cord. Statistical
significance was assigned to each site using Student's unpaired t-test, and the t values
thus obtained plotted against depth within the spinal cord. A p value of less than 0.05
was taken as showing a statistically significant difference between groups.
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5.3 Results
5.3.1 In vitro testing
The NPY antibody used was C-terminus directed and showed minimal cross reactivity
with other peptides found in the dorsal horn, according to manufacturer's data and
confirmed by in vitro testing. Sensitivity tests found suppression of binding ranging
from approximately 90% with 10"5 M NPY to approximately 25% suppression with
lO^M galanin, indicating that the sensitivity of the NPY antibody was adequate to
detect significant areas of ir-NPY release in the spinal cord. Levels of non-specific
binding, as assessed by measurement of the degree of binding to probes coated in
protein A, were of the order of 7%. Microprobes incubated in 1251 Fab gave counts
within 8% of control counts, indicating good coating ofNPY antibody on the probe
surface. Cross-reactivity with other peptides found in the dorsal horn was negligible,
although significant cross-reactivity was found with the related peptides PYY and PP.
This is in agreement with data from the manufacturer. The results of in vitro testing of
the NPY antiserum from Peninsula Labs is shown in Table 8.
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Table 8. In vitro assay for NPY antiserum (Peninsula, Ca, USA)
This shows the results from microprobes used in in vitro assays to ensure adequate
sensitivity and specificity of the NPY antibody coating on the microprobes. Low
levels of non-specific binding are also demonstrated, and good antibody coating of the








Control (50) 1738 (+/-860)
10'5M NPY (51) 166(+/-77) 90
10^M NPY (17) 667(+/-129) 62
10"7M NPY (27) 1020(+/-93) 41
lO^M NPY (8) 1312(+/-140) 25
10"5M Galanin (8) 1674(+/-271) 4
10"5M SP (5) 2457(+/-224) +41
10"5M VIP (21) 1646(+/-108) 5
10"5M PP (4) 1067(+/-191) 39
10"5M PYY (6) 631(+/-74) 64
Fab (11) 1596(+/-58) 8
Cord perfusate (12) 1620(-+-/-101) 7
PrA (33) 116(+/-9) 7 (non-specific binding,
% of control)
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5.3.2. Effect of conduction block on ir-NPY release
A total of 154 probes were inserted into the spinal cord of rats with behavioural
evidence of neuropathic pain, and a further 56 probes were used as in vitro controls
to provide an estimate of probe shape in the absence of bound endogenously released
ir-NPY. An additional group of in vitro probes was incubated in 125I Fab, to allow
comparison with probes incubated in cord perfusate then in 125I Fab. This was to
exclude the possibility of antibody damage to the probes. The adequacy of the
conduction block was confirmed in all cases using electrical stimulation and central
measurement with a ball electrode, as described in section 2.2.2, and a typical example
of the recordings before and after conduction block is shown in Figure 21.
When in vitro microprobes ^=56) were compared to microprobes inserted into the
contralateral (n=27) side of the cord to the nerve injury, a similar pattern of ir-NPY
release was seen as is found in the spinal cord of normal rats 258. Thus an area of ir-
NPY release was found in the superficial dorsal horn, contralateral to nerve injury. As
already discussed, this area of ir-NPY release is likely to be from intrinsic neurones
rather than primary afferent neurones.
Microprobes inserted into the side of the cord ipsilateral to nerve injury (n=33)
showed a new area of ir-NPY release in the deeper dorsal horn, when compared to
probes inserted into the contralateral side (n=27). This is shown in Figure 29, and
confirms previous work in which I was involved 257. This new area of ir-NPY release
is occurring in an area of the dorsal horn where ir-NPY is not normally produced
100'184
or released 258. This is the same area where the large diameter primary afferent
neurones, that start to synthesise NPY after nerve injury, terminate, and ir-NPY
release is increased here by stimulation of these fibres 25T. It is highly likely therefore
that this new area of spontaneously released ir-NPY is arising from primary afferent
neurones.
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Figure 29. Effect of peripheral nerve injury on spinal ir-NPY
release
A. Microprobes were inserted into the spinal cord of neuropathic rats for 15 minutes
without any concurrent peripheral stimulus. The plot shows the mean image
analyses (+/-s.e.m.) of microprobes inserted into the ipsilateral (n=33) and
contralateral (n=27) sides of the spinal cord relative to the nerve injury, which is on
the right side. The microprobes inserted on the ipsilateral side are displaced above
those inserted into the contralateral side, indicating a new zone of ir-NPY release
under basal conditions.
B. The differences between the ipsilateral and the contralateral groups of microprobes
are shown as the t statistics relative to depth in the spinal cord. The hatched area
shows where there was a significant increase (p<0.05) in spontaneous ir-NPY
release in the deep dorsal horn.
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A Neuropathic rats - no stimulus
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After blocking input from the injured nerve proximal to the dorsal root ganglia, it was
found that ir-NPY release ipsilateral to the nerve injury was not altered. Probes
inserted after effective proximal conduction block (n=45) did not show any change in
ir-NPY release when compared to those inserted under basal conditions (n=33). Thus
complete block of neuronal input did not prevent the deeper area of ir-NPY release in
the dorsal horn ipsilateral to the side of nerve injury. The mean image analysis of
probes inserted into the spinal cord contralateral to nerve injury, before (n=27) and
after (n=41) conduction block proximal to the dorsal root ganglia from the injured
nerve, did not show any change in the pattern of ir-NPY release. Thus, unlike ir-
galanin release, there was no evidence of contralateral effects from blocking neuronal
input from the injured nerve. The effects of proximal conduction block on ir-NPY
release are shown in Figures 30 and 31. As a control, the effect of dorsal root
manipulation, without application of amethocaine gel was determined ipsilateral to the
nerve injury site. There was no difference in ir-NPY release before (n=33) and after
(n=8) manipulation of the dorsal roots.
To ensure that during the course of the experiment there had been no cell damage
with release of enzymes into the cord perfusate, that might damage the NPY antibody
coating of the probes, probes incubated in cord perfusate then l25I Fab (n=23) were
compared to in vitro probes (n=l 1) also incubated in 125I Fab. There was no evidence
of damage to the NPY antibody coating on the probe surface. This is shown in Figure
32.
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Figure 30. Effect of proximal conduction block on spinal ir-
NPY release in neuropathic rats
Microprobes were inserted into both sides of the spinal cord after conduction block
with amethocaine gel, on the dorsal roots of the injured nerve, had been tested for
effectiveness.
A. The mean image analyses (+/-s.e.m.) of microprobes inserted ipsilateral to the
injured nerve, shows no change in optical density of those probes inserted after
conduction block (n=45) compared to those inserted under basal conditions
(n=33). The differences between the basal and post-conduction block groups of
microprobes are shown as the t statistics relative to depth in the spinal cord, at CI.
There was no significant difference between these 2 groups, indicating no effect of
proximal conduction block on spontaneous ir-NPY release.
B. The mean image analyses (+/-s.e.m.) of microprobes inserted contralateral to
(n=41) the site of proximal conduction block and those microprobes inserted prior
to this (n=27). There was no change in optical density of those probes inserted
after conduction block compared to those inserted under basal conditions. The
differences between the basal and post-conduction block groups of microprobes
are shown as the t statistics relative to depth in the spinal cord at C2. As there was
no significant difference between these 2 groups, proximal conduction block did
not alter spontaneous ir-galanin release contralateral to the site of nerve injury.
It can be seen that proximal conduction block of neuronal input from the injured nerve
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Figure 31. Side to side comparison of ir-NPY release after
proximal conduction block
A. The mean image of analyses (+/-s.e.m.) of microprobes inserted into the ipsilateral
(n=45) and contralateral (n=41) side of the cord after blocking input from the
injured nerve show that the deep zone of ir-NPY release that was found under
basal conditions is still present.
B. The differences in ir-NPY release between the two sides of the cord, after proximal
conduction block are shown as the t statistics relative to depth in the spinal cord.
As there was no significant difference between these 2 groups, proximal
conduction block did not alter the new area of spontaneous ir-NPY release found
in the spinal cord of neuropathic rats, ipsilateral to the site of nerve injury. Thus,
blocking neuronal input from the injured nerve has not altered the central release of
ir-NPY in the spinal cord.
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Figure 32. Testing for damage to NPY antibody coating on
probe surface
A. The mean image of analyses (+/-s.e.m.) of microprobes incubated for 15 minutes in
cord perfusate (n=23), followed by incubation in 125I Fab, and in vitro probes
incubated in 125I Fab (n=l 1). There was no obvious deviation of the optical
densities of these two groups, thus giving no evidence of damage to the NPY
antibody coating on the probe surface.
B. The differences between the two groups of probes are shown as the t statistics
relative to the length of the probe. At no point was there any significant difference
between the two groups, confirming that there was no damage to the antibody
coating.
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5.3.3. Effect of NT-3 infusion on behaviour
No attempt was made to formally quantify the characteristic signs seen with this
model, but it was not possible to differentiate between the type of infusion that each
rat had received, dependent on the general behaviour of the animal, such as hopping,
foot position and grooming. There was no evidence of any difference in weight gain
between the NT-3 and the saline groups over the time period studied, as shown in
Table 9.
All rats that had undergone the CCI model did display evidence of mechanical
allodynia and hyperalgesia on the side of nerve injury, regardless of the infusion type.
This is shown in Figure 33 and the results are outlined in Tables 10 and 11. The paw
withdrawal thresholds, as determine by von Frey hairs, and paw withdrawal duration
to pin prick were compared at each time point using a Mann Whitney Rank Sum Test.
The values obtained for those rats with a NT-3 infusion were compared to those with
a saline infusion for right and left hindpaws. It was found that there was no significant
difference at any of the time points tested except for on the right side (nerve injury),
on the day of experiment at 10 to 14 days after the initial injury. At this point there
was found to be a small but significant difference between those rats receiving NT-3
infusions sand those receiving saline infusions. The rats receiving NT-3 had a
significantly higher paw withdrawal threshold to von Frey hairs (p=0.005) and a
significantly shorter paw withdrawal duration to pin prick (p^O.04) than those
receiving saline infusions. This would indicate that although NT-3 did not appear to
have any role in induction of neuropathic pain, lack ofNT-3 might be involved in the
maintenance of the painful syndrome.
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Table 9. Weight changes after nerve injury
The changes in weight of rats receiving either an infusion of saline (n=7) or NT-3






Pre-op NT-3 206 199-238
Pre-op Saline 206 192-252
Day3 NT-3 216 210-240
Day3 Saline 214 202-262
Day4 NT-3 222 214-247
Day4 Saline 232 206-273
Day5 NT-3 228 220-252
Day5 Saline 238 212-279
Day6 NT-3 234 228-267
Day6 Saline 270 219-292
Day7 NT-3 242 234-263
Day7 Saline 230 224-264
Exp day NT-3 288 265-295
Exp day Saline 266 247-319
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Table 10. Response to von Frey hairs
The paw withdrawal threshold (g) is shown for rats receiving either a NT-3 infusion
(A) or a saline infusion (B). Differences between right (nerve injured) and left
hindpaws were detected from day 3 onwards in both groups (p<0.001), and a
difference between the saline group and NT-3 group was detected on the right side on
the day of experiment.
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A. NT-3 infusion







PreopR (13) 65.01( +/-5.72) 75.86 47.02
PreopL (13) 65.01 (+/-5.72) 75.86 47.02
Day3 R(13) 7.38(+/-0.98) 5.5 11.51
Day3 L (13) 61.39(+/-6.26) 75.86 47.02
Day4 R (13) 6.99(+/-0.91) 5.5 11.51
Day 4 L (13) 56.72(+/-7.06) 75.86 60.72
Day 5 R (13) 8.27(+/-1.84) 5.5 25.21
Day 5 L (13) 53.1(+/-7.16) 75.86 60.72
Day 6 R (11) 5.22(+/-0.6) 5.5 6.47
Day 6 L (11) 67.31(+/-5.73) 75.86 47.02
Day 7 R (11) 4.15(+/-0.59) 3.63 6.47
Day 7 L (11) 63.03(+/-6.62) 75.86 47.02
DaylO/11 R (13) 4.03(+/-0.53) 3.63 7.03
Day 10/11 L (13) 72.72(+/-3.13) 75.86 47.02
Exp day R (13) 4.47(+/-0.73) 3.63 7.03
Exp day L (13) 65.01 (+/-5.72) 75.86 47.02
B. Saline infusion






Preop R (7) 62.42(+/-8.67) 75.86 47.02
Preop L(7) 62.42(+/-8.67) 75.86 47.02
Day3 R(7) 8.53(+/-1.56) 8.51 11.51
Day3 L (7) 69.14(+/-6.72) 75.86 47.02
Day4 R (7) 6.02(+/-1.16) 5.5 8.12
Day 4 L (7) 62.42(+/-8.67) 75.86 47.02
Day 5 R (7) 5.09(+/-1.73) 3.63 13.1
Day 5 L (7) 42.27(+/-8.67) 28.84 47.02
Day 6 R (5) 3.74(+/-0.77) 3.63 3.45
Day 6 L (5) 47.65(+/-l 1.52) 28.84 47.02
Day 7 R (5) 15.28(+/-5.77) 11.75 27.36
Day 7 L (5) 57.05(+/-l 1.52) 75.86 47.02
DaylO/11 R (2) 2.84(+/-0.79) 2.84 1.59
Day 10/11 L (2) 75.86(+/-0) 75.86 0
Exp day R (7) 1.6(+/-0.12) 1.48 0.84
Exp day L (7) 69.14(+/-6.72) 75.86 47.02
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Table 11. Response to pin prick
The paw withdrawal duration (s) to pin prick is shown for each group. Form day
three onwards there was a difference between right(nerve injured) and left hindpaws
within each group (p<0.001). On the day of experiment the NT-3 group had a
significantly shorted paw withdrawal duration than the saline group.
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A. NT-3 infusion






Preop R (13) 0.5 (+/-0) 0.5 0
Preop L (13) 0.5 (+/-0) 0.5 0
Day3-4 R (12) 11.5 (+/-4) 3 29
Day3-4 L (12) 0.5 (+/-0) 0.5 0
Day6-8 R (12) 10 (+/-3.5) 4.5 29.5
Day 6-8 L (12) 0.5 (+/-0) 0.5 0
Exp day R (13) 5.5 (+/-1) 5 13
Exp day L (13) 0.5 (+/-0) 0.5 0
B. Saline in]oision






Preop R (7) 0.5 (+/-0) 0.5 0
Preop L(7) 0.5 (+/-0) 0.5 0
Day 3-4 R (7) 16 (+/-5) 12 29.5
Day 3-4 L (7) 0.5 (+/-0) 0.5 0
Day 6-8 R (7) 8.5(+/-4) 5.5 28
Day 6-8 L (7) 0.5 (+/-0) 0.5 0
Day 10-14 R (7) 13.5(+/-4) 7 25
Day 10-14 L (7) 0.5 (+/-0) 0.5 0
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Figure 33. Response to behavioural testing
The results of behavioural testing for mechanical allodynia and hyperalgesia for rats
with a CCI injury and either a saline or NT-3 infusion are shown. The paw withdrawal
threshold to von Frey hairs is shown at A. and the paw withdrawal duration to pin
prick is shown at B. The right side is the side of the nerve injury, with the left hindpaw
being contralateral to the injury.
d=day
202
Figure 35. Response to behavioural testing
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5.3.4 Effect of NT-3 infusion on ir-NPY release
A total of 256 probes were inserted into the spinal cord of rats with implanted
osmotic pumps, containing either NT-3 or saline, all rats having undergone a CCI of
the right sciatic nerve 10 to 14 days previously. A further 58 probes were used as in
vitro controls to provide an estimate of probe shape in the absence of bound
endogenously released ir-NPY.
NPY antibody-coated probes were inserted into the spinal cord ipsilateral (n=46) and
contralateral (n=44) to the nerve injury, in rats that had a chronic infusion of 0.9%
saline to the nerve injury site. There was found to be an area of increased spontaneous
ir-NPY release on the side of the cord ipsilateral to nerve injury. This corresponded to
previous studies of ir-NPY release 257(see section 5.3.2. ), where there was a new area
of ir-NPY release deeper in the dorsal horn than that found in normal rats. Thus, the
surgery involved in placement of the osmotic pump, and the presence of the osmotic
pump did not in itself alter the pattern of ir-NPY release in the spinal cord of
neuropathic rats. This is shown in Figure 34.
Microprobes were inserted into the spinal cord, ipsilateral (n=84) and contralateral
(n=82) to the side of nerve injury, in rats that had a chronic infusion ofNT-3 to the
nerve injury site. There was an area of ir-NPY release in the deep dorsal horn
ipsilateral to the side of nerve injury, corresponding to that previously found in
neuropathic rats. The basal presence of ir-NPY release that was found in the
contralateral side of the cord was also still present when compared to in vitro probes
(n=58). This is shown in Figure 35. Thus, NT-3 infusion had no major effect on the
deep zone of spontaneous ir-NPY release.
When microprobes that had been inserted into the ipsilateral side of the cord to the
nerve injury in rats with either a saline infusion (n=46) or a NT-3 infusion (n=84)
were compared, there was found to be no difference between these two groups. The
same was true for probes inserted into the contralateral side of the cord for saline
(n=44) or NT-3 (n=82) infused rats. This is shown in Figure 36. NT-3 did not have
any effect on ir-NPY release from primary afferent fibres into the spinal cord of
neuropathic rats.
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Figure 34. Effect of saline infusion on ir-NPY release in the
spinal cord of neuropathic rats
A. This shows the mean image analyses (+/-s.e.m.) of microprobes inserted ipsilateral
(n=46) and contralateral (n=44) to a chronic constriction injury of the right sciatic
nerve in rats with a mini-osmotic pump implanted at the time of nerve injury to
infuse 0.9% saline until the day of ir-NPY release experiment. Similar areas of
decreased optical density can be seen in those probes inserted ipsilaterally as that
seen in Figure 29.
B. The t statistics obtained from comparison of probes inserted into both sides of the
cord are plotted next to a diagram of the spinal cord. There is an area of
significantly increased ir-NPY release in the ipsilateral side of the cord peaking in
laminae III-V. This corresponds with results from previous studies of spontaneous
ir-NPY release in neuropathic rats.
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Figure 35. Effect of NT-3 infusion on ir-NPY release in the
spinal cord of neuropathic rats
A. This shows the mean image analyses (+/-s.e.m.) of microprobes inserted ipsilateral
(n=84) and contralateral (n=82) to a CCI of the right sciatic nerve in rats with a
chronic infusion ofNT-3. The mean image analysis of in vitro probes is also shown
to demonstrate that there is a basal presence of ir-NPY found contralateral^, that
is similar to that found in the normal situation 258.
B. The t statistics obtained from comparing probes inserted on each side of the spinal
cord are shown next to a diagram of the spinal cord. A significantly increased area
of ir-NPY release is apparent ipsilateral to injury, with a peak in laminae III-V,
similar to that found in neuropathic rats without prior infusion of NT-3.
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Figure 36. Comparison of ir-NPY release in the CCI model in
rats with a saline or a NT-3 infusion
A. This shows the mean image analyses (+/-s.e.m.) of probes inserted into the side of
the spinal cord ipsilateral nerve injury in rats that had received a chronic infusion of
either saline (n=46) or NT-3 (n=84). There is no major deviation of the two lines
from each other, indicating no major difference in spontaneous sir-NPY release.
B. The mean image analyses (+/-s.e.m.) of probes inserted into the side of the spinal
cord contralateral nerve injury in rats that had received a chronic infusion of either
saline (n=44) or NT-3 (n=82). Again there is no major difference in optical density
at the areas of the probe shown within the spinal cord.
C. The t statistics obtained from comparison of probes inserted into both ipsilateral
(1) and contralateral (2) sides of the cord between saline or NT-3 infused rats, are
plotted relative to depth within the spinal cord. At no point was there any
significant difference between the saline and NT-3 groups, indicating that supplying
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The key new findings from the study of ir-NPY release in the spinal cord of the
neuropathic rat are:
1. Conduction block proximal to the dorsal roots using amethocaine gel did not alter
the new area of spontaneous ir-NPY release that had been found in the ipsilateral
dorsal horn of neuropathic rats.
2. Despite a small decrease in mechanical allodynia and hyperalgesia 10-14 days after
injury, chronic infusion ofNT-3 did not alter the spontaneous release of ir-NPY in
the spinal cord of neuropathic rats.
5.4.1. Stimulus for ir-NPY release
The stimulus for the deeper zone of ir-NPY release in the dorsal horn of neuropathic
rats does not appear to be spontaneously occurring ectopic discharges from the
injured nerve or the dorsal root ganglia, as complete conduction block did not alter
this spontaneous ir-NPY release. As the adequacy of the block was checked by
peripheral electrical stimulation to ensure no evoked activity within the cord, it is
unlikely that the lack of effect on release was due to inadequate conduction block,
particularly as ectopic discharges are inhibited at much lower doses of local
anaesthetic than those required for conduction block 57'91. There is increasing evidence
that TTX-sensitive sodium channels are involved in the generation of ectopic
discharges 327'328, and these are blocked by local anaesthetics 394,403. There must
therefore be an alternative stimulus resulting in the spontaneous release of ir-NPY
ipsilateral to a peripheral nerve injury. Several possibilities must be considered:
1. Spontaneous neuronal activity not originating from primary afferent neurones may
be involved. Activation of descending systems in the normal rat resulted in SP
release from primary afferent terminals, via a NMDA receptor mediated
mechanism, presumably by an action at a pre-synaptic site 242 In both normal 146
and neuropathic 387 animals, there is evidence for descending systems influencing
activity in the dorsal horn. In the CCI model, there was higher spontaneous activity
within the dorsal horn itself, that was inhibited by stimulation of descending
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systems 387, as well as an increase in inhibitory neurotransmitters from the
descending systems 360. Additionally, intrinsic spinal neurones may also act on the
primary afferent terminals 461, possibly altering neuropeptide release, with further
changes occurring after nerve injury 465. Thus, general alterations in spinal
excitability after nerve injury may alter neuropeptide release from primary afferent
terminals.
2. The possibility that ir-NPY secretion and release is occurring without influence
from neuronal activity must be considered. Peptides are normally packaged in large
dense core vesicles (LDCVs), in the Golgi complex before transport to both
synaptic and extra-synaptic sites 24,50\ Exocytosis of LDCVs is slower than that
seen with classical neurotransmitters packaged in small synaptic vesicles (SSVs),
but still requires an increase in intracellular calcium 259, and involves many of the
same membrane proteins34'81- There is evidence for an increase in exocytosis of
LDCVs after axotomy 501, but another factor may be alterations in the processing
of peptides. Normally, large diameter primary afferent neurones do not contain
many peptides, or LDCVs 49°, and the rapid increase in peptide synthesis after
nerve injury may be greater than the existing packaging systems can cope with.
Thus some of the newly produced peptide may be secreted via the non-regulated,
constitutive pathway, by which membrane components, enzymes, growth factors
and extracellular matrix molecules are normally secreted 24,81. There is some
evidence that this may be the case for NPY, as it is found not only in LDCVs, but
also diffusely in the cytoplasm of large diameter primary afferent neurones after
nerve injury 490. This is different from the situation with galanin, which is found
mainly in small to medium sized primary afferent neurones, that even in the normal
situation, synthesise and process peptides in LDCVs. There may also be changes in
ion channel types after nerve injury, that could result in altered secretion patterns.
There is evidence for changes in types of both sodium channels 322,445 and calcium
channels 1,350 after nerve injury that may alter mechanisms of neuronal activation
and neurotransmitter secretion.
3. Other substances that are secreted by the constitutive pathway, either from primary
afferent neurones, local dorsal horn neurones or supraspinal systems may act
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indirectly to stimulate ir-NPY release. Thus, brain derived neurotrophic factor
(BDNF) has been shown to increase glutamate release and exocytosis from cortical
neurones in culture 405, as well as modify the firing pattern of serotonergic
neurones 55. Both BDNF and NT-3 potentiated synaptic activity at the
neuromuscular junction of developing synapses in culture 243, and there is evidence
that neurotrophins can alter synaptic efficacy by effects on neurotransmitter release
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Role of NT-3 in the CC1 model
NT-3 had a small but significant effect on the maintenance of pain-related behaviour,
with a slight attenuation of both mechanical allodynia and hyperalgesia on the day of
the ir-NPY release experiments, at 10-14 days after nerve injury. In a different model
of a large fibre sensory neuropathy, NT-3 was found to alleviate the signs of
neuropathy, although pain-related behaviour was not studied 158-238 in addition, other
neurotrophins such as NGF, have been shown to partially alleviate some of the
neuropathic signs developing after nerve injury, both in the CCI model 349, and in
diabetic sensory neuropathy9. Infusion of NT-3 into the rat midbrain had
antinociceptive actions j80 and NT-3 inhibited SP release from an isolated spinal cord
preparation, as well as inducing mechanical hypoalgesia after systemic administration
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It is clear from studies of knockout mice deficient in the genes for NT-3 or its high
affinity receptor, the trkC receptor, that NT-3 and trkC are essential during
development, as the homozygotes from both NT-3 and trkC studies die shortly after
birth 3.123>124409,37^ with a ^1-1^ decrease in large diameter sensory neurones.
However, NT-3 is not necessary for survival of adult sensory neurones, but may have
a role in the control of the adult neuronal phenotype 239 Many large diameter
neurones express trkC receptors 239 and there is evidence of rapid retrograde transport
of trk receptors, from the periphery along the length of the axon to the cell body 37'38.
The effects of nerve injury on this retrograde transport and changes in the supply of
NT-3 to the cell body may be important in alterations in the phenotype ofNT-3
sensitive neurones 93. Furthermore, although the effect ofNT-3 on behaviour was
limited, this is not surprising, as there is evidence that many of these factors act in a
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synergistic fashion 238'266. Although outwith the scope of the current study, the effects
ofNT-3 at time periods longer than 10-14 days after nerve injury, plus combination
with other neurotrophins, deserve further investigation. It may be that, similar to the
situation during development 5-237'384; the relative importance of different
neurotrophins, either individually or in combination, changes as the pain syndrome
develops.
The lack of effect of exogenously supplied NT-3 on ir-NPY release indicates that this
neurotrophin is not an important factor in the spontaneous release of ir-NPY in the
deep dorsal horn ipsilateral to nerve injury. In an immunohistochemical study ofNPY-
ir distribution, Ohara et al, 199 5 326, found that after bilateral axotomy, exogenous NT-
3 supplied to one of the transected sciatic nerves significantly attenuated the increase
in NPY-ir in the dorsal horn and the gracile nuclei on that side of the cord. There is
some discrepancy between the Ohara study of NPY levels in the spinal cord, and the
current study on NPY release. There may be several reasons for this. Firstly, the
Ohara study was ofNPY distribution in post mortem specimens, as opposed to ir-
NPY release in vivo. It does however seem unlikely that a decrease in NPY-ir in the
dorsal horn was accompanied by no change in release. Secondly, a bilateral complete
nerve transection was being studied, as opposed to a unilateral partial nerve injury.
Rats with bilateral axotomy must find hindleg movement very difficult, with possible
effects on feeding ability and increased stress due to an inability to move normally.
Additionally, the contralateral side of the cord was used as the control group, and no
evidence was presented that the effects of the contralateral saline infusion to the nerve
had the same effect as simple axotomy on NPY changes. It may be that the silicone
chamber around the nerve had effects on NPY distribution, either due to a chemical
constituent of the chamber, or as a direct physical effect due to tissue irritation, and
pressure. Other factors, such as differential changes in neurotrophin receptors,
retrograde transport ofNT-3 and alternative sources ofNT-3 may also be involved
when comparing a bilateral complete injury to a unilateral partial injury.
Although large fibres are thought to be mainly responsive to NT-3, because of the
expression of its high affinity receptor, some of them also express the low affinity
neurotrophin receptor, p75 3955 at which several neurotrophins can act, including NT-
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3 and NGF. It may be therefore that the changes in ir-NPY release are regulated via
other neurotrophins acting by this alternative pathway. The sprouting of large
myelinated fibres into lamina II that occurred after nerve injury was not prevented by
either intrathecal NT-3 29 or NT-3 applied to the nerve injury site l2°, whereas NGF
did prevent this reorganisational change. Additionally, NGF partially prevented the
increase in NPY synthesis in dorsal root ganglia, after axotomy 424. Although the
majority of neurones that increase NPY production after nerve injury do not have the
high affinity NGF receptor, trkA, they do have the low affinity p75 receptor. It may
be therefore that one of the stimuli resulting in spontaneous ir-NPY release is due to
actions ofNGF, or other neurotrophin. This is an area that requires furthers study.
This current study has demonstrated that there was not a correlation between
spontaneous ir-NPY release and behavioural changes induced by NT-3 infusion. The
stimulus for spontaneous ir-NPY release was not due to lack ofNT-3, but may be due
to other secreted factors from primary afferent neurones, supraspinal sources or
intrinsic dorsal horn neurones. Alternatively, ir-NPY may be released in the absence of
any stimulus, via the constitutive pathway.
5.4.3. Functional effects of ir-NPY after nerve injury
It is important to consider the possible functional role ofNPY released in the dorsal
horn after nerve injury.
It may be acting to limit abnormal input from the damaged nerve and decreasing
excitability in the dorsal horn, thus reducing abnormal pain transmission There is a
considerable amount of evidence that NPY has an inhibitory action, both from studies
of its electrophysiological actions 72-73-267'421 and its inhibition of SP release in the
dorsal horn uo. Additionally, studies ofNPY knockout mice show an increased
tendency to seizures 119, with intracerebroventricular NPY infusion preventing death
from kainic acid induced seizures in these NPY deficient mice 19, indicating a possible
generalised role in dampening neuronal excitability. There is evidence of
antinociceptive actions 47'78,12, including depression of the nociceptive flexor reflex
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However, there is evidence that NPY may have excitatory actions, presumably due to
actions at different receptor subtypes. Thus NPY has been shown to potentiate the
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response to NMDA in the hippocampus 290'291; tc> increase spontaneous activity of
paraventricular neurones 10 and to potentiate the contractile effect of noradrenaline 36.
A few studies have also found that NPY administered either peripherally 4I7, or
centrally 448 can result in mechanical hypersensitivity.
Overall, however, the evidence for inhibitory actions appears to predominate. NPY
inhibited calcium currents 262, prevented increases in intracellular calcium 278 and
inhibited cAMP production in the brainstem 318. NPY also had inhibitory effect on
other neurotransmitters, as it inhibited glutamate release in the hippocampus 147,
transmitter release from capsaicin-sensitive terminals 141 and catecholamine release
from sympathetic ganglia 323, as well as suppressing neurogenic inflammation 15j and
having potential as a novel analgesic 78-301'433.
The fact that NPY appears to be released from primary afferent terminals without any
neuronal activity, is rather strange if it is acting as an inhibitory neurotransmitter. An
alternative explanation for its increased synthesis and release in response to peripheral
nerve injury may be that it plays a part in the reorganisational changes that occur in
the dorsal horn. It may be involved in the sprouting of the large diameter fibres from
their deep termination into the superficial dorsal horn. Although the area where ir-
NPY release was detected is deeper than where the newly sprouted fibres terminate,
ir-NPY could be released from extra-synaptic sites 5t>1, or there could be diffusion
from its site of release to induce sprouting .It has already been demonstrated that ir-
NPY persists for some significant length of time after its evoked release 257, and it
could be that it induces growth along a diffusion gradient. There is evidence that NPY
has growth inducing properties in neurones in culture 449, in vascular smooth muscle
cells 122'373 and in fibroblasts 42. Other peptides increased after nerve injury have also
been shown to have growth stimulating properties, particularly VIP I26-212 Thus, NPY
may act, either alone or in combination with other substances, to induce the
reorganisational changes occurring in the spinal cord after nerve injury, possibly with
the additional function of inhibiting excess abnormal activity during the period of
recovery.
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Chapter 6. Concluding Remarks
6.1 Summary of significant results
The key findings from the present studies of the CCI model are:
1. There was an increase in spontaneous ir-galanin release in the superficial dorsal
horn ipsilateral to nerve injury. Peripheral electrical stimulation of the injured
nerve sufficient to activate both A and C fibres was required to further increase
ir-galanin release in the dorsal horn, while stimulation of AP fibres alone did not
alter spinal release of ir-galanin. Ir-galanin did not persist for any significant
length of time after its evoked release. Blockade of all neuronal input from the
injured nerve did not significantly alter basal ir-galanin release in the dorsal horn
ipsilateral to nerve injury, but markedly increased ir-galanin release contralateral
to nerve injury. This increase in basal ir-galanin release contralateral to the
injured nerve, after conduction block, was such that the side to side difference in
ir-galanin release seen in the neuropathic rats was eliminated.
2. Previous studies 257,258 of the CCI model, have shown the appearance of a new
area of ir-NPY release in the deep dorsal horn ipsilateral to nerve injury. Ir-NPY
release in this area was increased by electrical stimulation of the injured nerve
sufficient to activate AP fibres. This ir-NPY could still be detected for up to one
hour after its evoked release. Blockade of all neuronal input from the injured
nerve, proximal to the dorsal root ganglia, had no effect on spontaneous ir-NPY
release in this area of the dorsal horn. Chronic infusion ofNT-3 to the site of
nerve injury did not alter the spontaneous release of ir-NPY, although a minor
alleviation of mechanical hypersensitivity was detected on the day of the ir-NPY
release experiments.
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6.2 Relation of findings to other studies on animal models of
neuropathic pain
It is important to consider how the findings from these studies relate to other changes
occurring in the spinal cord after nerve injury, that may result in the development of
neuropathic pain. A major finding from studies of peripheral nerve injury was the
change in adult sensory neuronal phenotype 30S. As discussed in section 1.2.8, this
included dramatic alterations in neuropeptide synthesis 316. Thus synthesis of
neuropeptides normally thought to be involved in nociceptive transmission, such as SP
and CGRP, was markedly decreased 164>183-280-425; whereas there was induction of
neuropeptides not normally found in primary afferent neurones 308. This change was
seen in all sizes of primary afferent neurones, with neuropeptides such as galanin and
VIP increasing in small to medium sized neurones 493-495 and NPY being found in large
diameter neurones not normally associated with the production of neuropeptides
300,490
consequence 0f the altered neuropeptide production and distribution was a
change in the pattern of coexistence of neuropeptides in primary afferent neurones
194,196,492,493 onjy was there an increase in synthesis of galanin and NPY by
different classes of primary afferent neurones, but the present release studies have
demonstrated that there was also a change in their spinal release in the CCI model.
There are some similarities between galanin and NPY changes after nerve injury:
1. Both galanin and NPY were up-regulated and released spontaneously in the
ipsilateral dorsal horn of the spinal cord;
2. Whereas peripheral stimulation did not alter central release in normal rats, in the
CCI model, release of both galanin and NPY could be evoked by stimulation of the
injured nerve.
There were also, however, some quite marked differences between the patterns of ir-
galanin and ir-NPY release, that may indicate different functional roles for these two
neuropeptides.
It is apparent from the release studies, that different stimuli regulate the release of
galanin and NPY. Low intensity stimulation of the injured nerve evoked only ir-NPY
release in the deep dorsal horn, and it was only as the intensity of stimulation was
increased in order to activate C as well as A fibres that ir-galanin release was evoked
218
in the superficial dorsal horn. This correlates well with the increased synthesis ofNPY
in large fibres and galanin in small to medium sized primary afferent fibres.
Blocking ectopic discharges did have an effect on basal ir-galanin release, mainly on
the contralateral side of the spinal cord. Interpretation of this is complicated by the
fact that there were probably at least two sites of origin of ir-galanin in the superficial
dorsal horn of the spinal cord - small diameter primary afferent neurones, and intrinsic
dorsal horn neurones. Nevertheless, alteration in neuronal input, either by blocking
ectopic discharge or by high intensity stimulation, did alter central ir-galanin release,
indicating that abnormal input from the injured nerve may play at least some role in
regulating ir-galanin release. In contrast, the new area of spontaneous ir-NPY release,
deep in the dorsal horn, was not altered at all by blocking neuronal input from the
injured nerve. Additionally, unlike ir-galanin, ir-NPY released by low intensity
stimulation, persisted for some time after its release. Thus, released ir-NPY may
diffuse to sites distant from its release, with widespread actions on neuronal activity.
There is evidence from studies of other neuropeptides that they may act in a paracrine
fashion 109,167. It has been proposed that some neuropeptides may not act by standard
synaptic release-receptor interaction, but instead act by volume transmission, with
many diffuse effects, by spreading from release sites 105-132-241. This does not exclude
the possibility of direct neuropeptide-receptor interaction at synapses, but instead may
provide an additional mode of action, that may become more important as the amount
of released ir-NPY is increased, for example after nerve injury.
Galanin, however, appears to act more like a classical neurotransmitter, with release
in the area of its receptors, and little persistence after release. In addition, neuronal
activity altered ir-galanin release, with bilateral effects on its release secondary to
blocking neuronal conduction from the injured nerve. As discussed in section 1.3.6,
inhibitory effects of galanin predominate after nerve injury 453'454,456'474. It may be
therefore that the ir-galanin released from small diameter primary afferent fibres in the
superficial dorsal horn acts to reduce onward transmission of abnormal impulses from
ectopically firing neurones. Abnormal impulses have been detected in all classes of
neurones after nerve injury 187, with the possibility of interactions between ectopically
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firing A fibres and the C fibres that may release ir-galanin. There is certainly evidence
for interactions between ectopically firing cells at the level of the dorsal root ganglia 8.
As well as ir-galanin released from primary afferent fibres, ir-galanin released from
intrinsic neurones must be considered. As demonstrated in normal rats, galanin is both
produced by 497 and released from 168 intrinsic neurones in the superficial dorsal horn.
There is no evidence that galanin synthesis is altered in these neurones after nerve
injury, but changes in neuronal input may alter control of release from these cells. In
neuropathic rats, there appears to be some form of bilateral tonic inhibition of ir-
galanin release, due to impulses from the injured nerve, as revealed by the effects of
conduction block. Ifgalanin is indeed acting primarily as inhibitory neurotransmitter,
and its release from intrinsic neurones is prevented from increasing after nerve injury,
then this may result in a generalised increase in spinal cord excitability. Whether this
results in perception of pain is unclear, but there has been shown to be a link between
the rate of ectopic discharge and degree of spontaneous pain in both animal 407 and
human studies j2°. Alternatively, the increase in spontaneous activity may be one of
the factors involved in stimulating and guiding the regenerative changes in the spinal
cord.
The changes in ir-galanin and ir-NPY release may also be influenced by changes in the
pattern of co-existence of neuropeptides with other neurotransmitters after nerve
injury. In normal rats, both galanin 379 and NPY 355 have been found to coexist with
GABA in the dorsal horn. However, after nerve injury, there is bilateral decrease in
GABA levels in the dorsal horn I75, as opposed to a unilateral increase in galanin and
NPY. The pattern of neuronal firing may alter the type of neurotransmitter released,
as shown in studies of noradrenaline and NPY in the sympathetic nervous system 82,
with firing frequency influencing the relative release of neurotransmitter from the
nerve terminal 246. There is also evidence of feedback from released NPY altering
subsequent release of noradrenaline 39. Thus, there may be complex interactions
between the pattern of peripheral neuronal input, neurotransmitter co-existence and
regulation of release from both primary afferent neurones and dorsal horn neurones.
The summation of these effects may contribute to the development of neuropathic
pain.
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Previous studies have found evidence of altered peripheral input, with increased
activity evoked in the dorsal horn of neuropathic rats from Ap fibre stimulation of the
injured nerve 75. This same stimulus resulted in increased release of ir-NPY in the
deep dorsal horn. The question of whether or not stimulation of these fibres, which
are normally concerned with light touch transmission, is related to the generation of
mechanical allodynia, and the role of evoked ir-NPY remains to be answered. There is
some evidence from inflammatory models that phenotypic switches can occur in large
myelinated fibres. This may be related to the development of pain related behaviour,
possibly arising from impulses in large fibres not normally involved in the transmission
of nociceptive information 313.
There is considerable evidence for reorganisational changes occurring in the dorsal
horn after nerve injury, with both degeneration and regeneration occurring. The
stimuli driving this restructuring are not fully understood, but NPY may have a role as
a growth inducing substance, possibly in conjunction with other substances produced
in or transported to the spinal cord. Chronic administration of intrathecal NPY was
shown to result in increased neurite outgrowth from cultured dorsal root ganglia
neurones 449. This study also found that NPY added to dorsal root ganglia cultures
from normal rats had no effect alone ,but only increased neurite outgrowth when
given in conjunction with dorsal spinal cord explant. Ir-NPY release in the deep dorsal
horn may initiate sprouting of large fibres from this area to the superficial dorsal horn.
The new site of termination of these sprouted fibres does correlate better with the
area of ir-galanin release, and the location of C fibre-derived GAP-43 71>97'467; but ir-
NPY may still have stimulated the initial growth of these fibres. Thus NPY may act as
inhibitory neurotransmitter, perhaps with a generalised damping of spinal cord
activity, but may also have a role in the spinal cord reorganisation occurring in
response to nerve injury.
The nature of the factors needed for central "remodelling" after peripheral injury is
obscure, but neurotrophins may be important in the changes occurring. Not only are
they essential for growth and survival during development, but changes in their supply
may be important in the primary afferent changes seen after nerve injury 239 Thus,
NT-3 seems to modulate large myelinated fibres, although the present studies did not
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demonstrate any relationship between ir-NPY release from large fibres and lack of
NT-3 after nerve injury. The interaction between neuropeptide synthesis and release
and neurotrophins is complex. Neurotrophins have been found to have rapid actions
on neurotransmitter release at synapses 243,405> as well as effects on sensory neurone
regrowth 38. It may be therefore that after nerve injury both neuropeptides and
neurotrophin are involved in the central consequences of peripheral injury, as
neurotransmitters or neuromodulators, and as growth promoting substances.
As the present studies have demonstrated, the spontaneous release of ir-NPY in the
deep dorsal horn is neither altered by primary afferent input, nor by supplying
exogenous NT-3 to the nerve injury site. It may be therefore that this ir-NPY release
is occurring by an alternative secretory pathway to that normally associated with
neurotransmitters. If ir-NPY has a role as a growth-promoting substance, then it may
be released from primary afferent neurones by a non-vesicular mechanism, utilising the
constitutive secretory pathway by which membrane components and growth
promoting substances are normally released 24-49°. In this hypothetical situation,
compounds with neurotransmitter actions could be released without regulation from
neuronal activity and contribute to the development of abnormal, and uncontrolled,
activity in the spinal cord.
6.3 Future directions
The present studies have provided information about the factors influencing the spinal
release of galanin and NPY, but certain areas require further investigation in order to
understand the functional significance of these findings in context with other changes
known to occur after nerve injury.
Further studies are needed to elucidate the factors regulating bilateral ir-galanin
release, including investigation of the involvement of supraspinal systems. Although
the origin of the increased ir-galanin in the superficial dorsal horn ipsilateral to nerve
injury is likely to be from primary afferent neurones, this also needs further study.
Potentially, one of the most significant findings from the present studies is that the
spontaneous release of ir-NPY does not appear to be regulated by primary afferent
activity. Thus investigation of the nature of the stimulus resulting in release, and the
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secretory mechanisms involved might provide valuable information about the effects
of peripheral nerve injury on a novel central release pathway of neurotransmitters.
For both galanin and NPY, it would be useful to relate release to receptor activation
in the spinal cord before and after nerve injury. This would add to the knowledge of
the functional roles of galanin and NPY, as well as the spatial relationship between
sites of release and sites of action. This could be further investigated by using some of
the newer galanin and NPY antagonists, with improved sensitivity and specificity, in
electrophysiological studies in the CCI model.
Another area worthy of further study is the interaction between neurotrophins,
neuropeptides and behaviour. The present studies found a very minor alleviation of
mechanical allodynia and hyperalgesia on the day of ir-NPY release experiments, 10-
14 days after nerve injury. It would be interesting to continue this study further,
following the time course of the behavioural syndrome over a longer period, as well
as extending the testing to include measurement of other responses. The effect of
other neurotrophins, either alone or in combination could also be studied, in
conjunction with studies of peptide release.
The ultimate aim of studies of animal models of neuropathy has to be improvements in
the management of patients with neuropathic pain. This can only be achieved by
understanding the responses to peripheral nerve injury that result in the development
of pain, and subsequently targeting these changes in a logical fashion. This will include
new analgesic agents, as those currently available are often ineffective. In view of the
major changes in neurotransmitters and neuronal phenotype after nerve injury, this is
not surprising. The exact functional roles of galanin and NPY still require further
study, as does the complex interplay between neuropeptides, neurotrophins and other
neurotransmitters in the spinal cord. Whether or not galanin and NPY are directly
involved in modulation of nociceptive transmission, or simply involved in the central
restructuring that occurs after peripheral nerve injury, it seems increasingly likely that
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ENHANCED SYNAPTIC ACTIVITY IN THE SPINAL CORD IN A RAT MODEL OF
PERIPHERAL MONONEUROPATHY
L.A. Colvin*. M.A. Mark* and A.W. Duggan (SPON: V. Molony), Dept of Preclinical Veterinary
Sciences, University of Edinburgh, Summerhall, Edinburgh EH9 1QH, Scotland, U.K.
Aim of Investigation: This study was designed to investigate the central mechanisms underlying
mechanical allodynia. We used a rat model of peripheral mononeuropathy to investigate the
functional changes which occur in the spinal cord in response to peripheral stimulation of large
myelinated fibres.
Methods: A peripheral mononeuropathy was produced by placing four loose ligatures around
the right sciatic nerve at mid thigh level, as described by Bennett and Xie (1988). All the
experiments were carried out on urethane anaesthetized male Wistar rats that displayed
mechanical allodynia, at ten to fifteen days after nerve ligation. Control groups consisted of normal
animals and those in which a sham operation had been performed. Large myelinated fibres in each
sciatic nerve were stimulated 3 times threshold and the resulting cord dorsum potentials and field
potentials (from 100 to 1200 microns from the cord dorsum) were measured on both the ipsilateral
and contralateral sides of the cord.
Results: Paired t-tests of the means revealed that there was a significant difference between
stimulation of the normal nerve and of the ligated nerve for: 1. The afferent volley from the ligated
nerve was smaller on the ipsilateral side of the cord. 2. When the cord dorsum potentials were
measured, the smaller afferent volley from the ligated nerve evoked greater activity in the spinal
cord than the normal nerve on both the ipsilateral and contralateral side of the cord. 3. The field
potential measurements also showed greater evoked activity from the ligated nerve on the ipsilateral
side of the cord. This difference was most marked at a depth of 400-600 microns from the surface
of the cord.
Conclusions: This study provides new electrophysiological evidence that nerve injury can result
in enhanced central responses to a peripheral stimulation of large myelinated fibres. The major site
of this increase appears to occur at a specific area in the dorsal horn - a depth of 400-600 microns.
This may reflect the anatomical changes which have been shown recently, of central reorganisation
and sprouting of the large myelinated fibres in the dorsal horn. Mechanical allodynia may result
from these altered spinal cord responses.
Congress Abstracts, IASP Publications, 8th World Congress on Pain (1996) 133,
All.
Antibody microprobe studies of immunoreacttve neuropeptide Y in the
spinal cord of the rat.
Mark, M.A., Colvin, L.A., Duggan, A.W., Dept of Preclinical Veterinary Sciences, University of
Edinburgh, Summerhall, Edinburgh EH9 1QH, Scotland, U.K.
Aim of Investigation: To study the spinal release of immunoreactive Neuropeptide Y (ir-NPY) in
normal rats and determine the origin of this release. This was investigated by: 1/ determining the
extracellular levels of ir-NPY in rats in the absence of any active peripheral stimulus. 2/
investigating whether peripheral stimulation releases ir-NPY. 3/ examining whether spinalisation
alters ir-NPY basal levels to determine the involvement of the descending bulbospinal pathways.
Methods: Microprobes bearing immobilised antibodies to NPY were inserted 2.25mm into the
lumbar spinal cord ( at the site of the sciatic nerve distribution) of anaesthetised rats and remained
insitu for 15 minutes. Following incubation in radioactivity, the autoradiographic image of each
probe tip was analysed by an image analysis system.
Results: A surprisingly high basal presence of immunoreactive (ir)-NPY was found throughout the
entire dorsal horn. Electrical stimulation of large diameter afferents of the ipsilateral sciatic nerve
(1Hz, 20Hz both at 3 x threshold) and unmyelinated primary afferents (2 Hz, 20 volts) did not
release NPY in the spinal cord. Spinalisation did not alter the extracellular levels of ir-NPY in the
distal segment of the cord.
Conclusion: Failure of electrical stimulation of primary afferents and of spinalisation to alter the
extracellular basal presence of ir-NPY suggests that this basal presence originates from intrinsic
neurones.
Presented at the 19th Annual Meeting of the European Academy of Anaesthesiology.
1997;
European Journal ofAnaesthesiology (in press)
"IMMTJNOREACTIVE (ir)-GALANIN RELEASE EN THE SPINAL CORD OF THE
NEUROPATHIC RAT"
L.A. Colvina'b. M.A. Markb, A.W. Dugganb
aDept of Anaesthetics, Royal Infirmary of Edinburgh & ^ept of Preclinical Veterinary Sciences,
University of Edinburgh, Edinburgh, UK,
Introduction
After peripheral nerve injury, galanin synthesis is significantly increased in dorsal root ganglia, with
a corresponding increase in galanin levels in the superficial dorsal horn1,2. Galanin has an increased
inhibitory action after nerve injury and may therefore act as an endogenous analgesic during nerve
regeneration3. Previously extensive basal ir-galanin release has been found in normal rats, which is
not affected by peripheral stimulation4.
The aim of this study was to investigate the effects of peripheral stimulation on ir-galanin release
after peripheral nerve injury. The persistence of stimulus-released ir-galanin was also studied.
Methods and Materials
A chronic constriction injury was produced in male Wistar rats (n=42), by placing four 4/0 chromic
gut ligatures loosely around one sciatic nerve5. The guidelines for the care of experimental animals of
the International Association for the Study of Pain were followed6.
At 10-14 days after ligature placement, the lumbar spinal cords of urethane-anaesthetised rats were
exposed. Microprobes bearing immobilised antibodies to galanin (Peninsula Labs) were inserted
2.25mm into the dorsal spinal cord. Following removal from the spinal cord and incubation in 125I-
labelled galanin (Peninsula Labs), autoradiographic images of each microprobe tip were analysed and
compared using a computerised image analysis system. Binding of endogenous galanin to the
microprobes resulted in deficits in binding of 125I-labelled galanin. Differences between specified
groups of microprobes were assigned statistical significance using Student's unpaired t-test.
Results
There was a new peak of ir-Gal release in the superficial dorsal horn, ipsilateral to nerve injury, when
compared to the contralateral side. This area of spontaneous release was increased further by
electrical stimulation of the injured nerve at a strength sufficient to activate A and C fibres, but not by
stimulation of A fibres alone. Unlike other neuropeptides, such as neurokinin A, there was no
evidence of persistence of the new areas of galanin release after the stimulation had finished.
Conclusions
These studies showed that ir-galanin was continuously released in the superficial dorsal horn
ipsilateral to nerve injury. This release was increased further by stimulation of small primary afferent
fibres. Although functional studies are required to elucidate the role of galanin after nerve injury,
these studies of release suggest an important role in the modulation of nociceptive transmission. Its
lack of persistence after stimulation would indicate that its main site of action is close to its site of
release.
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Following peripheral nerve injury
dramatic changes are seen in
neuropeptide synthesis in the dorsal
root ganglia [1], with significant
increases in galanin and neuropeptide
Y mRNA and a decrease in both
CGRP and substance P mRNA [2].
The aim of this study was to
investigate changes in central galanin
release after peripheral nerve injury.
Although the significance of galanin
up-regulation is unknown, it has been
postulated to play an inhibitory role in
dorsal horn transmission.
Under sodium pentobarbitone
anaesthesia, four 4/0 chromic gut
ligatures were placed loosely around
one sciatic nerve of male Wistar rats
to produce a chronic constriction
injury [3]. The International
Association for the Study ofPain
guidelines for the care of experimental
animals were followed.
At 10-14 days after ligature
placement, the lumbar spinal cords of
urethane-anaesthetized rats (n^O)
were exposed. Using a
micromanipulator, microprobes
bearing immobilised antibodies to
galanin were inserted into the dorsal
spinal cord to a depth of 2.25mm.
Following removal from the spinal
cord and incubation in 125I-labelled
Journal ofAnaesthesia, 78 (1997) 462P.
galanin, autoradiographs of each
microprobe tip were analysed using an
image analysis system. In vitro
microprobe images for each
experiment were also analysed and
normal rats were used as controls.
Binding of endogenous galanin results
in deficits in binding of 125I-labelled
galanin. Mean image analysis of
defined groups of microprobes were
compared, at 30p intervals, and the
differences between specified groups
were assigned statistical significance
using Student's t-test.
In normal animals, there was a fairly
extensive presence of ir-galanin
throughout the dorsal horn, with a
peak in the superficial dorsal horn. In
the neuropathic rats there was a
significantly greater peak of ir-galanin
release in the superficial dorsal horn
(p<0.05). As there is significant up-
regulation of galanin synthesis in small
to medium sized dorsal root ganglia
cells, the likely source of this new
zone of central galanin release is from
primary afferent fibres, affected by the
peripheral nerve injury. Since this
increased release occurred
spontaneously, and there is evidence
for spontaneous pain in this model, the
two may be linked.
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The effect of conduction
block on basal
immunoreactive-neuropeptide
Y (ir-NPY) release in the spinal
cord of the neuropathic rat
L.A. Colvin*
Dept of Preclinical Veterinary Sciences,
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Edinburgh EH9 1QH7 Dept of Anaesthetics,
Royal Infirmary of Edinburgh, Edinburgh,
EH3 9YW.
In rats, ir-NPY is released spontaneously in
the dorsal horn of the spinal cord, on the side
ipsilateral to a chronic constriction injury of
the sciatic nerve1. The likely site of origin is
from primary afferent neurones2, although
the stimulus resulting in release in not
known. After nerve injury, primary afferent
neurones behave abnormally, with the
generation of spontaneous ectopic activity
both at the nerve injury site and the dorsal
root ganglia3'4. If the spontaneous release of
ir-NPY is due to ectopic discharges, then
blocking these impulses should abolish the
new zone of spontaneously released ir-NPY
found in the spinal cord of neuropathic rats.
In male Wistar rats, a chronic constriction
injury was induced by placing four 4/0
chromic gut ligatures loosely around the
sciatic nerve, under sodium pentobarbitone
anaesthesia5. The International Association
for the Study of Pain guidelines for the care
of experimental animals were followed. After
10-14 days, levels of ir-NPY release were
determined in rats (n=12) showing
behavioural evidence of neuropathic pain.
Under urethane anaesthesia, the lumbar
spinal cord was exposed and microprobes
coated with immobilised antibodies to NPY
were inserted bilaterally into the spinal cord
to a depth of 2.25mm. Ir-NPY release was
studied, firstly, under basal conditions, and
then after conduction block with
amethocaine gel proximal to the dorsal root
ganglia. Following removal from the spinal
cord and incubation in 125I-labelled NPY, the
microprobe tip was placed on X-ray
monoemulsion film, to give an
autoradiographic image for each microprobe,
that was then analysed. Binding of
endogenous NPY results in deficits in
binding of 125I-labelled NPY, which was
detected as a decrease in the optical density
by a computerised image analysis system.
Mean image analysis of defined groups of
microprobes were compared, at 30p
intervals, and the differences between
specified groups were assigned statistical
significance using Student's unpaired t-test.
Spontaneous release of ir-NPY was
confirmed on the side of the cord ipsilateral
to the nerve injury6. This spontaneous ir-
NPY release was not altered by conduction
block proximal to the dorsal root ganglia,
when studied for up to three hours after
conduction block. It is unlikely, therefore,
that the spontaneous release of ir-NPY is due
to ectopic activity developing after nerve
injury. Indeed, NPY may not be acting as a
neurotransmitter at all, but is instead
involved in the regenerative changes that
occur in the dorsal horn after peripheral
nerve injury.
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Abstract
The pattern of ir-galanin release in the spinal cord of rats with a peripheral mononeuropathy was studied. On the side of the cord
ipsilateral to the nerve injury enhanced ir-galanin release was found in the superficial dorsal horn. It is probable that, after nerve injury,
some primary afferent neurons spontaneously release galanin from their central terminals. © 1997 Elsevier Science B.V.
Keywords: Chronic constriction injury; Dorsal horn; Galanin; Antibody microprobe; Spontaneous release
After a peripheral nerve injury, there are striking alter¬
ations in neuropeptide synthesis in primary afferent cell
bodies in the dorsal root ganglia and in neuropeptide levels
in the dorsal horn of the spinal cord [12,21], Galanin,
neuropeptide Y and vasoactive intestinal peptide (VIP)
synthesis is markedly increased, while substance P, calci¬
tonin gene-related peptide and somatostatin synthesis is
decreased [13]. With galanin the largest increases were
found in small to medium sized cells of the dorsal root
ganglia [5,23] with an associated increase in ir-galanin
distribution in the superficial dorsal horn [22].
The functional significance of these changes is un¬
known, with evidence of both inhibitor}' [Id,18] and exci
tatory [8] effects. It has been postulated that galanin may
be part of an endogenous analgesic system that becomes
important after peripheral nerve injury [17,19].
In the spinal cord of the normal rat, Hope and co¬
workers [6] did find ir-galanin release in the dorsal horn,
which was unaffected by primary afferent stimulation.
They proposed that the main source of ir-galanin was from
intrinsic neurons of the spinal cord.
The aim of this study was to examine the effects of a
peripheral nerve injury on the central release patterns of
ir-galanin.
Corresponding author at 'b'. Fax: +44 (131) 536-3672; E-mail:
lcolvin@labO.vet.ed.ac.uk
A peripheral neuropathy was induced in 32 male Wistar
rats (200-320 g, Charles River Ltd., UK) under sodium
pentobarbitone anaesthesia (40-50 mg/kg, intraperi¬
toneal), to produce a chronic constriction injury as de¬
scribed by Bennett and Xie [1], Four 4/0 chromic gut
sutures were placed loosely around the sciatic nerve at mid
thigh level. The International Association for the Study of
Pain guidelines for the care of experimental animals were
followed [24].
Regular monitoring of the development of neuropathic
pain behaviour was carried out in all animals post-oper-
atively. The lowest threshold at which paw withdrawal to a
series of von Frey hairs occurrod provided an indication of
the development of mechanical allodynia. The duration of
paw withdrawal response to pin prick was used to detect
mechanical hyperalgesia. An arbitrary value of 0.5 s was
assigned to the rapid response normally seen [15], The
mean values, for each paw, obtained at each time point
were compared using Student's paired Mest, for both paw
withdrawal threshold and duration. Both paw withdrawal
threshold to von Frey hairs and duration of paw with¬
drawal to pin prick showed a significant difference (P <
0.001) between ligatured and non-ligatured hindpaws from
day 3 after ligature placement until the day on which
ir-galanin release was studied.
Spinal release of ir-galanin was studied with antibody
microprobes bearing immobilised galanin (rat) antiserum
(Peninsula Labs., CA) The details of this technique are
0006-8993/97/$ 17.00 © 1997 Elsevier Science B.V. All rights reserved.
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described in Duggan [3]. The microprobe technique detects
bound endogenous galanin by the failure of binding of
exogenous [125I]galanin (rat, Peninsula Labs., CA) to the
immobilised galanin antibody. Prior to commencing in
vivo work, in vitro assays were carried out to ensure
adequate specificity and sensitivity for the immobilised
galanin antibody, using a range of related peptides and
range of galanin concentrations. No evidence of cross
reactivity was found between the galanin antiserum and
neuropeptide Y, VIP and substance P. Sensitivity tests
showed greater than 90% suppression of [125I]galanin bind¬
ing by 10~5 M galanin and approximately 40% suppres¬
sion of binding with 10~9 M galanin.
Ten to 14 days after ligature placement, neuropathic
rats were anaesthetized with urethane (up to 1.25 g/kg,
intraperitoneal). Six normal rats were also used. A
laminectomy was performed to expose the spinal seg¬
ments, L2-L6, the dura removed and the exposed cord
irrigated with sterile, warmed Ringer's solution. Using a
micromanipulator, microprobes were inserted bilaterally,
to a depth of 2.25 mm into the lumbar dorsal spinal cord.
The probes were left in place for 15 min, then washed in
cold 0.1% Tween/phosphate buffered saline, incubated for
24 h at 4°C in a solution of [125I]galanin and then washed
again. The distal portions were placed on a sheet of
monoemulsion film (Kodak NMC) for 8 to 10 days to
produce an individual autoradiographic image for each
microprobe.
A computerised image analysis system (Imaging Tech¬
nology PC Vision Plus frame grabber board) was used to
analyse the autoradiographic images [4], Each image was
scanned to give a measure of optical density at 10-/xm
intervals along the length of the microprobe [2], For each
microprobe, a plot of grey scale (i.e. optical density)
against depth of the probe in the spinal cord was obtained.
Areas of endogenous galanin binding were shown by areas
of low optical density and thus a low value on the grey
scale. The means of defined groups of microprobes, were
compared at 30 yum intervals along the length of the
probes using Student's unpaired /-test.
Microprobes inserted into the spinal cord of normal rats
in the absence of peripheral stimulation (n = 57) showed
an extensive basal release of ir-galanin, when compared to
in vitro microprobes (n— 187), confirming previous re¬
sults from this laboratory [6]. In vitro microprobes had not
been inserted into the central nervous system, but simply
incubated in [125I]galanin, thus representing zero endoge¬
nous galanin binding. There was no significant difference
between the pattern of ir-galanin release between the right
and left sides of the spinal cord in these normal rats.
The mean image analysis of microprobes (n = 58) in¬
serted into the spinal cord of normal rats and the mean
image analysis of microprobes (» = 50) inserted into the
side of the spinal cord contralateral to the nerve injury, in
neuropathic rats, were not significantly different. Thus, the
initial extensive basal release of ir-galanin seen in the






Fig. 1. Spontaneous ir-galanin release in the spinal cord of neuropathic
rats. A: mean image analysis ( + S.E.M.) of microprobes inserted into the
ipsilateral (right, n= 109) and contralateral (left, n= 101) sides of the
spinal cord relative to the nerve injury. An estimate of zero endogenous
galanin binding is shown by the mean image analysis of in vitro
microprobes (n = 158). B: the t statistics derived from the differences (at
30-yU.m intervals) between the groups of microprobes inserted into the
right and left sides of the spinal cord of neuropathic rats (illustrated in A)
are plotted with respect to a diagram of the spinal cord. The hatched areas
representing where t > 2 and P < 0.05. The positions of the laminae are
taken from Molander et al. [11].
spinal cord of normal rats was unchanged in the spinal
cord of neuropathic rats, contralateral to the peripheral
nerve injury.
By contrast, a new area of spontaneous ir-galanin re¬
lease was detected with a peak in the superficial dorsal
horn ipsilateral to the side of nerve injury, both when
compared to the release pattern found in normal rats, and
in the side of the cord contralateral to the nerve injury (see
Fig. 1). This new zone of ir-galanin release is in the same
area as the termination of the small to medium sized
primary afferent fibres, that start synthesising galanin after
nerve injury [5,12,13,23].
Normally, primary afferent fibres require a peripheral
stimulus before central neuropeptide release occurs, in
contrast to the spontaneous release of ir-galanin found in
the neuropathic rat. However, recent work from this labo-
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ratory has also demonstrated spontaneous release of neu¬
ropeptide Y in the dorsal horn of nerve injured rats [9],
There is an increasing amount of evidence that after nerve
injury primary afferent neurones behave abnormally, with
the generation of spontaneous ectopic activity both at the
nerve injury site [10,16], and at cell bodies in the dorsal
root ganglia [7,20], This high level of spontaneous activity
from primary afferents is likely to contribute to changes in
somatosensory processing that occur centrally in response
to peripheral nerve injury. Tal and co-workers [16] have
indeed found that there was a correlation between sponta¬
neous activity in primary afferent neurons and the develop¬
ment of thermal hyperalgesia.
As these afferents are firing spontaneously, it is possi¬
ble that the central release of ir-galanin is due to these
abnormal impulses. A corollary to this is that ectopic
impulse-evoked release of galanin may be related to the
generation of spontaneous pain.
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Abstract
The release of immunoreactive (ir-) neuropeptide Y (NYP) was studied in the anaesthetized rat and cat by means of microprobes
bearing immobilized antibodies to the C terminus of NPY. An extensive basal release of ir-NYP was detected throughout the dorsal and
upper ventral horn of the rat. This spontaneous release was not significantly altered by sectioning the spinal cord at the thoraco-lumbar
junction nor by electrical stimulation of peripheral nerves. Since NPY is virtually absent in primary afferents it is probable that
spontaneous release within the spinal cord comes from active NPY-containing intrinsic spinal neurones. In the spinal cat spontaneous
release of ir-NPY was detected in the mid-dorsal horn and this was unaltered by peripheral noxious thermal or noxious mechanical
stimuli. As in the rat, release from intrinsic spinal neurones is most probable. The extensive spontaneous release of ir-NPY in both species
suggests a widespread role in spinal cord function.
Keywords: Neuropeptide Y; Antibody microprobe; Spontaneous release; Rat spinal cord; Cat spinal cord; Spinal transection
1. Introduction
Structural and functional studies imply that neuropep¬
tide Y (NPY) has a role in the spinal processing of
information conveyed by primary afferent fibres. This was
first suggested by histochemical studies of the distribution
of NPY in the spinal cord. In the normal rat there is
negligible NPY in primary afferents [47] but a dense
plexus of NPY-containing fibres in laminae I and II of the
dorsal horn [18,33] where many small diameter primary
afferents terminate [26], In the lamprey NPY-containing
varicosities were observed closely opposed to ascending
and descending branches of primary afferents [3] and in
the cat an ultrastructural study observed NPY-containing
synapses on both primary afferent terminals and axo-den-
dritic synapses in the superficial dorsal horn [9], These
observations in the cat suggest that NPY may control
transmitter release from the central terminals of primary
afferents. Supporting this are the reports that microinjec-
Corresponding author. Fax: +44 (131) 650-6576; E-mail:
awd@labO.vet.ed.ac.uk
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tion of NPY into the superficial dorsal horn of the cat
reduced peripheral stimulus-evoked release of SP [13] and
when added to the superfusate of cultured dorsal root
ganglion neurones, NPY reduced high K+-evoked release
of SP [45], Administered intrathecally, NPY produced
behavioural analgesia in the rat [22] but had dose-depen¬
dent facilitatory or inhibitory effects on nociceptive rat
spinal reflexes measured electrophysiologically [46],
There are, however, no reports of the release, and the
processes controlling release, of NPY in the dorsal horn.
The possible sources of release of NPY are intrinsic
neurones of the spinal cord [6,40,44] and the terminals of
brainstem neurones projecting to the spinal cord [15,16,20],
Although the near absence of NPY in dorsal root ganglion
neurones implies that this compound cannot be released in
significant amounts from the spinal terminations of pri¬
mary afferents, peripheral inputs could still evoke in¬
traspinal release of NPY by activating spinal or supraspinal
processes. Hence in addition to studying basal release of
immunoreactive (ir-) NPY in the spinal cord of the rat and
the cat, the effects of peripheral nerve stimulation were
studied in the rat and the effects of noxious peripheral
thermal and mechanical stimuli were examined in the cat.
Because of the known presence of NPY in the spinal
0006-8993/97/S17.00 Copyright © 1997 Elsevier Science B.V. All rights reserved.
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terminations of fibres of supraspinal origin, the effect of
spinal transection on spinal release of ir-NPY was also
studied in the rat.
2. Materials and methods
2.1. Animal preparation
2.1.1. Rats
Experiments were performed on 25 male Wistar rats
(weight range 300-400 g; Charles River, UK) anaes¬
thetized with intraperitoneal urethane (1.25 g kg-1 ini¬
tially, supplemented when necessary). Cannulae were in¬
serted into the trachea, a carotid artery and an external
jugular vein. The depth of anaesthesia was regularly as¬
sessed by continuous measurement of blood pressure and
ensuring that the corneal blink and hind paw withdrawal
reflexes remained absent. Blood oxygenation was assisted
by directing a gentle jet of humidified oxygen towards the
opening of the tracheal cannula. The animal's core temper¬
ature was maintained between 36 and 38°C using a con¬
trolled heating system. In experiments involving stimula¬
tion of high threshold afferents of the sciatic nerve, ani¬
mals were artificially ventilated following neuromuscular
paralysis with intravenous gallamine triethiodide (3 mg
kg"1) and the end-tidal C02 levels were continually moni¬
tored. The depth of anaesthesia was assessed prior to each
injection of gallamine.
An extended laminectomy was made at vertebral levels
T12 to L2 to expose the dura mater of the L2-L6 spinal
cord segments. The animal was supported in a metal frame
by six swan neck clamps positioned under the mammillary
processes of the exposed vertebrae. The spinal cord was
covered with Ringer-agar at the site of the laminectomy
with a window over the lumbar spinal segments. Following
opening of the dural sac with sterile forceps, the exposed
spinal cord was irrigated with sterile Ringer's solution at
37°C continuously throughout the experiment. Unlike ex¬
periments on the cat it was not necessary to remove the pia
arachnoid in the rat to allow microprobes to be inserted
into the spinal cord. The sciatic nerve on one side was
isolated and freed close to its trifurcation by separating the
medial and lateral knee flexor muscles. This nerve was
then gently mobilized for 1-2 cm to permit mounting on
platinum electrodes in a liquid paraffin pool.
Before microprobes were inserted into the spinal cord,
the suitability of potential penetration sites was examined
functionally. A silver ball electrode was gently pressed
onto the dorsum of the spinal cord just medial to the line
of entry of the dorsal roots and the threshold stimulus
current and voltage needed to evoke a field potential was
measured. The ball electrode was positioned at several
rostro-caudal locations as a measure of the distribution of
afferent input from the sciatic nerve.
In four experiments, the spinal cord laminectomy was
extended to include the lower thoracic cord. Prior to
dividing the spinal cord a micromanipulator was used to
inject, from a micropipette, 5 /xl of lignocaine 1% solution
in both sides of the spinal cord at segments T9-T10. The
spinal cord was then teased apart using watchmaker's
forceps, taking care to leave the dorsal vein intact.
2.1.2. Cats
Experiments were performed on six cats anaesthetized
with pentobarbitone sodium (35 mg kg-1 initially and
maintained by a constant intravenous infusion of 3 mg
kg-1 IT '). A carotid artery was cannulated to measure
blood pressure and a tracheostomy performed for artificial
respiration with humidified air. End-tidal C02 levels were
monitored continuously. Body temperature was maintained
at 37-38°C with a controlled heating pad.
The lumbar spinal cord was exposed over its whole
length and the spinal cord was transected at the thoraco¬
lumbar junction after injection of 0.1 ml of 2% lignocaine.
Each cat was suspended in a metal frame by means of
pelvic and vertebral clamps. The lumbar dura mater was
incised longitudinally and retracted laterally and a thin
layer of Ringer-agar was placed on the dorsal surface of
the spinal cord. This agar layer was removed at the area of
proposed microprobe penetrations and the exposed spinal
cord was continually irrigated wtih sterile Ringer's solu¬
tion. The pia-arachnoid was removed at sites of micro-
probe insertion. Peripheral nerve stimulation was not per¬
formed in the cat experiments but noxious thermal or
mechanical stimuli were applied to the hind paws. Noxious
thermal stimulation consisted of immersing a hind paw in
a water bath maintained at temperatures from 48°C to
52°C. The hind paw was immersed for 3 min and then
removed for 2 min and this cycle was repeated for the total
duration of the stimulus. Noxious mechanical stimulation
was provided by alligator clips applied to the glabrous skin
of a hind paw, on for 3 min and removed for 2 min.
2.2. Microprobe preparation
Antibody microprobes for the detection of ir-NPY were
prepared as previously described [10]. Briefly, fine glass
micropipettes, heat sealed at both ends, were incubated for
up to 24 h in a 10% solution of y-aminopropyltriethoxysi-
lane in toluene. This procedure produced a fine, granular
siloxane polymer layer on the outer surface of each mi¬
cropipette. This polymeric coating possessed free amine
groups to which Protein A (Sigma) was immobilized using
glutaraldehyde coupling. Protein A is a staphylococcal
derived protein which binds to the Fc region of some
subclasses of IgG antibodies and this property was utilized
to bind, to microprobes, immunoglobulins present in a
polyclonal antiserum. Two antisera were used. In the rat
experiments the antiserum was purchased from Peninsula
Laboratories and had been raised against the C terminus of
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human, rat NPY. Tests of specificity of the microprobes
bearing this antibody are described later. In the cat experi¬
ments the antiserum was raised in rabbits against the C
terminus of porcine NPY as described by Maccarrone and
Jarrott [31]. Before insertion into the spinal cord, micro-
probes were broken back to give tip diameters of approx.
10 /u,m.
2.3. Rat protocol
All microprobes were inserted into the cord (two at a
time) with a pair of stepping motor micromanipulators to a
depth of 2.25 mm from the dorsal surface and left in situ
for 15 min. In the absence of peripheral stimulation,
microprobes were inserted into both sides of the cord (at a
level determined by the electrophysiological recordings).
Due to uncertainty on the persistence of any possibly
released ir-NPY following peripheral stimulation, only one
stimulation period of 15 min was used in each experiment.
With electrical stimulation, microprobes were positioned
only in the ipsilateral spinal cord. The stimulus parameters
were: 0.5 ms pulses, either X3 threshold at 1 or 20 Hz or
> 100 X threshold at 2 Hz. Following electrical stimula¬
tion it was usual to insert microprobes for three periods of
no stimulation.
In the rat experiments in which spinalization was per¬
formed midway through the experiment, four pairs of
microprobes were inserted into both sides of the spinal
cord before spinalization. After spinalization. this protocol
was repeated with a further four pairs of microprobes thus
ensuring that both sides of the cord were sampled equally.
No peripheral stimulation was used in these experiments.
2.4. Cat protocol
In the cat experiments the sites of microprobe insertion
were determined by recording extracellular neuronal re¬
sponses (with a 4 M NaCl filled micropipette) to innocu¬
ous mechanical stimulation of the hind paws. Microprobes
were inserted 3 mm into the spinal cord, two at a time, into
the ipsilateral spinal cord and remained in place for 15 or
30 min. When peripheral stimulation was used it was usual
to insert four control (no stimulus) microprobes both be¬
fore and after each period of stimulation.
Following the insertion of microprobes, pontamine sky
blue was ejected electrophoretically at several defined sites
in the spinal cord. The cords were then removed, fixed,
and sectioned to determine the location of resultant dye
spots. These data were essential to allow locations on the
probes to be related to the laminae of the spinal cord.
2.5. Microprobe treatment
The antibody microprobe technique detects bound en¬
dogenous ligand by the failure of binding of exogenous
radiolabelled ligand. Thus, following removal from the
spinal cord, microprobes were washed for 15 min in
ice-cold phosphate-buffered saline (PBS) containing 0.1%
Tween and then incubated for approx. 24 h at 6°C in a
PBS-azide solution of i25I-radiolabelled porcine NPY (ap¬
prox. 2000 counts p\~x min^1) containing casein (0.1%,
rat experiments) or bovine serum albumin (0.1%, cat ex¬
periments). In the rat experiments Bolton-Hunter-labelled
peptide was purchased from Amersham (UK). In the cat
experiments NPY was labelled by the iodogen method [7],
Probes were washed for 15 min in ice-cold PBS-Tween
while continually drawing the solution through the tips to
remove any radiolabelled NPY from within. The distal
portions of the microprobes were broken off and mounted
onto a sheet of paper, which was placed in an X-ray film
cassette with a sheet of monoemulsion film (Kodak NMC)
for 6-14 days. Two films were derived from each experi¬
ment.
The resultant microprobe autoradiographs were anal¬
ysed with an image analysis system employing an Imaging
Technology PC Vision Plus frame grabber board operating
in a Data Control System 286e (AT based) computer, as
previously described [19]. A charged coupled device cam¬
era scanned each image starting at the tip and following
background subtractions, a transverse integration of optical
density on a scale of 0-255 was performed for each
microprobe at defined intervals. With the magnification of
the system used, and the resolution of the image analysis
system (512 X 512 locations per frame) this corresponds to
a 10 /um interval for transverse integrations. However, this
is beyond the biological resolution of the microprobe
method [10] and therefore the average of three successive
integrals was taken to give a final resolution of 30 pm.
For each microprobe, the resultant plot of integrated opti¬
cal density (grey scale) with respect to length together with
coded information which described the experimental con¬
ditions for that particular microprobe were stored on a
computer file. Regions of bound endogenous ir-NPY along
the length of each microprobe have been equated with
relative deficits in the tracer binding, that are represented
graphically as comparatively low grey scale values.
A sorting programme was used to retrieve groups of
microprobes which met stated criteria and produced for
each group a plot of the mean grey scale values ( + S.E.M.
in 30 pm steps) with respect to depth within the spinal
cord. Each site is treated independently and hence, for
selected groups of microprobes, statistical significance can
be assigned to differences between mean optical densities
at each site. The significance of the differences at each 30
pm analysis point was estimated using Students' r-test. It
should be noted that the pooling of microprobe images
introduces errors in determining sites of release since
between-animal variations in anatomy are not accurately
accounted for and even within one experiment not all
probes are introduced at the same distance from the mid¬
line. With large numbers of microprobes it is likely that
the peak sites of release are accurately determined but that
198 MA. Mark et al. /Brain Research 754 (1997) 195-203
the spread of sites of release around such peaks is magni¬
fied by the pooling of images.
2.6. In vitro tests
Because the antisera used were C terminus directed they
recognized porcine, human and rat NPY equally as these
forms of NPY differ by only one amino acid at position
17. The sequence for cat NPY is unknown but a C
terminus directed antiserum was considered most appropri¬
ate because of the known sequences of NPY variants [14],
Data from the manufacturer stated that the antiserum used
in rat experiments recognized peptide YY but not prepro
NPY(68-97). In parallel with present experiments, the
sensitivity of the prepared antibody microprobes was regu¬
larly assessed by incubating ten to 15 either directly in
i25I-NPY or in a range of concentrations (10-5-lCT9 M)
of unlabelled NPY at 37°C for 30 min prior to the incuba¬
tion in a solution of 125I-NPY for approx. 24 h at 6°C.
Following washing in PBS-Tween, the distal portions of
these microprobes were broken off, mounted on small
pieces of cardboard and placed in tubes for processing by a
y-counter. In vitro tests indicated that a 10~7 M solution
of NPY suppressed such binding by greater than 50% with
a 10"5 M solution resulting in greater than 80% suppres¬
sion.
3. Results
3.1. Microprobes present in the spinal cord in the absence
ofperipheral stimulation
3.1.1. Rat
A basal extracellular presence of a neuropeptide can be
inferred by observing differences in the mean image analy¬
sis of microprobes not inserted into the central nervous
system (but simply incubated in the radiolabelled peptide,
termed in vitros in Fig. 1) and that of microprobes present
in the nervous system in the absence of any peripheral
stimulus and then incubated with the labelled peptide
(termed no stimulus microprobes in Fig. 1). With the latter
it was relatively common for autoradiographs to show
sharply defined zones of failure of binding of 125I-NPY
and a density scan of one is shown in Fig. 1A. This zone
corresponds to the upper dorsal horn. Fig. IB compares the
mean image analysis of 56 in vitro microprobes and that of
73 no stimulus microprobes. The zone of maximal differ¬
ence between these groups corresponds to the zone of
reduced binding in the microprobe of Fig. 1A but the total
area of significant differences encompasses a much broader
area. This is shown in Fig. 1C where the /-statistics
derived from the differences between these groups are
plotted in relation to a diagram of the spinal cord. The
hatched area indicates where the differences are significant



















Depth within the spinal cord (mm)
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Fig. 1. Spontaneous release of immunoreactive (ir-) NPY in the spinal
cord of the rat. A: density scan of the autoradiograph of a single
microprobe inserted 2.25 mm into the spinal cord of a rat and which
remained in place for 15 min in the absence of any applied stimulus. B:
the mean image analysis of 56 microprobes simply incubated in I_5I-NPY
(in vitro microprobes) and that of 73 microprobes inserted 2.25 mm into
the spinal cord and which remained there for 15 min in the absence of
any applied stimulus (no stimulus microprobes). A line joins the mean
grey scale values and +S.E.M. is plotted at each analysis point for the no
stimulus group of microprobes and — S.E.M. is plotted for the in vitro
microprobes. C: the f-statistics derived from the differences (in 30 /am
intervals) between the groups of microprobes illustrated in B are plotted
with respect to a diagram of the rat spinal cord. The hatched areas
indicate where t > 2 and hence where the difference is significant at
P < 0.05. The positions of the spinal laminae are taken from Molander et
al. [34],
the dorsal horn and dorsal columns merging into the upper
ventral horn and a further zone in the deep ventral horn
extending into the ventral white matter. The site of maxi¬
mal difference corresponds to the upper dorsal horn.
The high basal levels of ir-NPY found in intact animals
could represent release from the spinal terminations of
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Fig. 2. Spinal transection and the spontaneous release of ir-NPY in the rat
spinal cord. A: the two plotted image analyses were derived from 35
microprobes present in lumbar spinal cord in the absence of peripheral
stimulation and prior to transection of the lower thoracic spinal cord
(pre-spinal transection microprobes) and 22 comparable microprobes
inserted after spinal cord transection (post-spinal transection microprobes).
B: the f-statistics derived from the differences of the image analyses
shown in A are plotted in relation to a diagram of the rat spinal cord.
fibres of supraspinal origin. To examine this four rats were
spinalized midway through an experiment for comparison
of basal levels of ir-NPY found by microprobes inserted
into the spinal cord before and after spinalization at a
mid-thoracic level. Fig. 2A illustrates the mean image
analyses of these two groups. Although the post-spinaliza-
tion microprobes (n — 22) are displaced above the pre-spi-
nalization group (n = 35), suggesting higher extracellular
levels of ir-NPY following sectioning of the spinal cord,
the differences are not significant (Fig. 2B), except for a
restricted area of the ventral horn.
3.1.2. Spinal cats
Microprobes inserted into the spinal cord of previously
spinalized cats also detected a basal presence of ir-NPY.
Fig. 3A compares the mean image analysis of 31 such
microprobes and that of 22 microprobes not inserted into
the spinal cord but simply incubated in radiolabelled NPY.
The plot of the former is uniformly displaced above that of
the in vitro microprobes, but Fig. 3B shows that this
attains significance at the P < 0.05 level only in the upper
dorsal horn.
3.2. Microprobes present in the spinal cord during electri¬
cal stimulation of large and small diameter fibres of the
ipsilateral sciatic nerve of the rat
3.2.1. Stimulation at X 3 threshold (large myelinated fi¬
bres)
In eight of these experiments large myelinated fibres in
the sciatic nerve were stimulated electrically at 1 Flz for
one 15 min period. Probes were inserted before, during
and after stimulation. The mean image analyses of 26
microprobes inserted 2.25 mm into the spinal cord and left
in situ for 15 min in the absence of any active peripheral
stimulus and 16 microprobes inserted for the same time
and same depth, but during electrical stimulation of large







Fig. 3. Spontaneous release of ir-NPY in the spinal cat. A: the mean
image analysis of 22 in vitro microprobes is compared with that of 31 no
stimulus microprobes inserted 3 mm into the spinal cord and in the
absence of any peripheral stimulus (no stimulus microprobes). B: the
f-statistics derived from the differences between the two groups shown in
A are plotted with respect to a diagram of the cat lumbar spinal cord.
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myelinated fibres at 1 Hz, showed no significant differ¬
ences. Microprobes inserted after a period of electrical
stimulation at 1 Hz also failed to show significant alter¬
ations from pre-stimulation microprobes (not illustrated).
In six experiments large myelinated fibres in the sciatic
nerve were stimulated at 20 Hz for one 15 min period. The
mean image analyses of 22 microprobes inserted 2.25 mm
into the spinal cord and left in situ for 15 min in the
absence of any active peripheral stimulus and 11 micro¬
probes inserted for the same time and same depth in the
same experiments but during electrical stimulation of large
myelinated fibres at 20 Hz are illustrated in Fig. 4. The
plots for both groups are very similar and there are no
statistical differences between them at any 30 yam interval.
Both groups are displaced above the plot of the mean
image analysis of the in vitro microprobes from these
experiments.
3.2.2. Stimulation at > X 100 threshold
In six experiments the stimulus intensity was 20 V
(> 100 X threshold) and hence both myelinated and un¬
myelinated fibres of the sciatic nerve were stimulated. The
stimulus frequency used was 2 Hz since unmyelinated
fibres do not follow high stimulus frequencies.
The mean image analyses of 24 microprobes inserted
2.25 mm into the spinal cord and left in situ for 15 min in
the absence of any active peripheral stimulus and 12
microprobes inserted for the same time and to the same
depth during electrical stimulation at 2 Hz (> I00X
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Fig. 4. The failure of electrical stimulation of large diameter primary
afferent fibres to release ir-NPY in the rat. The three mean image
analyses plotted were derived from 21 in vitro microprobes, 22 micro¬
probes present in the spinal cord prior to peripheral nerve stimulation (no
stimulus microprobes), 11 microprobes present in the spinal cord while
the ipsilateral sciatic nerve was stimulated at 20 Hz, 0.5 ms pulses,
stimulus strength X3 threshold for producing a dorsal column volley
(nerve stimulation microprobes). All microprobes are derived from the
same experiments.
Depth within the spinal cord (mm)
Fig. 5. The failure of noxious mechanical stimulation to release ir-NPY in
the cat spinal cord. The mean image analyses of 31 microprobes present
in the spinal cord without peripheral stimulation (no stimulus micro¬
probes) is compared with that of 22 microprobes present in the spinal
cord while noxious mechanical stimuli were applied intermittently to the
ipsilateral hind paw (noxious mechanical stimulation microprobes).
3.2.3. Microprobes present in the spinal cord of the spinal
cat during noxious peripheral stimulation
A total of 35 microprobes remained in the spinal cord
while noxious peripheral stimuli were applied to the ipsi¬
lateral hind limb (24 noxious mechanical stimulation, 11
noxious thermal stimulation). The images of these micro¬
probes showed no significant differences from those mi¬
croprobes inserted in the absence of any peripheral stimu¬
lation. Fig. 5 illustrates the near coincident mean image
analyses of 31 no stimulus microprobes with that of 22
microprobes present in the spinal cord during noxious
mechanical stimulation.
4. Discussion
The most significant finding of the present study was
the relative ease with which ir-NPY was detected in the
spinal cord of both the rat and the cat in the absence of any
applied peripheral stimulus. This is in marked contrast to
other peptides studied in the spinal cord of the rat and cat,
such as substance P [11,25], dynorphin [39] and galanin
[21,36], This probably indicates a significant role for NPY
in spinal cord function in both species but requires some
consideration of what is being detected by microprobes
and of the possible sources of spontaneously released
ir-NPY.
The antibodies immobilized to the microprobes of the
present experiments were C terminus directed and hence,
as well as detecting NPY, it is possible that shorter frag¬
ments resulting from enzymic degradation might also bind
to microprobes. Little is known of the degradation of NPY
following its release within the central nervous system.
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degradation of NPY by peptidases found in the central
nervous system [29]. This is believed to result from the
unique structure of NPY: a polyproline-like helix lying
antiparallel to an amphiphilic a helix and the possession
of an amidated C terminus [43]. Degradation by the non-
brain-occurring peptidases endopeptidase 24.18, amino-
peptidase P and dipeptidylpeptidase IV has been shown
[32,38]. With cultured cortical neurones slow degradation
by presumed plasmin and plasminogen activator activity
occurred [28], It is probable, therefore, that with micro-
probes remaining in the spinal cord for 15-30 min what
was bound, and subsequently prevented the binding of
radiolabelled NPY, was predominantly NPY. Although the
immobilized antibodies used in the present experiments
did recognize peptide YY, analysis of chromatographic
and radioimmunoassay data led De Quidt et al. [8] to
conclude that NPY is the main, if not the only, member of
the pancreatic polypeptide family in the central nervous
system of the rat, pig and human.
Although microprobes are fine diameter micropipettes,
they do detect very small quantities of neuropeptides in
their immediate environment [10]. Thus it is possible that
NPY-containing cell bodies or fibres, ruptured by the
passage of microprobes, contributed to the basal levels
detected. We do not consider this to be a major contribu¬
tion since very differing patterns of basal extracellular
presence have been detected for differing neuropeptides
both in the spinal cord of the rat [21,25,39] and cat
[11,12,37,41] despite the passage of microprobes through
areas enriched in the relevant neuropeptide.
Microprobe studies of release of neuropeptides in the
spinal cord are performed on animals which have been
anaesthetized and subjected to considerable surgery. De¬
spite general anaesthesia such animals could have a contin¬
ued spinal input of impulses in nociceptors of both superfi¬
cial and deep origin. This has been proposed as the source
of the small basal presence of ir-SP in the superficial
dorsal horn of cats [11] and rats [25] since SP is readily
released in this area by peripheral noxious stimuli particu¬
larly as inflammation develops peripherally [42]. In the
present experiments, however, no evidence was obtained
for an alteration in basal levels of extracellular ir-NPY by
impulses in small diameter primary afferents (intact rat) or
nociceptors (spinal cat). Hence it is improbable that the
large basal presence of ir-NPY can be attributed to contin¬
ued activity in peripheral nociceptors.
The spinalization experiments were performed in the
present series to test whether continued activity in de¬
scending fibres was contributing to the basal release of
ir-NPY in the rat. This cannot have been a major source
since the shift in the mean image analysis of post-spinali-
zation microprobes was in the direction of increased re¬
lease (implying inhibition of release) but the measured
differences did not attain statistical significance at any of
the dorsal horn sites. By a process of exclusion, it appears
that spontaneous firing of intrinsic spinal neurones was
predominantly responsible for the large basal presence of
ir-NPY detected in the present experiments.
We were unable to perform experiments on the persis¬
tence of NPY following release since the stimuli used did
not produce a spinal release of ir-NPY. The ability of a
neuropeptide to resist rapid degradation following release
is an important determinant of its ability to access recep¬
tors and influence neurones remote from sites of release
[1,17,27]. As discussed previously, there is evidence that
NPY is not degraded rapidly within the central nervous
system and hence the wide distribution of basal extracellu¬
lar ir-NPY may represent wide diffusion rather than re¬
lease from a multiplicity of sites. Our finding of a basal
presence of ir-NPY in the dorsal and ventral white matter
may also relate to diffusion after release.
Electrophysiological studies [2,4,5,24] and transmitter
release studies [13,45] indicate that NPY inhibits transmit¬
ter release at a number of sites, probably by an action on
calcium channels [30]. Additionally in the central nervous
system, potentiation of excitation of hippocampal neurones
by NMDA [35] and of inhibition by noradrenaline [23] has
been reported. How these actions apply to events in the
spinal cord is currently unknown but the present results
suggest that NPY is a widely used neuropeptide in spinal
cord function.
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NEUROPEPTIDE Y FROM THE CENTRAL TERMINALS OF
LARGE DIAMETER PRIMARY AFFERENTS OF RATS WITH
PERIPHERAL NERVE INJURY
M. A. MARK,* L. A. COLVIN*f and A. W. DUGGAN*+
*Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies,
University of Edinburgh, Summerhall, Edinburgh EH9 1QH, U.K.
fDepartment of Anaesthetics, University of Edinburgh. Royal Infirmary of Edinburgh,
Lauriston Place, Edinburgh EH3 9YW, U.K.
Abstract—Microprobes bearing immobilized antibodies to the C-terminus of neuropeptide Y were used to
measure the release of this neuropeptide in the spinal cords of rats with a unilateral peripheral neuropathy
and in sham-operated animals. All neuropathic animals showed the characteristic behavioural syndrome
and were studied at 14 days postsciatic nerve loose-ligation. An extensive spontaneous release of
immunoreactive neuropeptide Y was detected in the spinal cords of the neuropathic rats and, compared
to sham-operated rats, a new zone of release was found in the deep dorsal horn. Electrical stimulation of
large diameter primary afiferents proximal to the nerve ligature produced widespread release of
neuropeptide Y in the dorsal horn which persisted for up to 1 h poststimulation.
It is possible that ectopic impulses arising in the injured nerve were responsible for the spontaneous
central release of neuropeptide Y and this neuropeptide may play a role in the central response to
peripheral nerve injury. © 1997 IBRO. Published by Elsevier Science Ltd.
Key words', neuropeptide Y release, spinal cord, neuropathic rat. antibody microprobes.
When the peripheral axons of primary afferent neu¬
rons of the rat are damaged or divided changes occur
in the neuroactive compounds which these cells syn¬
thesize. Notable among these changes are decreased
numbers of cells containing substance P and calci¬
tonin gene-related peptide and increased numbers
immunoreactive for galanin, vasoactive intestinal
polypeptide and neuropeptide Y (NPY).'9-23-26-35-47
50,54 Studies of mRNA expression indicate that these
changes result from altered synthesis.37'38 The syn¬
thesis of NPY is remarkable since this neuropeptide
is virtually absent from the dorsal root ganglion
neurons of normal rats.57 Quantitative studies of cell
body size suggest that it is predominantly neurons
with large myelinated peripheral fibres which syn¬
thesize NPY following peripheral axotomy and that
this occurs in approximately 25% of the total neurons
of a dorsal root ganglion.38 The functional signifi¬
cance of these neuropeptide changes is unknown. If
the newly-synthesized peptides are released in the
spinal cord during nerve regeneration they could
produce widespread changes in neuronal excitability
relevant to recovery of function in the deafferented
spinal neurons or could even promote structural
{To whom correspondence should be addressed.
Abbreviations'. IR, immunoreactive, NGF, nerve growth
factor, NPY, neuropeptide Y, NT-3, neurotrophin-3,
PBS, phosphate-buffered saline.
changes also relevant to functional recovery.32-45-53-55
Rats with a peripheral nerve constriction injury
which damages a proportion of fibres within the
nerve have a behavioural syndrome likened to a
complex regional pain syndrome of humans.4'24'44
Thus there is evidence for the occurrence of spon¬
taneous pain, allodynia and an alleviation of the
syndrome by sympathectomy.56 These rats have
neuropeptide changes in the spinal cord and dorsal
root ganglia similar to those produced by nerve
transection.22,37,49
Nerve constriction differs from complete transec¬
tion in that there is a partial loss of fibres distal to the
site of injury3'34 and hence an afferent input (albeit
reduced) from the periphery can occur. It is possible
that it is an interaction between these impulses and
the altered central stale relevant to reorganization
following complete transection that contributes to
the dysesthetic state of partial nerve injury. Such
considerations indicate the need to study spinal
release of neuropeptides from primary afferent
neurons in rats with peripheral nerve injury.
We have previously studied release of immuno¬
reactive NPY (IR-NPY) in the normal rat and found
evidence for considerable basal release resulting from
activity in intrinsic spinal neurons.29 The present
experiments have examined release of IR-NPY in rats
with a unilateral constriction injury of the sciatic
nerve.
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There are several aspects of release in this model
requiring investigation. The first is whether the
newly-synthesized NPY contained within dorsal root
ganglion neurons can be released from such struc¬
tures since release of NPY from primary afferents
does not occur in normal rats. If release occurs, does
this occur spontaneously or is it necessary to evoke
impulses in NPY-containing neurons by peripheral
stimuli to produce release? Since microprobes can
localize sites of release with some accuracy it needs to
be determined whether release of NPY from primary
afferents is at different sites in the spinal cord from
those in normal rats, since with the latter there is
evidence that intrinsic cord neurons are the main
sources of release. Finally, persistence and diffusion
after release occurs with some neuropeptides and this
needs to be investigated for NPY.
EXPKRIMENTAL PROCEDURES
The nerve injury model
For the production of nerve injuries adult male Wistar
rats (weight range 300-450 g, Charles River Ltd, U.K.) were
anaesthetized with sodium pentobarbitone (50 mg/kg i.p.).
Using full aseptic technique, four 4/0 chromic gut loose
ligatures were placed around the right sciatic nerve, proxi¬
mal to its trifurcation.4 In the sham group, the right sciatic
nerve was exposed and manipulated but not ligated. Post¬
operatively, the International Association for the Study of
Pain guidelines for the care of experimental animals were
followed.5* The animals used displayed the changes associ¬
ated with this model such as hopping, licking, everted paw
and ventroflexed toe. An analgesymeter (Ugo Basile) was
used to test for the development of mechanical allodynia.
Rats were tested prior to surgery and then at one to three
day intervals over the next two weeks. A difference score
was calculated for paw withdrawal thresholds obtained
from right and left hind paws, as this gives a more consistent
value.4
Microprobe preparation
Antibody microprobes for the detection if IR-NPY were
prepared following the technique previously described."
Briefly, fine glass micropipettes, heat sealed at both ends,
were incubated for up to 24 h in a 10% solution of
y-aminopropyltriethoxysilane in toluene. This procedure
produced a fine, granular siloxane polymer layer on the
outer surface of each micropipette possessing free amine
groups to which Protein A (Sigma) was immobilized using
glutaraldehyde coupling. Protein A then bound immuno¬
globulins present in a polyclonal antiserum raised in
rabbits against the carboxy terminus of NPY (Peninsula
Laboratories). Tests of specificity of the microprobes bear¬
ing this antibody were carried out prior to in vivo exper¬
iments. Before insertion into the spinal cord, microprobes
were broken back to give tip diameters of approximately
10 pm.
Experimental protocol
For microprobe experiments rats were anaesthetized with
intraperitoneal (i.p.) urethane (1.5 g/kg initially, supple¬
mented when necessary). Cannulae were inserted into the
trachea, a carotid artery and an external jugular vein, to aid
unobstructed breathing, and to permit direct measurements
of arterial blood pressure and the intravenous injection of
substances respectively. The depth of the anaesthesia was
continually assessed by the corneal blink reflex, hindpaw
withdrawal and blood pressure response to pinching the
paw. Blood oxygenation was assisted by directing a gentle
jet of humidified oxygen towards the opening of the tracheal
cannula. The animal's body temperature was monitored
with a rectal probe connected to a controlled heating system
and maintained between 36-38°C. In experiments involving
stimulation of the sciatic nerve, animals were artificially
ventilated following paralysis with vecuronium injected
intravenously (1 mg/kg) and the end tidal CO, levels were
continually monitored and maintained approximately at
4%. Vecuronium was only given as neuromuscular paralysis
declined which enabled regular assessment of depth of
anaesthesia. An extended laminectomy was performed at
vertebral levels Tl2-L2 to expose the dura mater of the
lumbar spinal cord (spinal segments L2-L6). The animal was
supported in a metal frame and six swan neck clamps were
positioned under the mamillary processes of the exposed
vertebrae. Agar was allowed to set over the exposed spinal
segments and a window was made at sites of proposed
microprobe entry. Following opening of the dural sac with
sterile forceps, the exposed spinal cord was irrigated with
sterile Ringer solution at 37°C continuously throughout the
experiment. This continuous irrigation minimized the col¬
lection of exudates on the surface of the cord and excess
fluid was removed by suction at an edge of the agar window.
The sciatic nerve on the operated side of each rat (both
sham-operated and nerve-ligatured animals) was isolated
and gently mobilized proximal to the ligated or sham-
manipulated area to permit mounting on platinum elec¬
trodes. To support the leg a nerve pool was constructed and
filled with paraffin oil at 37°C.
Before microprobes were inserted into the spinal cord, the
suitability of potential penetration sites was examined. A
silver ball electrode was gently pressed on to the dorsum of
the spinal cord just medial to the line of entry of the dorsal
roots and the threshold stimulus current and voltage needed
to evoke a field potential was measured. The ball electrode
was positioned at several rostrocaudal locations to deter¬
mine the distribution of afferent input from the sciatic nerve
and hence to select sites of insertion for microprobes.
All probes were inserted into the cord (two at a time) with
a pair of stepping motor micromanipulators to a depth of
2.25 mm from the dorsal surface and left in situ for 15 min
with or without an active peripheral stimulus. When a
peripheral nerve was stimulated, only one period of 15 min
stimulation was used in each experiment due to uncertainty
on the persistence of released IR-NPY. In these experiments
the first two pairs of microprobes were inserted into both
sides of the spinal cord in the absence of any nerve
stimulation. Electrical stimulation at either 20 Hz
(3 x threshold) or 2 Hz (>100 x threshold) began when the
next pair of microprobes were inserted into the spinal cord.
The effects of unilateral nerve stimulation were studied
bilaterally in the spinal cord. Following peripheral nerve
stimulation it was usual to insert microprobes into both
sides of the spinal cord for three periods of no stimulation.
At the end of each experiment Pontamine Sky Blue was
ejected ionophoretically at a defined site in the spinal cord.
The cords were then removed, fixed and sectioned to
determine the location of resultant dye spots. This data was
essential to allow locations on the probes to be related to
sites within the spinal cord. The antibody microprobe
technique detects bound endogenous ligand by the failure of
binding of exogenous radiolabelled ligand. Thus, following
removal from the spinal cord, microprobes were washed for
15 min in ice-cold phosphate-buffered saline (PBS) contain¬
ing 0.1% Tween 20 and then incubated for approximately
24 h at 6°C in a PBS-azide solution of l25I-radiolabelled
NPY (Amersham) containing casein (0.1%). The final dilu¬
tion of the radiolabelled peptide resulted in approximately
2000 counts/min/pl. Probes were then washed for 15 min
in ice-cold PBS-Tween 20 while continually drawing the
solution through the tips to remove any radiolabelled
NPY which may have entered. The distal portions of the
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microprobes were broken off and mounted on to a sheet of
paper, which was placed in an X-ray film cassette with a
sheet of monoemulsion film (Kodak, NMC) for six to 10
days. Two films were derived from each experiment.
The resultant microprobe autoradiographs were analysed
with an image analysis system employing an Imaging Tech¬
nology PC Vision frame grabber board operating in a Data
Control System 286e (AT based) computer, as previously
described.11* A charged coupled device camera scanned each
autoradiograph and, following background subtraction,
transverse integrations of optical density on a scale of 0-255
were performed along the length of each microprobe at
defined intervals. With the magnification of the system used,
and the resolution of the image analysis system (512x512
locations per frame) this corresponds to a 10 pm interval for
transverse integrations. However, this is beyond the biologi¬
cal resolution of the microprobe method (see Ref. 10) and
therefore the average of three successive integrals was taken
to give a final optical resolution of 30 pm. For each micro¬
probe, the resultant plot of integrated optical density (grey
scale) with respect to length along the microprobe, together
with coded information which described the experimental
conditions for that particular microprobe, were stored in a
computer file.
A sorting program was used to retrieve groups of micro-
probes which met stated criteria and produce for each group
a plot of the mean integrated grey scale values (±S.E.M. in
30 pm steps) with respect to depth within the spinal cord.
Each site was treated independently and statistical signifi¬
cance was assigned to differences between mean optical
densities at each site when comparing selected groups of
microprobes. The significance of the differences at each
30 pm analysis point was estimated using the Student's
/-test.
In vitro tests
The antiserum used was polyclonal and directed against
the C terminus of NPY (porcine). The manufacturer stated
that this antibody detected human and rat NPY and porcine
and rat peptide YY equally well. In parallel with present
experiments, the sensitivity of the prepared antibody micro¬
probes was regularly assessed by incubating a small number
either directly in [l25I]NPY or a range of concentrations
(10~5-10~9M) of unlabelled NPY in vitro at 37°C for
30 min prior to the incubation in a solution of [125I]NPY for
approximately 24 h at 6°C. Following washing in PBS-
Tween 20, the distal portion of these microprobes were
broken off, mounted on small pieces of cardboard and
placed in tubes for processing by gamma counter. X-Ray
images of these in vitro probes were also obtained.
The counts of total radioactivity of microprobe tips
indicated that over 10% of the total radioactivity in which
they had been incubated bound to the microprobes. In vitro
tests indicated that a 10~7 M solution of NPY suppressed
such binding by greater than 50%, with 10 ~5 M resulting in
greater than 80% suppression. Hence it can be assumed that
the non-specific binding for these microprobes accounts for
less than 20% of the total binding.
RESULTS
Spontaneous release of immunoreactive neuropeptide
Y in sham-operated rats
A basal presence of IR-NPY was found in the
spinal cord of sham-operated rats. Figure 1A illus¬
trates the mean image analysis of 42 microprobes
inserted into either side of the spinal cords of these
animals and that of 23 in vitro microprobes derived
from the same experiments. Figure IB plots the
/-statistics derived from the differences between these
Depth within the spinal cord (mm)
groups of microprobes is plotted with respect to depth
within the spinal cord: those present in both sides of the
spinal cord of sham-operated rats for 15 min in the absence
of any active peripheral stimulation (no stim, /i=42) and
those which were not inserted into the spinal cord but
simply incubated in [12T]NPY (in vitros, n=23). For each
group the mean grey scale was determined in 30 gm inter¬
vals and a line joins these points. At each analysis point the
standard error of the mean (S.E.M.) is also plotted (+) for
no stimulus and ( —) for in vitros. (B) A plot of the
"/"-statistics derived from the standard errors of the differ¬
ences of the means at each analysis point for the two groups
shown in (A), is related to an outline of a transverse section
of the lumbar spinal cord. The hatched area indicates where
these sites are significant at the P<0.05 level.
two groups and the hatched areas indicate where
these differences are significant at the P<0.05 level.
The latter includes all of the dorsal horn, dorsal
columns and extends into the perfusate of the spinal
cord for 0.5 mm. We have previously observed the
latter in studies of IR-NPY release in normal rats.
The zone of most significant release of IR-NPY
extends from 0.3 mm to 0.6 mm from the cord dor¬
sum and this approximates to laminae I, II and III of
the dorsal horn.
A separate analysis (not illustrated) showed no
differences in the mean image analyses of micro¬
probes inserted into the left side and into the right
side of the spinal cord of animals subjected to the
sham operation (which was always on the right side).
No stimulus microprobes
Nerve ligated rats (contra side)
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Fig. 2. The basal presence of IR-NPY in the contralateral
spinal cord of sham-operated and nerve-ligated rats. (A)
The mean image analysis of 23 microprobes present for
15 min in the side of the spinal cord contralateral to the leg
incision and in the absence of any active peripheral stimuli
of sham-operated animals (sham-operated rats, contra side)
is compared with that of 55 microprobes present for the
same time period in the contralateral side of the spinal cord
of the nerve-ligated rats and in the absence of any active
peripheral stimuli (nerve-ligated rats, contra side). (B) The
"/"-statistics derived from the differences between the two
groups of microprobes are plotted with respect to an outline
of the spinal cord. These differences are not significant at
the P<0.05 level.
2 mm
Fig. 3. An additional zone of release of IR-NPY in the
ipsilateral side of the spinal cord of rats with unilateral
sciatic nerve injury. (A) The mean image analysis of two
groups of microprobes present in the spinal cord for 15 min
in the absence of any active peripheral stimuli are plotted
with respect to depth within the spinal cord: those present in
the side of the spinal cord ipsilateral to the nerve ligation
(nerve-ligated rats, ipsi side, n=53) and those present in the
side of the spinal cord ipsilateral to the sham operation
(sham-operated rats, ipsi side, n= 19). The "/"-statistics
derived from the differences between the two groups
of microprobes are plotted with respect to an outline of
the spinal cord. The hatched areas indicates where these
differences are significant at the P<0.05 level.
Spontaneous release of immunoreactive neuropeptide
Y in rats with a unilateral constriction nerve injury
Figure 2 compares the mean image analysis of
microprobes inserted into the spinal cord of nerve
constricted rats, but on the side (L) contralateral to
the nerve injury with that of comparable microprobes
used with sham-operated animals. Although the
mean analysis of the neuropathic rats is displaced
above that of the sham-operated animals at several
sites (suggesting increased basal levels), none of these
differences were significant at the P<0.05 level.
On the side of the spinal cord ipsilateral to the
injured nerve however, there were significant differ¬
ences from the sham-operated rats. This is illustrated
in Fig. 3. The plot derived from the microprobes used
with the neuropathic group is clearly displaced above
that of the sham group over a restricted area. Figure
3 shows that this was significant from 0.5 mm to
1.5 mm from the dorsal surface with a broad peak
of greatest difference from 0.7 to 1.1 mm from the
dorsal surface. The latter zone approximates to lami¬
nae IV, V and VI of the dorsal horn and the total
area of significantly increased release includes
laminae III, IV, V, VI and upper lamina VII. It
should be noted that these areas were not the only
sites of significant levels of extracellular IR-NPY
in this side of the spinal cord of nerve ligatured
animals, but that they were superimposed on that
equally present in sham operated rats. Figure 4 has
been compiled to illustrate this point. This compares
the mean image analyses of microprobes inserted
into the side of the spinal cord ipsilateral to the
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Fig. 4. The basal presence of IR-NPY in the ipsilateral side
of the spinal cord of rats with a peripheral sciatic nerve
injury. (A) The mean image analysis of 53 microprobes
present for 15 min in the side of the spinal cord ipsilateral to
a peripheral nerve injury and in the absence of any active
peripheral stimulus (no stimulus microprobes, ipsi side) is
compared with that of microprobes simply incubated in
[i25I]NPY (in vitro microprobes). (B) The "/"-statistics
derived from the differences between the means of the two
groups shown in (A) are plotted with respect to a transverse
section of the rat spinal cord. The hatched areas indicate
where these differences are significant at the P<0.05 level.
ligatured nerve with that of the in vitro microprobes
derived from the same experiments (Fig. 4A). The
differences between these groups are shown in
Fig. 4B. This shows that significant levels of IR-NPY
occurred throughout the whole of the spinal cord,
extending into the perfusate, and that this was
greatest at an area approximating to laminae III
and IV.
Release of immunoreactive neuropeptide Y following
peripheral nerve stimulation in nerve ligatured rats
Our previous experiments found no spinal release
of IR-NPY following electrical stimulation of the
sciatic nerve in the normal rat.29 By contrast, in the
present experiments IR-NPY was readily released by
electrical stimulation of the sciatic nerve proximal to
the site of the nerve ligatures.
2 mm
Fig. 5. Release and persistence of 1R-NPY in the ipsilateral
spinal cord of nerve ligated rats by large myelinated fibre
stimulation proximal to the ligature at 20 Flz. (A) The mean
image analysis of three groups of microprobes present in the
spinal cord of nerve-ligated rats for 15 min were plotted
with respect to depth within the spinal cord: those present in
the side of the spinal cord ipsilateral to the nerve ligation in
the absence of peripheral stimuli (ipsi, n=21), those present
in the same side of the cord during stimulation of large
myelinated fibres at 20 Hz, 3 x T (nerve stim microprobes,
large fibres, 20 Hz, n=l4) and that of microprobes present in
the same side of the spinal cord but 5-60 min following a
period of large fibre stimulation (post-stim microprobes).
A plot of the "/"-statistics is related to an outline of the
lumbar spinal cord. Significant differences at the /><0.05
level are indicated by the hatched areas.
Figure 5A illustrates the mean image analyses of
microprobes present in the side of the spinal cord
ipsilateral to the injured nerve, before, during and
after electrical stimulation of large diameter afferents
of the ligatured nerve with a frequency of 20 Hz. The
plot for microprobes present during nerve stimula¬
tion is displaced above that of the prestimulus micro¬
probes throughout the whole of the spinal cord areas
sampled. Figure 5B shows that the differences be¬
tween these groups are significant 0.3-1.5 mm from
the dorsal surface. Not illustrated is that stimulation
of large fibres at 2 Hz gave comparable results to
stimulation at 20 Hz.
Figure 5A also contains the mean image analysis of
microprobes present in the spinal cord for up to 1 h
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Fig. 6. Release of IR-NPY in the ipsilateral spinal cord of
the nerve ligated rat during stimulation of large myelinated
fibres and unmyelinated fibres proximal to the ligature. (A)
The mean image analysis of two groups of microprobes
present in the spinal cord of nerve-ligated rats for 15min
was plotted with respect to depth within the spinal cord:
those present in either side of the spinal cord in the absence
of any active peripheral stimuli (pre-stim, ipsi, «=18) and
nine microprobes present in the side of the spinal cord
ipsilateral to the nerve ligation during stimulation at 2 Hz,
100 x T (nerve stim microprobes, large+small fibres, 2 Hz).
(B) A plot of the "h'-statistics derived from the differences
of the means of the two groups shown in A at each 30 pm
interval is related to an outline of the lumbar spinal cord.
The hatched area indicates where these sites are significant
at the P<0.05 level.
after a period of prior electrical stimulation and this
is still clearly displaced above the prestimulus group
at many sites in the spinal cord.
The effects of electrical stimulation with a strength
adequate to excite unmyelinated as well as myelin¬
ated fibres is shown in Fig. 6. Because unmyelinated
fibres do not follow high stimulus frequencies for
prolonged periods, the stimulus frequency used was
2 Hz. The mean image analysis of microprobes
present in the spinal cord during stimulation is
almost uniformly displaced above that of the pre¬
stimulus group but Fig. 6B shows that the differences
between these groups only attained significance at
P<0.05 over laminae III, IV and V, with the peak
approximating to the III/IV junction. This is a
relatively restricted area when compared with
large fibres-alone stimulation. Microprobes inserted
after stimulation of both large and small fibres
found elevated levels of IR-NPY relative to pre¬
stimulus microprobes which was significant at all
three time periods examined (5-20 min, 25^10 min
and 45-60 min).
DISCUSSION
Our previous experiments found an extensive basal
release of IR-NPY in normal anaesthetized rats, but
concluded that this was predominantly derived from
activity in intrinsic spinal neurons.29 Comparable
basal release in sham-operated animals and on the
side of the spinal cord contralateral to the ligatured
nerve was found in the present experiments but
release in the ipsilateral spinal cord in nerve ligatured
animals with a behavioural neuropathy showed
significant departures from the normal pattern. These
can be summarized as:
(i) superimposed on the normal pattern of spon¬
taneous IR-NPY release there was an additional
zone of spontaneous release resulting in raised
extracellular levels in the mid and deep dorsal horn
(approximating to laminae IV, V and VI);
(ii) whereas peripheral nerve stimulation did not
result in spinal release of IR-NPY in normal
rats, electrical stimulation of large myelinated
afferents proximal to the site of nerve ligature in
neuropathic rats did elicit release.
We believe that release from the terminals of large
diameter primary afferent fibres is the most likely
source of the additional zone of extracellular
IR-NPY detected by microprobes. Thus electrical
stimulation of these fibres did not alter the spatial
distribution of extracellular IR-NPY but simply
elevated these levels in a pattern similar to that
present prior to electrical stimulation. The peak
of IR-NPY following large fibre peripheral nerve
stimulation remained in the deep dorsal horn, upper
ventral horn.
Within dorsal root ganglia, the increased presence
of NPY which follows either axotomy38'48'50 or nerve
constriction35'49 occurs predominantly in a popula¬
tion of large- to medium-sized dorsal root ganglion
neurons. This correlates with our finding that electri¬
cal stimulation restricted to low threshold (large
diameter) fibres proximal to the constriction site was
adequate to elicit release of IR-NPY. Large diameter
dorsal root ganglion neurons are functionally a very
heterogeneous group, but there is recent evidence
on the relevant phenotypes. Administration of
neurotrophin-3 (NT-3)41 or nerve growth factor
(NGF)46 at a site of nerve section reduces by at least
50% the ensuing synthesis of NPY by dorsal root
ganglion neurons. This implies that de novo synthesis
of NPY is a response to deprivation of retrogradely
transported NT-3 and NGF. Mice deficient in
the gene for NT-3 have impaired development of
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cutaneous slowly adapting mechanoreceptor1 fibres
which project to laminae III and IV of the spinal
cord.6 Supporting this is a study of mice lacking the
trkC receptor believed to be the receptor acted upon
by NT-3.25 The animals were deficient in afferents
projecting to the ventral horn although deep dorsal
horn projections appeared normal. Another group15
have found that mice deficient in the gene for NT-3
have an absence of proprioceptive (muscle spindle
and tendon organ derived) afferents. The latter
project predominantly to the ventral horn.6 Amongst
large diameter dorsal root ganglion cells there is
no evidence linking the development of a particular
functional phenotype to a dependence on NGF.
Indeed only a small proportion of these cells express
the high affinity trkA recptor for NGF.2,31 Although
it is an assumption that dependence during develop¬
ment can be linked to the response of neurons to
deprivation of growth factors following peripheral
injury, if the phenotypes of large neurons synthesiz¬
ing NPY following peripheral axon damage include
both proprioceptive and large fibre mechanorecep-
tors, then impulses in these fibres would result in
release of NPY in the mid and lower dorsal horn and
the upper ventral horn.
Immunocytochemical studies of 1R-NPY distribu¬
tion in the dorsal horn following either transection40
or partial injury35 have found increases predomi¬
nantly in laminae III and IV. In the transection
study, this increase was prevented by dorsal rhizo¬
tomy implying an origin in primary afferent fibres.40
An increase in laminae III/IV is consistent with NPY
contained within slowly adapting mechanoreceptors6
but not with a presence within muscle spindle affer¬
ents as these terminate more deeply. The reasons
for this discrepancy are unknown but it is possible
that the roles of the neurotrophins differ during
development and regeneration after injury.
It has been proposed that NPY acts to inhibit the
transmission of impulses from primary afferents dur¬
ing the regenerative phase36 since an inhibition of
transmitter release by NPY has been shown by both
electrophysiological studies5 and direct measures of
transmitter release.13 An alternate hypothesis is that
NPY is responsible for some of the reported organi¬
zational changes in the dorsal horn following periph¬
ery axonal damage55 since the dendritic outgrowth
property of cultured dorsal root ganglion neurons
has been shown to be increased by added NPY.53 It
has been shown that following peripheral nerve in¬
jury, a proportion of large diameter afferents migrate
dorsally within the dorsal horn of the spinal cord and
established connections within lamina III the major
site of termination of small diamter cutaneous affer¬
ents. This migration has been established on the basis
of transported markers applied to whole nerves27'55
or injected into single dorsal root ganglion neurons.55
An important consideration is whether these fibres
contain and release NPY. We consider this improb¬
able. As cited previously, increases in NPY following
peripheral nerve injury occur in laminae III, IV and
not in lamina II35-40 and the present study found that
the major change in where extracellular NPY was
detected was in laminae IV to VI.
Where a neuropeptide is found following release,
however, is not necessarily coincident with sites of
release, since, if the compound is slowly degraded,
considerable diffusion can occur following re¬
lease.12'16'43 In the present studies the increases in
extracellular IR-NPY evoked by nerve stimulation
did persist for up to 1 h after release suggesting
a slow degradation of released NPY. Thus, it is
possible that the new zone of presence of IR-NPY
revealed in the present studies is more extensive than
the area of releasing neurons. Supporting this is the
extensive presence of IR-NPY in the dorsal columns
and even the surface perfusate which almost certainly
resulted from diffusion from the adjacent gray
matter.
CONCLUSIONS
An important conclusion from the present exper¬
iments is that IR-NPY is spontaneously released
from the central terminals of large diameter primary
afferents in the absence of added peripheral stimula¬
tion. It is improbable that impulses originating from
the periphery in undamaged, myelinated fibres con¬
tributed to such release since there is extensive loss of
myelinated fibres distal to the ligatures in the pro¬
cedure of Bennett and Xie.3 A possible explanation
for this extensive presence of IR-NPY in the spinal
cord of nerve ligatured rats is release produced by
ectopic impulses arising in regenerating or damaged
fibres. Ectopic impulses have been described in dorsal
roots of rats with sciatic nerve ligatures20'21 with
evidence that such impulses arise at or near the site
of the ligatures or dorsal root ganglion neurons.
Ectopic impulse generation has been most extensively
studied following complete nerve transection and
spontaneous impulses in large diameter primary
afferents have been recorded by several labora¬
tories.7_9-33'42'51-52 There is evidence for such im¬
pulses arising both at the site of nerve injury9-20-51
and from cell bodies in dorsal root ganglia.9'21'30
Several authors have proposed that spontaneous
activity in primary afferent fibres may be responsible
for spontaneous pain following nerve injury in
man8'39 and for the development of allodynia and
hyperalgesia in animals with an experimental nerve
injury.17,20 An obvious sequela to the present exper¬
iments is to examine the effects of local anaesthetic
applied either proximally or distally to dorsal root
ganglia, on spinal release of NPY. We cannot exclude
the possibility of spontaneous release occurring in the
absence of impulse invasion since there is structural
evidence for neuropeptide-containing dense core
vesicles fusing with non-junctional areas of axon
terminal membranes.14 In the present experiments,
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however, peripheral nerve stimulation did result in
release of IR-NPY. Spontaneous release could also
occur through a continued depolarization of the
spinal terminals of the relevant fibres. Such a mech¬
anism has been proposed as important for release
from the terminals of small diameter primary affer-
ents.28 Irrespective of the mechanisms, the finding of
a relatively large spontaneous release of IR-NPY of
probable primary afferent origin, suggests a role for
this neuropeptide in the phase of regeneration which
follows injury to these fibres.
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